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Ubiquitination is a type of post translational modification that principally functions in protein 
turnover via the ubiquitin-proteasome system (UPS), however it also has roles in 
endocytosis, cell signalling, and DNA repair. Ubiquitination is a diverse modification with 
each ubiquitin molecule able to form differently linked polyubiquitin chains by any one of the 
seven lysine residues or the N-terminal methionine residue. Ubiquitin is conjugated to target 
proteins by enzymes called ubiquitin E3 ligases. HECTD1 is a HECT (Homologous to the 
E6-AP Carboxyl Terminus) E3 ubiquitin ligase. The HECT domain is responsible for 
HECTD1 E3 ligase activity and is conserved from yeast to humans. Interestingly, our lab 
showed that, at least in vitro, HECTD1 synthesises K29/K48-linked ubiquitin chains. The 
cellular function of these atypical ubiquitin chains remains poorly understood. Therefore, in 
order to elucidate the function of this chain type, gain and loss-of-function studies of 
HECTD1 in mammalian cells were carried out. This revealed that HECTD1-depleted or 
CRISPR/Cas9 knockout cells, exhibited reduced cell proliferation, were enriched in 
metaphase, and were slower to progress through mitosis.  Furthermore, expression of HA-
FL-mHectd1 revealed a mitotic spindle specific localisation during metaphase further 
suggesting a mitotic function. Strikingly, only the catalytically active wild-type HECTD1 was 
able to rescue the observed cellular phenotypes, strongly suggesting that K29/K48 chains 
might be involved in cell cycle function. Taken together, this suggests that cells are being 
delayed at the spindle assembly checkpoint (SAC), and that HECTD1 may regulate mitotic 
spindle formation, however further work would be required to establish this. In order to 
define the mechanism involved and identify cell cycle components, which might carry K29 
chains assembled by HECTD1, we have optimised the enrichment of K29 chains from 
synchronised cells using the TRABID1-200 ubiquitin binding domain. Finally, given that 
HECTD1 has been implicated in Wnt signalling, cell migration, and the cell cycle, and now 
in cell proliferation, its role in cancer was studied. It was identified that overexpression of 
mHectd1 wild-type only resulted in increased proliferation in glioblastoma cells, and that 
depletion of HECTD1 resulted in decreased cell proliferation, suggesting that inhibition of 
HECTD1 may lead to a reduction in cell proliferation. Thus, demonstrating the potential of 
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1.1. The cell cycle 
The cell cycle is a fundamental process that needs to be tightly regulated. The discovery of 
key regulators of the cell cycle led to the Nobel Prize in Physiology or Medicine being 
awarded to Leland H Hartwell, Timothy Hunt, and Paul M Nurse in 2001. The cell cycle 
functions to yield two daughter cells that contain the same genetic information. This process 
is divided into two main stages, the phase in which the cell grows and duplicates its DNA 
(interphase) and the phase where the cell physically divides into two identical daughter cells 
(M phase) (Vermeulen, et al. 2003). Interphase is further subdivided into G1 (Gap 1), G2 
(Gap 2), and S (synthesis) phase. The gap phases, so called as they represent the “gaps” 
between DNA replication and mitosis, function to gather information to determine the 
readiness of the cell to enter S or M phase (Figure 1.1) (Norbury, & Nurse. 1992; Vermeulen, 
et al. 2003). The first gap, G1 phase, is the stage of the cell cycle where the cell prepares 
for DNA synthesis, and precedes S phase, where 2N DNA content becomes 4N. The 
second gap phase, G2, prepares cells for mitosis, a process that is further divided into five 
stages (Figure 1.2) (Norbury, & Nurse. 1992).  
 
 
Figure 1.1. Diagram illustrating the main phases and events in the cell cycle. The 
cell cycle is subdivided into G1, S, G2, and M phase. M phase is then divided into 5 further 
stages allowing mechanical division of the DNA and the cellular components. Adapted from 
Vermeulen, et al. 2003 and Inside the Cell I Cellular Reproduction: Multiplication by Division, 
U.S. Department of health and human services. NIH Publication No. 05-1051, September 
2005. 
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1.1.1. Mitotic stages 
M phase comprises Prophase, Prometaphase, Metaphase, Anaphase, Telophase, and 
finally cytokinesis, where the cell physically divides into two daughter cells (Figure 1.2A).  
Mitosis is the most mechanical phase of the cell cycle; whereby large reorganisation of the 
cell is needed to mediate nuclear division and cellular division (Pines. 2006).  
 
During prophase two main events occur, the condensation of mitotic chromosomes, 
mediated by a five-subunit complex called condensin, and the formation of the mitotic 
spindle (Sager, et al. 1986; Strunnikov. 2003). The breakdown of the nuclear envelope and 
movement of centrosomes to each pole marks the initiation of prometaphase, where 
chromosomes start to move towards the centre of the cell (Aubin, et al. 1980; Beaudouin, 
et al. 2002). During this time, the kinetochores begin to form around the centromeres, a 
central process in the joining of the sister chromatids and in linking chromosomes to the 
mitotic spindle (Hayden, et al. 1990). The kinetochore consists of two regions; the inner 
kinetochore, which is associated with the centromere and the outer kinetochore, which 
interacts with the microtubules (Brinkley & Stubblefield. 1966; Van Hooser & Heald. 2001). 
Microtubules originating from the centrosomes at either pole reach the chromosomes and 
attach to the kinetochores. Dynamic instability of the microtubules allows for the “search 
and capture” of the chromosomes with their plus ends (Hayden, et al. 1990; Holy & Leibler. 
1994). Chromosomes are captured by the lateral surface of the microtubule rather than the 
tip, forming lateral attachments. Eventually kinetochores interact with more microtubules, 
where the plus ends become embedded into the kinetochore plate (Rieder & Alexander. 
1990; Hayden, et al. 1990; Merdes & De May. 1990). Under normal attachment of the 
microtubules to the kinetochore, amphitelic attachment, the microtubules originate from 
opposite poles in a bipolar fashion (Figure 1.2B) (Musacchio & Salmon. 2007). However, 
because the microtubule-kinetochore attachment occurs via microtubules from one pole 
first and then from the other pole, monotelic, syntelic, or merotelic attachments often 
precede amphitelic attachments (Figure 1.2B) (Musacchio & Salmon. 2007). In the instance 
of monotelic and syntelic attachments, a “wait” signal is in place to prevent chromosome 
segregation, this is called the spindle assembly checkpoint (SAC) and is active until the 
centromeres are under sufficient tension (Stern & Murray. 2001; Uchida, et al. 2009).  
 
During metaphase, once the chromosomes are attached to the microtubules, the 
chromosomes then move to align themselves in the middle of the cell (Rieder & Alexander. 
1990). This alignment along the equatorial plane is aided by counterbalance forces that 
originate from the spindle microtubules and the kinetochores (Inoué & Salmon. 1995; Heald, 
et al. 1996). During metaphase, the spindle assembly checkpoint remains active, until all 
chromosomes are aligned along the equatorial plane and correct (“end-on”) kinetochore 
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attachment has occurred (Stern & Murray. 2001; Kuhn & Dumont. 2017). Anaphase begins 
only once the checkpoint has been satisfied, and results in the separation of sister 
chromatids (Rieder, et al. 1994). The process of anaphase occurs in two phases, Anaphase 
I, where the sister chromatids begin to segregate to opposite poles of the spindle, and 
Anaphase II, where elongation of the spindle and further separation of the sister chromatids 
occurs (Baskin & Cande. 1990; Pines. 2006). The fifth and final phase of mitosis, telophase, 
is the process that separates the chromatids into two daughter cells. It is during this phase 
that the nuclear envelope forms around each set of chromosomes in the daughter cells, and 
the chromosomes uncoil (Chaudhary & Courvalin.1993; Schwalm. 1969). Finally, the 
cleavage furrow develops at the  location of the metaphase plate, and aides in final splitting 
























Figure 1.2. Diagram illustrating the stages of mitosis. A) Chromosomes condense, the 
nuclear envelope breaks down, chromosomes align in the centre of the cell, separate, 
nuclear envelope reforms resulting in cell division. Adapted from Inside the Cell I Cellular 
Reproduction: Multiplication by Division, U.S. Department of health and human services. 
NIH Publication No. 05-1051, September 2005. B) In the event of improper attachment of 
the mitotic spindle to the kinetochores (monotelic, syntelic), a “wait” signal known as the 
spindle assembly checkpoint (SAC), prevents anaphase onset. In amphitelic attachment 
the centromeres are under sufficient tension to remove the “wait’ signal, SAC, allowing for 
proper division of the chromosomes. This is also true for merotelic attachment but in this 
case it will result in lagging chromosomes, and improper division of chromosomes. In both 
monotelic and syntelic attachments, neither create sufficient centromeric tension, therefore 
resulting in the “wait” signal persisting, preventing anaphase onset. Adapted from 
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1.1.2. Cell cycle checkpoints 
Cell cycle checkpoints are supervision mechanisms that ensure the correct order, integrity, 
and fidelity of the cell cycle. Briefly, the three major cell cycle checkpoints are, the G1 
checkpoint, the G2 checkpoint, and the spindle assembly checkpoint (SAC) (Murray. 1994) 
(Figure 1.3). The G1 checkpoint is the first checkpoint of the cell cycle, and controls entry 
into S phase. This checkpoint is also known as the restriction point, whereby cells ensure 
that there is the correct environment to divide, after which they are committed to the cell 
cycle (Johnson, & Skotheim. 2013). Two Cyclin-dependent kinases (CDKs), CDK4/6-Cyclin 
D and CDK2-Cyclin E, work to relieve inhibition of retinoblastoma protein (Rb) and E2F, 
allowing for transcription of genes required for DNA replication (Besson, et al. 2008). The 
checkpoint is active under TGF-b signalling, DNA damage, replicative senescence, and 
growth factor withdrawal (Murray. 1994). DNA damage activates response pathways 
mediated by ATM/ ATR and CHK1/2 kinases, which block CDK activity, therefore leading 
to cell cycle arrest because the G1 checkpoint is still active (Reinhardt & Yaffe. 2009).  
Furthermore, p53 is a critical component of DNA damage checkpoints, particularly in the 
G1 checkpoint (Giono & Manfredi. 2006).   
 
The G2 checkpoint is known as the DNA damage checkpoint, specifically because it 
prevents cells with DNA damage from entering mitosis (Löbrich & Jeggo. 2007). Both WEE1 
and MYT1 function to keep Cyclin B-CDK1 inactive because it is vital for ensuring the G2 
to M phase transition (Takizawa & Morgan. 2000). Activation of CDK1 is thought to occur 
via the kinases Aurora A and PLK1 (Polo-like kinase 1) (Lens, et al. 2010). DNA damage 
results in the inhibition of CDK1 by the ATM/ ATR kinases, preventing the cells from entering 
mitosis (Nam & Cortez. 2011). Here, p53 is also important for regulating entry into mitosis, 
where CDK1 is inhibited simultaneously by three transcriptional targets of p53 GADD45, 
p21, and 14-3-3 (Taylor & Stark. 2001).  
 
Finally, the SAC occurs during mitosis, and prevents anaphase onset until each kinetochore 
is attached to the mitotic spindle, ensuring proper chromosome segregation (Murray. 1994; 
Stern & Murray. 2001). The SAC comprises the serine/threonine kinases MPS1, and BUB1, 
as well as MAD1, MAD2, BUB3, and BUBR1 (Hoyt, et al. 1991; Li & Murray. 1991; Weiss 
& Wilney. 1996). Together, these proteins function to ensure proper chromosome 
segregation, by delaying anaphase onset until each kinetochore is attached to the mitotic 
spindle. This is achieved by the sequestering of CDC20 by these proteins to inactive the 
APC/C (Fang, et al. 1998; Hwang, et al. 1998; Kramer, et al. 1998). The APC/C ubiquitinates 
and therefore triggers proteasomal degradation of Cyclin B1 and securin, the separase 
inhibitor, triggering sister chromatid separation and exit from mitosis (Glotzer, et al. 1991; 
Holloway, et al. 1993; Cohen-Fix & Koshlan. 1999). The SAC is responsible for the 
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formation of the Mitotic Checkpoint Complex (MCC), an inhibitory complex, responsible for 
sequestering CDC20. The MCC is a heterotetramer composed of CDC20, MAD2, BUBR1, 
and BUB3 (Sudakin, et al. 2001). Kinetochores play a central role in SAC signalling, 
whereby the MCC forms at unattached kinetochores, sequestering and therefore inhibiting 
CDC20, preventing anaphase onset. Furthermore, it has been suggested that the APC/C 
degrades CDC20 to maintain the checkpoint, not to release CDC20 from the MCC (Nilsson, 
et al. 2008). Upon microtubule binding, the SAC is satisfied and CDC20 is released (Rieder, 
et al. 1995). The exact mechanism by which this occurs is still largely unknown however, 
the APC/C subunit APC15 has been shown to be required for SAC deactivation and release 
of the MCC in response to microtubule attachment (Mansfeld, et al. 2011). A lack of inter-
kinetochore tension has been associated with activation of the SAC in budding yeast cells, 
in contrast stretching of the kinetochores results in SAC inactivation (Stern & Murray. 2001; 
Uchida, et al. 2009). Therefore, it can be assumed that microtubule tension creates 
















Figure 1.3.  Cell cycle checkpoints. The G1 checkpoint ensures that the cell is in the right 
environment to divide, after which point the cell is committed to the cell cycle. This is 
followed by DNA damage checkpoints at the G1/S border and in S phase. The G2 
checkpoint prevents cells with damaged DNA from entering mitosis, and the spindle 
assembly checkpoint ensures that the chromosomes are attached to the spindle before 
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1.2. Regulation of the cell cycle by post-translational modifications 
Protein post-translational modifications (PTMs) such as phosphorylation and ubiquitination 
play key roles in driving cells through the different phases of the cell cycle. Phosphorylation 
is the best characterised PTM, and in the cell cycle it is conferred by serine/threonine-
specific kinases, called CDKs. These kinases are activated at different stages of the cell 
cycle and ensure the faithful progression of the cell cycle (Lim & Kaldis. 2013). CDK/Cyclin 
complexes were first discovered as cell cycle regulators from work carried out in yeast. A 
single CDK, Cdc28 in S. Cerevisiae and Cdc2 in S. Pombe, was found to promote 
transitions between different cell cycle phases (Nurse, et al. 1976; Nurse & Thuriaux; 
Beach, et al. 1982; Reed, et al. 1982). CDKs control the cell cycle through oscillation of 
activity mediated by proteins called Cyclins (Pines. 2011; Lim & Kaldis. 2013). They are 
expressed constitutively in cells but their activity is controlled by the availability of their 
binding partner, Cyclins. Therefore, the turnover of Cyclins is fundamental for the temporal 
regulation of CDKs’ activity and the control of cell cycle (Evans, et al. 1983; Shaik, et al. 
2012). Using sea urchin embryos as a model system, Cyclin B1 was found to accumulate 
and disappear suggesting for the first time protein turnover was key to cell division (Evans, 
et al. 1983). The work carried out in Tim Hunt’s lab led to the hypothesis that synthesis of 
Cyclin B1 drove cells into mitosis, and its destruction allowed cells to complete cell division 
(Murray. 2004). Cyclin B1 was later described to complex with CDC2 (CDK1) to initiate 
mitotic onset (Pines & Hunt. 1987; Draetta & Beach. 1988). Importantly, the destruction of 
Cyclin B1 was later found to be mediated by the ubiquitin proteasome system (UPS) 
(Glotzer, et al. 1991). Defining how Cyclin B1 is regulated and the machinery driving protein 







Protein turnover is essential to maintain cell homeostasis. However, it was not until the early 
1980s that the molecular mechanisms mediating protein turnover were uncovered. The 
discovery of the UPS as a pathway for protein degradation led to the Nobel Prize in 
Chemistry being awarded to Aaron Ciechanover, Avram Hershko, and Irwin Rose in 2004. 
Ubiquitin was first identified as a polypeptide, which had lymphocyte-differentiating 
properties (Goldstein, et al. 1975). It was characterised as an 8.5kDa protein, 76 amino 
acids in length, that was speculated to be found universally in all living cells (Schlesinger, 
et al. 1975).  Experiments carried out in reticulocytes found that ubiquitin-mediated 
proteolysis was ATP-dependent (Ciechanover, et al. 1978) and, more specifically, that the 
formation of a ubiquitin-substrate isopeptide bond was ATP-dependent (Hershko, et al. 
1980; Ciechanover, et al. 1981). The isopeptide bond forms via the C-terminal glycine 
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residue (G76) of ubiquitin and the ε-amino group of a substrate lysine residue (Pickart. 















Figure 1.4. Isopeptide bond in lysine ubiquitination. Ubiquitin is attached via its C-
terminal glycine residue (G76) and the ε-amino group of the side chain of a substrate lysine 
residue forming an isopeptide bond. Own figure. 
 
  
The conjugation of ubiquitin to a target protein requires a cascade of three enzymes, an E1 
ubiquitin-activating enzyme (Ciechanover, et al. 1982; Haas, et al. 1982), E2 ubiquitin-
conjugating enzyme, and E3 ubiquitin-protein ligases (Hershko, et al. 1983) (Figure 1.5). 
The E1 enzyme uses ATP in the presence of Mg2+ to form an intermediary ubiquitin-
adenylate (activated ubiquitin), which is then bound to the catalytic cysteine of the E1 via a 
thioester bond (Ciechanover, et al. 1981; Ciechanover, et al. 1982). The activated ubiquitin 
is transferred from the E1 enzyme to a catalytic cysteine on the E2 enzyme, again forming 
a thioester bond. The final stage of ubiquitin transfer is mediated by an E3 ligase, which 
transfers ubiquitin onto a lysine residue on the substrate forming a isopeptide bond with its 
e-amino group (Hershko, et al. 1983). The E3 ligase can either behave as a scaffold to bring 
the E2 into close proximity to the substrate to aid ubiquitin transfer (e.g. RING ligases), or 
can go via an intermediate step where ubiquitin is accepted onto the E3 ligase via the 
formation of a thioester bond, before transferring the ubiquitin to the substrate (e.g. HECT 
ligases) (You & Pickart. 2001; Wang, et al. 2006; Kim & Huibregtse. 2009). Ubiquitin-
conjugated substrates are degraded in an ATP-dependent manner, by a protein complex 
known as the 26S proteasome, which is conserved from archeabacteria to all eukaryotes 









































Figure 1.5. Protein ubiquitination cascade. Ubiquitination of a substrate is achieved via 
an enzymatic cascade. First, the E1 ubiquitin-activating enzyme, in an ATP-dependent 
mechanism, forms an activated intermediary ubiquitin-adenylate. This intermediary 
ubiquitin-adenylate is then bound to the catalytic cysteine of the E1 enzyme. The E1 then 
transfers the activated ubiquitin to the E2 conjugating enzyme. Finally, the ubiquitin is 
transferred from the E2 to the substrate lysine facilitated by an E3 ubiquitin ligase to form 
an isopeptide bond with the lysine ε-amino group. This can be facilitated by the E3 by the 
formation of an E3-ubiquitin intermediate or it can indirectly attach the ubiquitin to the 
substrate. The diagram shows the mechanism of RING E3 ligases compared to HECT E3 





Ubiquitin is a highly conserved and diverse protein modifier. It can either be conjugated to 
a substrate as a monomer (mono-ubiquitination) or as polymers (polyubiquitination), 
forming ubiquitin chains.  Ubiquitin contains seven lysine residues K6, K11, K27, K29, K33, 
K48 and K63 (Figure 1.6), which are able to form an isopeptide bond with the C-terminus 
of another ubiquitin molecule. In addition, linear ubiquitin chains can form through the N-
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terminal Met1 residue on ubiquitin forming linear ubiquitin chains (Kirisako, et al. 2006). 
Therefore, two ubiquitin molecules can assemble through 8 linkages in order to form a chain 
(see section 2.3) (Komander. 2009). The substrate selectivity of this pathway is conferred 
through the enzymatic cascade in which there are many more E3 enzymes than E1 and E2 
enzymes. The human genome encodes two E1-activating enzymes, 37 E2-conjugating 
enzymes and >600 E3 ligases (Deshaies & Joazeiro. 2009). Ubiquitination is a reversible 
modification, and substrates can indeed be deubiquitinated by proteases known as 
deubiquitinases (DUBs) (Nijman, et al. 2005). The human genome encodes around 100 
DUBs, which function to mediate the removal and processing of ubiquitin (Nijman, et al. 
2005; Clague, et al. 2013). DUBs were initially subdivided into five families: ubiquitin C-
terminal hydrolases (UCHs), ubiquitin-specific proteases (USPs), ovarian tumour proteases 
(OTUs), Josephins, and JAB1/ MPN/ MOV34 metalloenzymes (JAMMs). While the UCHs, 
USPs, Josephins and OTU are cysteine proteases, the JAMM DUBs are zinc 
metalloproteases (Komander, et al. 2009; Clague, et al. 2013). However, more recently, a 
new family of DUBs have been identified known as motif interacting with Ub-containing 


























Figure 1.6. The structure of ubiquitin. Ubiquitin contains 7 lysine residues that facilitate 
the formation of an isopeptide bond; K(Lys)6, 11, 27, 29, 33, 48, and 63. In addition, 
ubiquitin can form a peptide bond via the N-terminal Met1. The isopeptide and peptide 
bonds are formed via the C-terminal Gly76. Annotated figure from the Protein Data Bank 
(PDB) 1UBQ.   
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1.3.1. E3 ubiquitin ligases  
E3 ubiquitin ligases are classified into four classes: Really Interesting New Gene (RING), 
Homologous to E6-AP Carboxyl Terminus (HECT), Ring Between Ring (RBR), and U box 




Table 1.1. The different families of E3 ligases. Domain features, including the presence 
of a catalytic cysteine, alongside the estimated number of each family in mammals (Ardley 
& Robinson. 2005).  
 Domain features Catalytic 
cysteine? 
Estimated number in 
mammals 
References 
RING RING: Zn2+ coordinating 
binding domain, recruits the 
Ub-charged E2. 
No 600 Borden. 2000; 
Pickart. (2001); 
Satija, et al. (2013).  
HECT Bilobed. 
N lobe: Ub-charged E2 
binding. 
C lobe: Catalytic Cys. With a 
flexible hinge domain in-
between. 
Yes 28 Rotin & Kumar. 
(2009); 
Grau-Bove, et al. 
(2013). 
RBR RING 1: domain recruits Ub-
charged E2.  
IBR: In-between RING 
domain. 
RING 2: contains catalytic 
Cys. 
Functional hybrid of RING 
and HECT. 
Yes 12 Marín, et al. (2004); 
Spratt, et al. 
(2014).  
U-box Similar fold to RING domain 
without Zn2+ coordination. 




RING ligases have the highest number of family members, followed by the HECT family 
(Ardley & Robinson. 2005; Grau-Bove, et al. 2013; Satija, et al. 2013). The main difference 
between the RING and HECT E3 ligases is their mechanism of ubiquitination (Figure 1.5). 
RING E3 ligases act as a scaffold protein whereby the type of polyubiquitin chain formed is 
usually determined by their partner E2. In contrast, HECT E3 ligases transfer ubiquitin from 
the E2 onto their catalytic cysteine located in the C-terminal HECT domain, via a thioester 
bond. HECT ligases have been shown to provide specificity for the chain type they 
synthesise (You & Pickart. 2001; Wang, et al. 2006; Kim & Huibregtse. 2009).  
 
Chapter 1: Introduction 
 
 13 
RING type ubiquitin ligases are conserved from yeast to humans, and form the largest family 
compared to the HECT family, containing over 600 ligases in mammals (Satija, et al. 2013). 
RING E3 ligases are further subdivided into; monomeric RING ligases such as GRAIL (gene 
related to anergy in lymphocytes), homodimeric RINGs for example RNF4, heterdimeric 
RINGs such as BRCA1-BARD1, the Cullin RING ligase SCF (SKP1-Cullin-F-box protein), 
and the multisubunit RING ligase, the APC/C (Brzovic, et al. 2001; Pickart. 2001; Lineberry, 
et al. 2008; Plechanovová, et al. 2011). RINGs are cysteine rich, zinc-binding domains 
characterised by several defining features. They are defined by a pattern of conserved 
cysteine and histidine residues, the binding of two atoms of zinc, and finally that zinc ligation 
is required for domain folding (Borden. 2000). RING E3 ligases can be seen as more of 
scaffold to support ubiquitin transfer rather than having a catalytic function (Pickart. 2001) 
(Huibregtse, et al. 1995) (Figure 1.5). The HECT ligase family, features and functions are 
further discussed in section 1.4.  
 
RBR ligases directly catalyse ubiquitin transfer via a catalytic cysteine present in the RING2 
domain, whilst ubiquitin-charged E2 binding is conferred by the RING1 domain. This group 
of multidomain enzymes includes the ligase PARKIN, a regulator of mitophagy, which its 
dysfunction has been linked to autosomal recessive juvenile parkinsonism (Shimura, et al. 
2000; Spratt, et al. 2014). Finally, the smallest group of ligases comprises the U-box ligases, 
which are characterised by a domain structurally similar to the RING domain that does not 
coordinate Zn2+. Given their structural similarity they display similar modes of activity to 
RING ligases, and can function as a monomer or part of a larger complex of proteins (Ardley 
& Robinson. 2005). CHIP (also known as STUB1) is the best characterised U-box ligase, 
and has been shown to interact with molecular chaperones such as HSP70 and HSP90 




1.4. HECT ligases  
The HECT family of E3 ligases were first discovered when investigating the function of E6-
AP. This E3 ubiquitin ligase forms a complex with E6, a protein of the cancer related human 
papillomavirus (HPV) types 16 and 18 and was shown to function in targeting the p53 
tumour-suppressor protein for degradation by the UPS (Scheffner, et al. 1993). HECT 
ligases are defined by the conserved C-terminal HECT domain, composed of ~350 amino 
acids. It contains a N-lobe, C-lobe, catalytic cysteine, hinge glycine, and an interface for E2 
and ubiquitin binding (Huibregtse, et al. 1995; Buetow & Huang. 2016). The HECT family of 
E3 ligases is now known to contain 28 members in humans and 5 members in yeast (Li, et 
al. 2008). The family has typically been subdivided into 3 groups based on N-terminal 
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domain architecture; the neural precursor cell-expressed developmentally downregulated 4 
(NEDD4) family containing 9 members, the HERC family contains 6 members, and the other 
HECTs which contains 13 members (Rotin & Kumar. 2009). The NEDD4 subfamily contains 
E3 ligases, which have a C2 domain, three or four WW domains, and a HECT domain 
(Kumar, et al. 1992). The WW domain comprises two conserved tryptophan residues that 
are spaced 20-22 amino acids apart. The domain forms a hydrophobic ligand-binding 
groove by three stranded antiparallel beta-sheets (Huang, et al. 2000; Verdecia, et al. 
2000). The C2 domain is a conserved lipid- and protein- binding domain, which can be 
regulated by calcium in some cases (Nalefski & Falke. 1996).  
 
The HERC subfamily of E3 ligases contains RLDs (RCC1 like domains). This subfamily can 
be further subdivided into large and small HERCs; the regulator of chromosome 
condensation 1 (RCC1)-like domains are present multiple times in large HERCs, but only 
once in small HERCs (Ohtsubo, et al. 1987; Rotin & Kumar. 2009). The RLD is 
characterised by a seven-bladed β-propeller fold, each blade made up of 51-68 amino 
acids. This seven-bladed β-propeller fold acts as a guanine exchange factor (GEF) for the 
GTP binding protein Ran (Renault, et al. 1998; Renault, et al. 2001). The third and final 
subfamily is called the “other” HECTs and contains all the HECTs that contain neither WW 
repeats or RLDs (Scheffner & Kumar. 2014). This subfamily contains HECT E3 ligases with 
many different domains these include ankyrin repeats; WWE domains, zinc fingers, PHD or 
RING domains, ubiquitin associated domains (UBA), as well as domain which are yet to be 
characterised, showing a high degree of diversity across this subfamily (Rotin & Kumar. 
2009).  
 
However, this widely accepted classification of the HECT family of E3 ligases into 3 
subfamilies has been said to be fundamentally incorrect from a phylogenetic viewpoint 
(Marín. 2010). Insights into the evolution of HECT E3 ligases has revealed that the family 
of 28 can in fact be subdivided into 16 subfamilies in humans based on structural data. In 
this investigation into the evolution of the HECT E3 ligases in animals, it was found that 
most of these 16 subfamilies predate or coincide with the evolution of animals (Marín. 2010). 
Whilst in eukaryotes as a whole the HECT family can be subdivided into 6 classes, based 
on phylogenetic analysis based on the last eukaryotic common ancestor (LECA) (Grau-
Bove, et al. 2013). The HECT system has evolved acquiring diversity through two parallel 
mechanisms, the first being through protein duplication, and the second by domain shuffling 
yielding new protein domains used to target substrates. This domain shuffling occurs 
predominantly at the N-terminus of the protein because the HECT domain being located in 
the C-terminus. This led to the diversification and expansion of the HECT family especially 
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in animals providing the substrate specificity needed to conduct diverse cellular functions 
(Grau-Bove, et al. 2013; Scheffner & Kumar. 2014). 
 
 
1.4.1. Mechanism of ubiquitin transfer by HECT ligases 
In order to elucidate the mechanism of action of HECT E3 ubiquitin ligases, the structures 
of HECT domains of 8 HECT E3 ligases have been solved (E6AP, WWP1, SMURF2, 
NEDD4-L, HUWE1, yeast Rsp5, NEDD4, and WWP2) (Huang, et al. 1999; Verdecia, et al. 
2003; Ogunjimi, et al. 2005; Kamadurai, et al. 2009; Pandya, et al. 2010; Kim, et al. 2011; 
Maspero, et al. 2011; Gong, et al. 2015). The HECT domain contains an N-terminal lobe 
that binds the E2, a flexible linker, and a C-terminal lobe harbouring the catalytic cysteine 
(Figure 1.7) (Huang, et al. 1999). The catalytic core is completed by a conserved C-terminal 
phenylalanine residue, which mediates the inter-lobe contacts, as seen with Phe896 in 
NEDD4 (Maspero, et al. 2013). In the absence of a ubiquitin-loaded E2, the distance 
between the catalytic Cys of the HECT domain and that of the unloaded E2 is large (as 
seen in E6AP 41Å, and WWP1 16Å) (Huang, et al. 1999; Verdecia, et al. 2003). Indeed, 
the reported distance of 8Å between the E2-Cys and E3-Cys is not close enough for trans-
thioesterification to occur, and it has been proposed that the C-lobe is able to rotate to 
shorten the distance further (Kamadurai, et al. 2009). Therefore, conformational flexibility 
between the N- and C- lobes is essential for ubiquitin transfer as shown in the crystal 
structure of the complex between HECTNEDD4L and Ub-loaded UBCH5B complex 
(Kamadurai, et al. 2009). 
 
HECTs use a two-step mechanism to conjugate ubiquitin to the substrate (Figure 1.7). The 
first step involves the transfer of ubiquitin from an E2 enzyme to the HECT domain forming 
a thioester-bonded HECT-ubiquitin intermediate (Berndsen & Wolberger. 2014; Buetow & 
Huang. 2016). The mechanism of the second step where the HECT-ubiquitin intermediate 
transfers ubiquitin was elucidated by structural studies into the NEDD4 family of HECT E3 
ligases. Both studies suggest that after the HECT-ubiquitin intermediate is formed, the C-
lobe remains associated with its thioester-linked ubiquitin (Maspero, et al. 2013; Kamadurai, 
et al. 2013). The crystal structure of yeast Rsp5 revealed that the C-lobe and ubiquitin 
together rotate ~130° to face the substrate bound the N-terminal WW domain (Kamadurai, 
et al. 2013). Due to steric hindrance, a ubiquitin-loaded E2 enzyme is unable to access the 
ubiquitin-binding site of the C-lobe until the E3 transfers the donor ubiquitin to the substrate 
(Maspero, et al. 2013). Therefore, the reloading of ubiquitin, for the next addition of ubiquitin 
has been theorised to be stimulated by the discharge of ubiquitin from the HECT domain 
onto the substrate (as described in Section 1.5).  
 




Figure 1.7. Ubiquitin transfer by HECT E3 ligases. Cartoon schematic demonstrating the 
mechanism of ubiquitin transfer by HECT ligases. The C-lobe of the protein is flexible 
relative to the N-lobe of the catalytic domain. The N-lobe binds the ubiquitin charged E2 
and the C-lobe is able to rotate to bind ubiquitin. Ubiquitin is then transferred from the 
catalytic cysteine of the E2 to the catalytic cysteine of the C-lobe, in a transthioesterification 
reaction. Once ubiquitin has been transferred, the E2 enzyme is then released. The 
substrate binds to the E3 via the substrate binding domain, and the C-lobe rotates so that 
the catalytic cysteine of the E3 and the lysine residue of the substrate are bought into close 
proximity for ligation. Adapted from Buetow & Huang (2016).  
 
 
The catalytic cysteine of HECT E3 ligases is vital for enzyme activity. HECT E3 ligases 
determine the chain type that is conjugated to the substrate, with different HECTs shown to 
synthesise different polyubiquitin chains. For example, E6AP forms K48 chains, UBE3C 
forms K48 and K29 chains, NEDD4 and ITCH form K63 chains and more recently AREL1 
(apoptosis-resistant E3 Ub protein ligase 1) was found to assemble K33-linked ubiquitin 
chains (Wang & Pickart. 2005; Wang, et al. 2006; Kim, et al. 2007; Scialpi, et al. 2008; 
Kristariyanto, et al. 2015). Ubiquitin chain specificity of HECTs is thought to be a function of 
the C-lobe of the HECT domain, and not determined by the cognate E2 (Kim & Huibregtse. 
2009). Indeed, analysis of chimeric and truncated HECTs, containing the N-terminus of 
yeast Rsp5 and the C-terminal lobes of other HECT E3 ligases showed different ubiquitin-
chain linkage specificity compared to that of wild-type Rsp5. Therefore, the C-lobe 
determines the chain type by the different orientations of the thioester-bound ubiquitin 
molecule imposed. The last few amino acids present in the C-terminal tail of HECTs may 
influence chain type specificity together with the determinants of the C-lobe. The last four 
residues of NEDD4 were replaced with the last three of E6AP, and interestingly, this hybrid 
HECT switched its activity from synthesising K63 to K48 (Maspero, et al. 2013). 
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Further to what determines chain specificity in HECTs, the mechanism by which the 
polyubiquitin chains are formed on the substrate is still under debate. The two predominant 
theories are the sequential addition of ubiquitin to the substrate forming a chain on the 
substrate, or the formation of the en-bloc chain on the catalytic cysteine of the HECT 
domain, which is then transferred to the substrate (Wang & Pickart. 2005). Early work 
suggested that both mechanisms were plausible, indicating that E6AP builds up K48 linked 
chains on the HECT cysteine, whilst UBE3C generated K48 and K29 chains as free entities 
(Verdecia, et al. 2003; Wang & Pickart. 2005; Wang, et al. 2006). However, more recent 
studies favour the sequential addition mechanism (Kim & Huibregtse. 2009; Kim, et al. 
2011; Maspero, et al. 2013). The NEDD4 ligase, WWP1, catalyses the formation of ubiquitin 
chains by sequential addition. In the first phase, chains are synthesised in a unidirectional 
manner and linked via K63, and in the second phase the chains are elongated in a 
multidirectional manner by the formation of K11 and K48 mixed and branched linkages 
(French, et al. 2017). This demonstrates the ability of HECT ligases to synthesise 
heterotypic ubiquitin chains.  
 
 
1.4.2. Regulation of HECT ligase activity 
Regulation of HECT ligases can either occur via regulation of the N-terminal domains, 
influencing localisation and substrate binding, and/or by the regulation of the HECT domain, 
preventing E2 binding and catalysis (Rotin & Kumar. 2009; Scheffner & Kumar. 2014). 
 
Targeting of HECT ligase activity by N-terminal domains 
While the HECT domain is responsible for the enzymatic activity of the protein, the N-
terminus of the ligase contains domains that target the activity of the ligase, either directly 
or via adapters, to specific complexes or organelles. For example, WW domains are found 
in a number of NEDD4 family members and mediate interaction with PPXY motifs that have 
a high affinity for WW domains (Chen & Sudol. 1995). The adapter protein, N4WBP5 (also 
known as NDFIP2), regulates NEDD4 ligase activity through this ability to bind the NEDD4 
WW domain via two PPXY motifs. NDFIP2 localises to intracellular membranes where it 
acts as an adapter for NEDD4-like proteins and regulates the sorting and trafficking of 
ubiquitinated cargoes (Harvey, et al. 2002; Shearwin-Whyatt, et al. 2004). Similarly, the PY 
motifs in α- and β- arrestins have been shown to interact with the WW domains of NEDD4 
mediating recruitment of the ligase to 7 transmembrane receptors such as, β2 adrenergic 
receptor. This recruitment allows for the ubiquitination and subsequent lysosomal trafficking 
or degradation of the receptor (Shea, et al. 2012; Han, et al. 2013). Adapter proteins also 
can bind the C2 domain of NEDD4 family proteins. For example, the C2 domain of NEDD4 
interacts with annexin XIIIb resulting in localisation to apical membranes (Plant, et al. 2000). 
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While, the SH2 domain of GRB10 associates with the C2 domain of NEDD4, promoting 
IGF1R (insulin-like growth factor 1 receptor) ubiquitin-mediated internalisation, and 
degradation (Huang & Szebenyi. 2010).  
Interestingly, adapter proteins can also mediate inhibition of the ligase. For example, the 
adaptor protein 14-3-3 is recruited to NEDD4-2 upon phosphorylation by AKT1 and SGK1 
(serum and glucocorticoid regulated kinase 1) kinases, which are activated by hormones 
such as insulin and aldosterone. The binding of 14-3-3 prevents dephosphorylation of 
NEDD4-2 rendering it unable to ubiquitinate the epithelial sodium channel ENaC, needed 
for transepithelial Na+ transport. 14-3-3 functions to maintain NEDD4-2 inhibition preventing 
degradation of ENaC, allowing Na+ absorption to increase (Debonneville, et al. 2001; 
Ichimura, et al. 2005; Bhalla, et al. 2005; Lee, et al. 2007). This inhibition occurs by the 
disruption of the interaction between the WW domains of NEDD4-2 and the PY motif of 
ENaC (Nagaki, et al. 2006). In addition, the adapter protein N4BP1 binds the WW domains 
of ITCH to inhibit its activity through a poorly understood domain that lacks a PPXY motif. 
This interaction interferes with substrate binding including p73 and c-JUN (Oberst, et al. 
2007). 
 
Regulation of HECT domain 
The regulation the HECT domain, controlling catalysis and E2 binding, is another way to 
regulate HECT ligase activity. For example, the HECT domain of SMURF2 is suboptimal 
for binding of its E2, UBCH7. In TGFβ signalling, the inhibitory protein SMAD7 recruits 
SMURF2 to the TGFβ receptor complex to facilitate receptor degradation. The N-terminus 
of SMAD7 stimulates SMURF2 activity by recruiting UBCH7 to the HECT domain (Ogunjimi, 
et al. 2005). Regulation SMURF2 exhibits intramolecular regulation, whereby interaction 
between the C2 and HECT domains inhibits SMURF2 activity, and the HECT binding 
domain of SMAD7 antagonises this inhibitory interaction. This interaction between C2 and 
HECT domains autoinhibits the degradation of SMURF2 and its substrates because the 
catalytic cysteine of SMURF2 is not accessible to UBCH7 (Wiesner, et al. 2007). This 
intramolecular interaction is not uncommon among the NEDD4 subfamily of HECTs. Small 
PY-containing membrane proteins, NDFIP1 and NDFIP2 also bind to release ITCH from its 
autoinhibitory intramolecular interaction, exposing the HECT domain and allowing 
ubiquitination of JUN proteins (Mund, & Pelham. 2009). The Wnt signalling protein 
dishevelled contains a PPXY, WW binding motif, which is able to bind WWP2 and relieve 
the autoinhibition by C2-HECT, WW-HECT interactions. This is dependent on DVL2 
(Dishevelled) polymerisation resulting in WWP2 activation in Wnt signalosomes (Mund, et 
al. 2015). In NEDD4L, the C2 domain binds Ca2+ and inositol 1,4,5-trisphosphate (IP3), 
using the same autoinhibitory interface that is used to bind to the HECT domain. The 
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concentration of Ca2+ therefore acts as a switch to modulate NEDD4L activation, as well as 
its intracellular localisation (Wang, et al. 2010; Escobedo, et al. 2014).  
 
Phosphorylation is also important in disrupting this autoinhibitory mechanism of some HECT 
ligases. For instance, JNK1 mediates phosphorylation of two serine residues and a tyrosine 
residue (S199, S232, and T222) in ITCH to disrupt the inhibitory intramolecular interaction 
between the WW domain and the HECT domain, enhancing catalytic activity (Gallagher, et 
al. 2006). Phosphorylation is also important in relieving the autoinhibitory interaction of the 
C2 and HECT domains of NEDD4. The receptor tyrosine kinase fibroblast growth factor 
receptor 1 (FGFR1) is degraded by NEDD4. Activation of FGFR1 leads to activated c-SRC 
mediated phosphorylation of NEDD4 enhancing its activity (Persaud, et al. 2014). Recently, 
it was found that peptide linkers between the WW domains found in NEDD4 family proteins, 
such as WWP1, WWP2, and ITCH are important for their catalytic regulation. These linkers 
were found to function to lock the ligase in an inactive conformation and that tyrosine 
phosphorylation was found to relieve this autoinhibition (Chen, et al. 2017).  
 
More recently the oligomerisation state of the HECT domain has emerged as a mechanism 
to regulate enzyme activity by locking the HECT domain in a closed conformation (Sander, 
et al. 2017; Attali, et al. 2017). In the case of HUWE1, the HECT domain forms an 
autoinhibitory dimer which locks the C-Lobe of HUWE1 in a position that prevents catalysis. 
This homo-dimerised form of HUWE1 is stabilised by the binding of the tumour suppressor, 
p14ARF. This provides a mechanistic explanation for the inhibition of HUWE1 activity in 
cancer (Sander, et al. 2017). Both Rsp5 and its mammalian orthologue NEDD4 also 
oligomerise into ligase-inactive trimers and hexamers, and in contrast to HUWE1 these 
mechanisms are ubiquitin-dependent. Here, ubiquitination of the a-1 helix in Rsp5 HECT 
domain resulted in trimerisation by the binding of the Ub-a-1 helix to the UBD in the HECT 
domain, and inhibition of HECT ligase activity (Attali, et al. 2017). Together these studies 
highlight that the regulation of HECT ligase activity is complex and suggest that most likely, 




1.5. Ubiquitin chains 
Substrates can be mono-ubiquitinated or polyubiquitinated. Mono-ubiquitination can take 
two forms, this can be either on one lysine residue (mono-ubiquitination) or on multiple 
lysine residues (multi-mono-ubiquitination) (Komander. 2009) (Figure 1.8). Mono-
ubiquitination has been associated with proteasomal degradation and also proteasome-
independent cellular functions, an example of which is intracellular protein movement. It 
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was found that multi-mono-ubiquitination of receptor tyrosine kinases (RTKs), led to the 
internalisation and degradation of the cell surface receptors in the lysosome, or recycling to 
the cell surface (Haglund, et al. 2003). DNA damage has been shown to induce mono-
ubiquitination of histone H2A close to DNA lesions (Bergink, et al. 2006). Furthermore, in 
some cases mono-ubiquitination has also been implicated in acting as a crucial priming 
event for the assembly of polyubiquitin chains (Rodrgio-Brenni & Morgan. 2007).  
 
Polyubiquitin chains are formed by the sequential addition of ubiquitin to the substrate 
(Mastrandrea, et al. 1999; Kim & Huibregtse. 2009). The polyubiquitin chains formed can 
be homotypic, exclusively of one chain type, or heterotypic, of different chain types (Figure 
1.8). Polyubiquitin chains are divided into typical ubiquitin chains and atypical ubiquitin 
chains (Kulathu & Komander. 2012). Ubiquitination is a diverse modification with different 
polyubiquitin linkages conferring different functions within a cell. This is because the 
different types of linkages have different 3-dimensional structures, which therefore affects 
the recognition by different ubiquitin-binding proteins (Tenno, et al. 2004; Komander, et al. 
2009). Furthermore, the conformations that these different ubiquitin linkages take, affects 
the recognition and activity of interacting proteins and downstream effectors. Interestingly, 
K63, and Met-1 linkages have been shown by single-molecule fluorescence resonance 
energy transfer to exist in an equilibrium between extended “open” conformations and 
compact “closed” conformations (Ye, et al. 2012). The fact that the conformation of ubiquitin 
chains is dynamic may suggest an additional level of regulation. 














































Figure 1.8. Diversity of ubiquitin linkages. Ubiquitin is a diverse modification, with 
different linkages conferring different functions by their different structures. Ubiquitin can be 
added to substrates as monoubiquitin, multi-monoubiquitin, and polyubiquitin. 
Polyubiquitination can occur via 7 lysine residues (K6, 11, 27, 29, 33, 48, and 63) or via the 
N-terminal residue M1. Heterotypic polyubiquitination occurs as either mixed or branched 
chains of different linkages. Known branched ubiquitin chains include K11/K48 and K48/K63 
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1.5.1. Canonical ubiquitin chains 
Typical ubiquitin chains are considered to be K48 and K63-linked chains, which are the 
most characterised and abundant type of ubiquitin linkage (Xu, et al. 2009; Dammer, et al. 
2011; Kulathu & Komander. 2012) (Table 1.2). K48-linked ubiquitin chains were first 
discovered as a polyubiquitin chain that formed on proteasomal substrates required for 
degradation (Chau, et al. 1989). Later work showed that mutation of K48 on ubiquitin 
prevented chain assembly, inhibiting proteolysis and cell cycle progression in 
Saccharomyces cerevisiae (Finley, et al. 1994). K48 chains form tetramers that act as the 
recognition motif for the 26S proteasome, responsible for the ATP-dependent degradation 
of target substrates (Pickart. 1997; Thrower, et al. 2000). DUBs present on the proteasome 
(RPN11, UCH37, and USP14), cleave ubiquitin from the substrate, leaving the ubiquitin to 
be recycled (Komander, et al. 2009; Lee, et al. 2011).  
 
K63 linkages have been implicated in DNA repair, where mutation of K63 resulted in defects 
in DNA repair (Spence, et al. 1995; Hoffman & Pickart. 1999). K63 has been shown to have 
a more open extended structure compared to K48, with more of ubiquitin surface exposed 
(Figure 1.8) (Sayto, et al. 2008; Weeks, et al. 2009). Furthermore, in contrast to K48, it is 
widely accepted that K63 linkages do not target substrates to the proteasome (Komander. 
2009; Nathan, et al. 2013). Whilst, K63 linked ubiquitin chains have been implicated in 
signal transduction rather than degradation, with roles in autophagy (Ferreira, et al. 2015), 
endocytosis (McCullough, et al. 2004), and Wnt signalling (Tran, et al. 2008). In NFκB 
signalling, IκB kinase (IKK) is activated by the E3 ligase, TRAF6, through the addition K63-
linked polyubiquitin chains (Deng, et al. 2000).  CYLD, a USP family DUB family member, 
functions as a tumour suppressor. CYLD antagonises NF-κB signalling by cleaving K63 
linked ubiquitin chains, therefore preventing interactions between the signalling 
components, further demonstrating the degradation-independent role of K63 chains in 
signal transduction (Kovalenko, et al. 2003).  
 
Table 1.2. Abundance of polyubiquitin chains in Yeast and Mammalian cells. 
Abundance generated from AQUA (absolute quantification)-mass spectrometry in Yeast 







Chain type Abundance in Yeast Abundance in Mammalian cells (HEK293) 
K6 11% ≤0.5% 
K11 28% 2% 
K27 9% ≤0.5% 
K29 3% 8% 
K33 3% ≤0.5% 
K48 29% 52% 
K63 16% 38% 
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1.5.2. Atypical ubiquitin chains 
Atypical ubiquitin chains are linkages through K6, K11, K27, K29, K33, or M1, which by 
comparison to K48 and K63 are not as well studied (Kulathu & Komander. 2012). These 
chain types tend to be less abundant in yeast and mammalian cells, with the exception of 
K11 in yeast (Xu, et al. 2009; Dammer, et al. 2011) (Table 1.2).   
 
K6 linked ubiquitin chains have been shown to be produced by a heterodimeric RING E3 
ligase complex consisting of the breast cancer-susceptibility protein BRCA1 and BARD1 
(Nishikawa, et al. 2004). Furthermore, BRCA1 is involved in the DNA damage response 
indicating a potential role for K6. Whilst the more abundant K11, has been reported to be 
involved in proteasomal degradation and endoplasmic reticulum-associated degradation 
(ERAD) (Xu, et al. 2009). K11 have most notably been shown to have a role in mammalian 
cell cycle regulation. The anaphase promoting complex/ cyclosome (APC/C), conjugates 
K11 chains to cell cycle substrates such as Cyclin B1, which targets it for degradation (Jin, 
et al. 2008). Since, it has been demonstrated that branched chains of K11 with K48 and/or 
K63 are synthesised by the ACP/C and UBE2S, leading to enhanced proteasomal 
degradation of cell cycle substrates (Figure 1.8) (Meyer & Rape. 2014). Interestingly, it has 
been demonstrated that pure homotypic K11-linked ubiquitin chains do not bind strongly to 
the proteasome and instead heterotypic K11/K48-linked ubiquitin chains bind strongly to the 
proteasome and stimulate degradation of Cyclin B1 (Grice, et al. 2015).  In addition, 
quantitative mass spectrometry revealed that mixed chains of K11 and K63 have been 
shown to be required for efficient internalisation of MHC class 1 (Boname, et al. 2010). 
Nevertheless, in contrast to homotypic chains, the composition, function and regulation of 
heterotypic polyubiquitin chains are poorly understood.  
 
K27 accounts for around 10% of all ubiquitin chains in yeast (Xu, et al. 2009), however only 
accounts for ≤0.5% in HEK293 mammalian cells (Dammer, et al. 2011), potentially 
indicating less of a role in mammalian cells, compared to yeast. K27 has been shown to 
function in mitophagy, where it is conjugated on VDAC1 (voltage-dependent anion channel 
1) by PARKIN, functioning in the regulation of a mitochondrial trafficking protein, MIRO 
(Geisler, et al. 2010; Birsa, et al. 2014). More recently mitochondrial damage has been 
shown to induce PARKIN to assemble K6, K11, and K63 chains on mitochondria. The 
deubiquitinase USP30 was shown to have a strong preference for cleaving K6 and K11, 
counteracting PARKIN and preventing apoptotic cell death (Cunningham, et al. 2015; Liang, 
et al. 2015). This suggests that although K27 has been implicated in the regulation of 
mitochondria, it is not the only chain type involved, and others may be involved. 
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Of the atypical ubiquitin chains, K29 is the most abundant in resting mammalian cells 
(Dammer, et al. 2011). The HECT ligase, ITCH, has been shown to assemble K29 linked 
chains on Deltex, a regulator of Notch signalling, leading to its lysosomal degradation 
(Chastagner, et al. 2006). Furthermore, K29 has been shown to exist as heterotypic 
polyubiquitin chains, mainly containing K48 linkages that are produced by the HECT E3 
ligase, UBE3C (You & Pickart. 2001). Interestingly, K29 linked chains have been implicated 
in the ubiquitin fusion degradation (UFD) pathway, which was first discovered to involve a 
HECT E3 ligase called Ufd5 found in S. cerevisiae (Johnson, et al. 1995). The UFD pathway 
is a proteolytic system that is conserved from yeast to mammals. The system involves an 
uncleavable ubiquitin moiety fused to the N-terminus of a protein during translation, which 
serves to function as a degradation signal. This contrasts with the canonical pathway or the 
N-end rule pathway where ubiquitin is added post-translationally onto Lys residues (Chau, 
et al. 1989) or onto the first N-terminal residue (i.e. Arg, Leu, Phe, Asp and Lys) (Bachmair, 
et al. 1986). 
 
This ubiquitin fusion protein is formed from the translation of a ubiquitin fusion gene. Only 
a handful of proteins have been found to have a fused ubiquitin moiety at their N-terminus 
including ribosomal proteins L40 and S27a in yeast (Ozkaynak, et al. 1987; Redman 
& Rechsteiner. 1989) and ribosomal protein P1, and interestingly actin in 
chlorarachinophyte algae (Archibald, et al. 2003).  This fused ubiquitin acts as a platform 
for further K29 or K48 ubiquitin chain conjugation, resulting in degradation of the substrate 
(Johnson, et al. 1995). Mutant ubiquitin (UBB+1), which was first discovered in the brain of 
patients with Alzheimer’s Disease (van Leeuwen, et al. 1998), is the only mammalian UFD 
substrate identified to date. A numbered of studies have tried to identify the E3 ligase and 
DUBs responsible for the regulation of UFD substrates. The HECT ligase TRIP12 was 
shown to ubiquitinate UBB+1 (Park, et al. 2009), while other studies have confirmed this 
suggesting that TRIP12 is a UFD ligase (Poulsen, et al. 2012). Interestingly, Hecd1 has 
also been implicated as UFD E3 ligase in a Caenorhabditis elegans genetic screen using 
the artificial UFD substrate UbG76V-GFP as readout, suggesting that the HECT family is 
the main ligase family implicated in the UFD pathway (Segref, et al. 2014).  
 
Ubiquitin chains are also formed via the C-terminal Gly76 of one ubiquitin and the N-terminal 
Met1 of another ubiquitin, forming a ‘head-to-tail’ linear chain. This chain type is made by 
LUBAC (linear ubiquitin chain assembly complex), a complex consisting of two RING finger 
proteins, HOIL-1L and HOIP, and was show to target substrates to the proteasome 
(Kirisako, et al. 2006). These Met1-linked linear ubiquitin have been shown to be involved 
in the canonical NF-κB pathway. LUBAC activates the canonical NF-κB pathway by binding 
to NEMO and forming linear polyubiquitin chains (Tokunaga, et al. 2009). Recently the 
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deubiquitinase OTULIN has been shown to act antagonistically to LUBAC, having specificity 
for Met1 linear chains, regulating NF-κB pathway signaling (Keusekotten, et al. 2013). 
Together this highlights the increasing knowledge into the study of atypical ubiquitin chains, 
and the complexity they exhibit.  Finally, very little is known about K33, some members of 
the AMP-activated protein kinases (AMPK)-related family of protein kinases are 
ubiquitinated with K29 and/or K33 linked ubiquitin chains (Al-Hakim, et al. 2008). 
Interestingly ubiquitination of these kinases resulted in blocking their kinase activation (Al-




1.6. E3 ligases and cell cycle regulation 
1.6.1 APC/C and SCF 
Ubiquitination is a key process in cell cycle regulation where ubiquitination and 
deubiquitination of substrates ensures unidirectionality (Hershko. 1997). Many DUBs have 
been implicated in cell cycle regulation, such as CYLD, which regulates the mitotic spindle, 
and USP15, which is required for restoring protein levels of REI silencing transcription factor 
(REST) at mitotic exit (Faronato, et al. 2013; Li, et al. 2014; Darling, et al. 2017). Equally, 
many E3 ligases have been demonstrated to regulate the cell cycle (Teixeira & Reed. 2013). 
The two most characterised E3 ligases in cell cycle regulation are the multi-subunit RING 
E3 ligases; the APC/C and SCF (Figure 1.9). These E3 ligase complexes are involved at 
key stages of cell division. For example, the APC/C controls the progression through mitosis 
and the subsequent G1 phase (Pines. 2011), whereas the SCF regulates the G1/S and 
G2/M transitions (Peters. 1998).  
 
The APC/C complex regulates the metaphase to anaphase transition through the ubiquitin-
dependent degradation of Cyclin A, Cyclin B, securin, and the mitotic Aurora kinase (Pines. 
2011). The APC/C E3 ligase, is a multiprotein complex which includes the APC11 RING 
finger subunit that interacts with the E2 enzyme, UBE2S (Acquaviva & Pines. 2006). Recent 
studies have defined the biochemical properties of APC/C and in particular its activity for 
the synthesis of K11 ubiquitin chains and branched K11 and K48 ubiquitin chains (Jin, et 
al. 2008; Meyer & Rape. 2014). From prophase to metaphase, the APC/C binds CDC20, 
while during anaphase it is tightly associated with CDH1 and remains bound until the next 
round of mitosis is initiated at prophase (Matsusaka, et al. 2014; Sivakumar & Gorbsky. 
2015). Depending on whether it is bound by different regulatory proteins, CDC20 or CDH1, 
the APC/C regulates different substrates and therefore exerts different functions during cell 
cycle progression (Pfleger, et al. 2001). The function of the APC/C is tightly regulated by 
phosphorylation as well as autoubiquitination of its E2 enzyme (Kraft, et al. 2003; Rape & 
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Kirschner 2004). Furthermore, as discussed previously, the cell cycle checkpoint, SAC, 
functions to inhibit the activation of the APC/C during metaphase, preventing the separation 
of sister chromatids until all of the chromosomes are attached to the mitotic spindle 
(Hagting, et al. 2002; Nilsson, et al. 2008).  
 
In contrast to the APC/C, the SCFSKP2 ligase complex controls entry into S phase and 
mitosis, by the degradation of G1 and S phase Cyclins, Cdk inhibitors and cell cycle kinases 
(Peters. 1998). This complex is composed of three primary subunits including SKP1 (S-
phase kinase associated 1), CUL1 (also known as Cdc53), and RBX1/ROC1 (also known 
as ROC1 and HRT1) (Kipreos, et al. 1996; Teixeira & Reed. 2013). The SCF complex relies 
on the F-box, which interacts with SKP1, for its substrate specificity (Cardozo & Pangano. 
2004). The SCF regulates the G1/S and G2/M transitions by the degradation of substrates 
such as Cyclin D, Cyclin E, the Cyclin/CDK inhibitor p27, CDC6 and the mitotic kinase 
WEE1 (Peters. 1998). The SCFSKP2 mediates substrate degradation by K48 linked 
polyubiquitination of its substrates, which target them for the proteasome (Petroski & 
Deshaies. 2005). The focus of ubiquitin in the cell cycle has primarily been on the function 
of RING E3 ligases, however recent discoveries are starting to shed light on the role that 
the smaller family of HECT E3 ligases has in the cell cycle.  
 
 
Figure 1.9.  Ubiquitination in the cell cycle. Examples of ubiquitination during the cell 
cycle. APC/C and SCF mediated degradation of cell cycle specific substrates. The 
degradation of the substrates provides directionality ensuring that the cell cycle progresses 
in one direction towards cell division. The CDKs with their partner Cyclin are active during 
specific stages of the cell cycle. Own figure.  
 
 
Chapter 1: Introduction 
 
 27 
1.6.2 HECT ligases and the cell cycle 
Yeast HECT ligases and cell cycle regulation 
The HECT domain is highly conserved, and has been identified in 879 sequences from 101 
species, ranging from yeast to humans, according to the Sanger Protein Domain Database 
(Rotin & Kumar. 2009). The fungal HECT family is small and very limited in N-terminal 
domain diversification, compared to mammalian HECTs, limiting the diversity of the ligases 
(Grau-Bove, et al. 2013). The HECT family of E3 ligases contains 5 members in yeast 
(Saccharomyces cerevisiae) (Li, et al. 2008). Furthermore, yeast HECT ligases have been 
implicated in cell cycle functions. In S. cerevisiae, the HECT E3 ligase Temperature-
dependent Organisation in Mitotic nucleus (Tom1) has been implicated in cell cycle 
progression. In a tom1 mutant, at high temperatures, cells were arrested at G2/M, with a 
dumbbell morphology, a single large nucleus, and short spindles, suggesting the Tom1 is 
required for mitosis and cell cycle exit (Utsugi, et al. 1999).  More recently Tom1 was shown 
to target Cdc6, an AAA+-ATPase involved in the establishment of pre-replicative complexes 
at replication origins through the loading of the Mcm2-7 replicative helicase complex at 
replication during G1 phase of the cell cycle (Kim. et al. 2012b). The SCF protein adaptor 
Dia2 also play key roles in this process, although early evidence suggesting that Tom1 and 
Dia2 contribute to Cdc6 ubiquitination and degradation during the G1 phase of the cell cycle. 
Deletion of Dia2 partially suppressed the temperature sensitive phenotype of tom1 mutants, 
suggesting that Tom1 and Dia2 act independently of SCFCdc4, the only other known E3 
ligase complex that regulates Cdc6 levels (Drury, et al. 1997; Kim. et al. 2012b). Tom1 also 
targets Dia2 for degradation by the UPS through a degradation/ NLS domain, however the 
significance of this regulation in the context of Cdc6 regulation during G1 remains to be 
established (Kim & Koepp. 2012a).  
 
In the fission yeast Schizosaccharomyces pombe, Pub1 and Pub2, two members of the 
Rsp5/ NEDD4 (mammalian homologue) family of HECT E3 ligases (Tamai & Shimoda. 
2002), have been shown to target the mitotic phosphatase Cdc25p for UPS-mediated 
degradation, allowing for the timely regulation of G2/M transition (Nefsky & Beach. 1996). 
Overexpression of the functionally similar Pub2p led to repression of cell division suggesting 
that although functionally similar, Pub1 and Pub2 exert distinct functions (Tamai & Shimoda. 
2002). A more recent study revealed that the serine-threonine phosphatase Flp1p in 
conjunction Pub1p/2p is responsible for the degradation of Cdc25p. Flp1p was shown to 
interact in vivo with Pub2p, a Pub1p-redundant ligase, suggesting that the phosphatase 
may regulate Pub1p/2p’s function (Esteban, et al. 2008). Taken together, this demonstrates 
the importance of yeast HECT ligases in the yeast cell cycle.  
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Mammalian HECT ligases and cell cycle regulation  
The mammalian family of HECT E3 ligases is more diverse than in yeast with 28 members, 
10 of which have been shown to function in the cell cycle. The evolutionary acquisition of 
N-terminal domains, allowed for greater diversification of the HECT family of ligases in 
mammals (Grau-Bove, et al. 2013). The increase and diversification of mammalian HECTs 
in cell cycle regulation mirrors the increased complexity of the cell cycle in mammals. Having 
multiple HECTs involved in cell cycle regulation allows for increased regulation, and many 
in turn have been shown to be regulated themselves in a cell cycle dependent manner.  
Some of the HECT ligases have been implicated in multiple roles, such as in DNA damage 
signalling, p53 signalling, and the SAC. However, other ligases have only one known role 
in cell cycle progression, for example in centrosome architecture, or the regulation of Golgi 
dynamics during mitosis (Table 1.3).  Interestingly, the majority of HECT ligases function in 




Table 1.3. HECT E3 ligases in cell cycle regulation. The substrate specificity and 
function for each HECT E3 ligase implicated in cell cycle regulation. Where known the 
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Prevents DNA replication, 
G1/ S phase. 
 
DNA damage induced cell 
cycle arrest, G1/S and 
G2/M transitions. 
 
DNA damage induced cell 
cycle arrest, G1 phase. 
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arrest. 
 
DNA damage checkpoint? 
G1/S checkpoint. 
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Degradation of CDC6. 
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Yoon, et al. (2005). 
 
 
Herold, et al. (2008). 
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WEE1 S phase progression. Degradation of WEE1. Wei, et al. (2017). 
SMURF2 MAD2 SAC regulation, M phase. Preventing 
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Degradation of Cyclin 
D1 (no direct 
evidence). 
















Miyazaki, et al. (2003). 
 




Cell cycle regulation and 




inactive HECT domain. 
 
Brooks, et al. (2006); 
Brooks, et al. (2008).  




HUWE1, also known as MULE1, HECTH9, ARF-BP1, and UREB1, is the human homolog 
of yeast Tom1, and has been shown to have a conserved role in the cell cycle. Similar to 
the function in yeast for Tom1, HUWE1 polyubiquitinates and degrades CDC6, and is 
associated with release of CDC6 from chromatin, therefore preventing DNA replication 
(Hall, et al. 2007). Specifically, upon DNA damage in G1 or S phase, CDC6 is degraded by 
HUWE1 and p53 is stabilised, resulting in cell cycle arrest (Hall, et al. 2007). In addition, 
HUWE1 has been shown to directly regulate p53 stability (Chen, et al. 2005; Yoon, et al. 
2005). The ARF tumour suppressor was shown to inhibit ligase function and thus prevent 
ubiquitination and inactivation of p53, resulting in p53 stabilisation and cell growth 
suppression (Chen, et al. 2005). Furthermore, mutation of the HECT domain in HUWE1 
also stabilised p53, in colorectal cell lines, further demonstrating the role of HUWE1 
ubiquitination in p53 regulation (Yoon, et al. 2005). Loss of HUWE1 has also been shown 
to induce DNA damage-dependent cell cycle arrest, independent of CDC6 degradation 




HERC2 belongs to the large HERC subfamily of HECT E3 ligases, which are over 500kDa 
in size, and contains a HECT domain and more than one RLD (Sánchez-Tena, et al. 2016). 
HERC2 has been implicated in many functions in the cell cycle including the DNA damage 
response. HERC2 has been shown to interact with the breast cancer suppressor, breast 
cancer 1 (BRCA1), leading to its degradation. The HERC2-BRCA1 interaction peaks in S 
phase of the cell cycle but rapidly reduces during G2/M, when BRCA1 associates with 
BARDI, and is stabilised (Wu, et al. 2010). The HERC2-BRCA1 interaction can be disrupted 
by the tumour suppressor protein tumour suppressor candidate 4 (TUSC4), which physically 
interacts with BRCA1 to prevent degradation by HERC2, therefore stabilising it (Peng, et al. 
2015). The function of BRCA1 needs to be tightly regulated as it maintains genomic stability 
by DNA damage repair and cell cycle checkpoint activation in S phase and G2/M transitions 
(Venkitaraman. 2002; Deng. 2006). Further to this, in the presence of BRCA1, HERC2 
interacts with Claspin, a protein essential for G2/M checkpoint activation and replication fork 
stability, and MCM2 a component of the pre-replication complex. HERC2 was shown to 
facilitate MCM2 phosphorylation, regulating DNA replication progression and origin firing, 
however the mechanism for this is not certain (Izawa, et al. 2011).  
 
HERC2 has also been implicated in p53 activity and centrosome regulation highlighting its 
function as a multitasked cell cycle regulator. HERC2 has been shown to regulate the DNA 
damage checkpoint and DNA damage response, via ATR-CHK1 mediated signalling (Yuan, 
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et al. 2014), and facilitates formation of a complex with the RING E3 ligase RNF8 and 
UBC13, facilitating K63 polyubiquitination of γH2AX at sites of DNA damage (Bekker-
Jensen, et al. 2010). Furthermore, HERC2 facilitates the recruitment of repair factors such 
as 53BP1, RAP80 and BRCA1 (Bekker-Jensen, et al. 2010). HERC2 has been 
demonstrated as a cell growth regulator through regulation of p53 activity, independent of 
the proteasome. HERC2 increases p53 transcriptional activity by inducing p53 
oligomerisation, initiating p53 signalling (Cubillos-Rojas, et al. 2014), and therefore 
inhibition of the G1/S transition. In addition, HERC2 has been identified in centrosome 
regulation, where together with neuralised homologue NEURL4 it binds to the centrosome 
protein CP110, to maintain normal centrosome architecture. CP110 controls centrosome 
duplication during the cell cycle. HERC2 was shown to ubiquitinate NEURL4 with K48 
chains, however it was shown that NEURL4 was stabilised by HERC2 when present in a 
complex, suggesting that the ubiquitylation may serve another function than regulating 
protein levels (Al-Hakim, et al. 2012). Furthermore, the deubiquitinating enzyme USP33 
was shown to deubiquitinate CP110 during centrosome duplication (Li, et al. 2013a). USP33 
itself was shown to be polyubiquitinated and regulated by HERC2, followed by proteolysis 
mediated by p97 and its adapter protein UFD1-NLP4, further demonstrating its role in 
centrosome amplification (Chan, et al. 2014). 
 
EDD 
In addition to HUWE1, E3 identified by differential display (EDD;  hHYD in Drosophila; UBR5 
in Human) has also been shown to interact with the DNA topoisomerase II binding protein 
1 (TopBP1) (Honda, et al. 2002). EDD ubiquitinates TopBP1, which is then degraded by the 
proteasome. However, during DNA damage TopBP1 is ubiquitinated resulting in localisation 
with γH2AX at DNA breaks, suggesting a role in EDD coordination of TopBP1 in the DNA 
damage response (Honda, et al. 2002) and DNA damage checkpoint. Furthermore, EDD 
has been reported to modulate activity of the DNA damage checkpoint kinase, CHK2, 
resulting in phosphorylation of downstream targets leading to cell cycle arrest, DNA repair, 
and apoptosis (Henderson, et al. 2006). EDD depletion led to decreased CHK2 activation 
and altered expression of the key cell cycle regulators CDC25A/C and E2F1, resulting in 
polyploidy and cell death via mitotic catastrophe. Furthermore, EDD is necessary for the 
maintenance of G2/M arrest after double strand breaks, in addition to its roles in G1/S and 
S-phase DNA damage checkpoint activation (Munoz, et al. 2007). EDD has also been 
suggested to regulate G1/S transition by regulation of p53 (Ling & Lin. 2011). It is suggested 
that EDD regulates p53 by controlling or processing one or more microRNAs (miRNAs) 
involved in negative regulation of p53 (Smits. 2012). This is further supported by the study 
that demonstrated that EDD is a key component in gene silencing mediated by miRNAs 
(Su, et al. 2011). 
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EDD has also been implicated in M phase through formation of the DYRK2-EDVP complex. 
The EDVP complex (composed of EDD, DDB1, and VPRBP) is responsible for the 
phosphorylation-dependent ubiquitination of katanin p60, and this is implicated in mitotic 
progression (Maddika & Chen J. 2009). Whilst EDD together with microspherule protein 58 
(MSP58) have been shown to control cell cycle progression, depletion of EDD leads to an 
increase of MSP58 protein level. This indicates that EDD controls MSP58 turnover by the 
UPS. Knockdown of either MSP58 or EDD in human lung fibroblast cells affects the levels 
of Cyclin B, D, and E as well as cell cycle progression (Benavides, et al. 2013) strongly 
indicating that EDD plays key role in the cell cycle. Finally, EDD has been shown to function 
in the SAC. EDD depletion abrogated the accumulation of cells in G2/M in response to SAC 
activation caused by Nocodazole treatment. This led to reduced mitotic cell viability, and 
increased expression of CDC20. Furthermore, EDD was shown to physically interact with 
BUB3 and BUBR1 which are components of the SAC, indicating that EDD helps to maintain 
the SAC (Scialpi, et al. 2015). The DNA damage checkpoint and the SAC have been shown 
to be linked in an ATR/ATM dependent manner (Kim & Burke. 2008). Due to that fact that 
EDD had been shown to function in DNA damage and the SAC, this led the author to 
speculate that EDD may act as a caretaker of genomic integrity through its ability to regulate 
cell cycle arrest in metaphase, and in interphase, in response to cellular stress (Scialpi. et 
al. 2015). 
ITCH 
The NEDD4 family E3 ligase, ITCH, binds and degrades the p53 family proteins, p63 and 
p73, but not p53 itself. ITCH is involved in the MDM2-independent ubiquitination and 
degradation of p73, a transcription factor that is upregulated in response to DNA damage, 
inducing cell cycle arrest and apoptosis. During DNA damage ITCH is downregulated, 
resulting in an increase in p73, to allow cell cycle arrest or apoptosis (Rossi, et al. 2005). 
ITCH also ubiquitinates and degrades p63, important in regulating both cell cycle and 
apoptosis. In ITCH knockout keratinocytes, the levels of p63 were significantly increased, 
showing a role for ITCH in p63 turnover (Rossi, et al. 2006). PY motifs are located near to 
the sterile alpha motif (SAM) domains in p63 and p73, but not in p53, hence why ITCH can 
bind via its WW domains and facilitate ubiquitination and degradation of the transcription 
factors (Rossi, et al. 2005; Rossi, et al. 2006; Bellomaria, et al. 2012). In addition to control 
of p63 and p73, ITCH was found to associate with and regulate Ras association 
(RalGDS/AF-6) domain family member RASSF5, which is a non-enzymatic RAS effector 
super family protein, involved in cell division. ITCH interacts with the RASSF5 PPxY motif 
via its WW domains, to cause its polyubiquitination and degradation via the 26S 
proteasome. ITCH overexpression showed a strong inhibitory effect on RASSF5-mediated 
G1 phase arrest, and apoptosis, indicating that ITCH is a regulator of RASSF5, which 
controls cell cycle arrest (Suryaraja, et al. 2013). 




HECTD3 was found to be a regulator of Trio-associated repeat on actin (TARA), which was 
originally identified as a Trio-binding protein (Seipel, et al. 2001; Yu, et al. 2008). Trio is a 
Rho guanine nucleotide exchange factor that regulates actin cytoskeletal reorganization, 
cell motility and cell growth (Seipel, et al. 1999). It was found that TARA also binds TRF1, 
which plays a role in regulation of the mitotic spindle (Nakamura, et al. 2002). It was found 
that overexpression of HECTD3 promotes the degradation of TARA in vivo, and inhibition 
leads to TARA stability. The depletion of HECTD3 resulted in an increased number of cells 
with multipolar spindles, suggesting that HECTD3 facilitates mitotic progression, and 
spindle regulation by the degradation of TARA (Yu, et al. 2008). HECTD3 has more recently 
been shown to conjugate K63 ubiquitin chains in the context of cancer cell survival, where 
polyubiquitination of caspase 8 decreases its activation, and apoptotic signalling (Li, et al. 
2013). However, K63 has not been shown to be relevant in the context of HECTD3 and cell 
cycle regulation, especially as it has a degradative role, suggesting another chain type may 
be involved.  
 
SMURF1 
The NEDD4 subfamily E3 ligase, SMAD ubiquitination regulatory factor 1 (SMURF1), has 
been implicated in S phase progression by the degradation of WEE1 kinase (Wei, et al. 
2017). It was observed that silencing of SMURF1 resulted in S phase arrest, and that 
progression through S phase was dependent of the ubiquitin-dependent degradation of 
WEE1. Interestingly, WEE1 was shown to interact to SMURF1 through both the WW and 
HECT domains, not just the WW domains alone. However, the exact mechanism by which 
this occurs remains unknown (Wei, et al. 2017). 
 
SMURF2 
The NEDD4 subfamily E3 ligase SMURF2 has been shown to function in the spindle 
assembly checkpoint. The spindle assembly checkpoint (SAC) prevents the separation of 
sister chromatids until all of the chromosomes are attached to the mitotic spindle, by 
inhibiting the APC/C recognition of key substrates such a Cyclin B1 and securin required 
for anaphase (Nilsson, et al. 2008). Depletion of SMURF2 resulted in misaligned and 
lagging chromosomes, premature anaphase onset, and defective cytokinesis. SMURF2 
depletion led to degradation of MAD2, a component of the SAC, by the UPS. As a result, 
SMURF2-depleted cells have defective SAC, indicating that SMURF2 is a novel mitotic 
regulator. Interestingly, it has been suggested that SMURF2 mediates this effect via the 
synthesis of K63-linked ubiquitin chains, although biochemical evidence are lacking 
(Osmundson, et al. 2008) 




During mitosis, the Golgi apparatus needs to be divided between daughter cells, this 
process occurs by disassembly and reassembly of the Golgi. At the onset of mitosis, the 
Golgi is fragmented, dispersing the stacks, leading to vesiculation resulting in vesicles 
disturbed throughout the cytoplasm (Acharya, et al. 1995). These vesicles are then evenly 
disrupted between the two daughter cells during telophase. Post-mitotic Golgi reassembly 
is mediated by membrane fusion controlled by two ATPases associated with various cellular 
Activities (AAA) ATPases, N-ethylmaleimide-sensitive factor (NSF), and p97 (Rabouille, et 
al. 1998). It was shown that HACE1 is targeted to the Golgi membrane through interactions 
with Rab proteins, a GTPase that is involved in membrane trafficking (Mizuno-Yamasaki, et 
al. 2012). Therefore, the ubiquitin ligase activity of HACE1 is required post-mitotic Golgi 
membrane fusion. Knockdown of HACE1, or expression of a catalytic mutant resulted in 
impaired post-mitotic Golgi membrane fusion. Conversely the expression of Rab1 inactive 
mutant caused the dissociation of HACE1 from the Golgi membranes and Golgi 
fragmentation, indicating a role for ubiquitin in Golgi biogenesis during the cell cycle (Tang, 
et al. 2011). Finally, HACE1 has been characterised as being a critical tumour suppressor 
in multiple cancers such as Wilm’s Tumour, pancreatic, and gastric carcinomas to name a 
few. At the molecular level, HACE1 appears to modulate cell proliferation by Cyclin D1 
degradation, causing cycle arrest in G1. However, there is no evidence to suggest that 
Cyclin D1 is directly targeted by HACE1 (Zhang, et al. 2007). 
NEDL2 
NEDD4-like ubiquitin ligase 2 (NEDL2) was shown to enhance p73-dependent 
transcriptional activation, by increasing p73 stability. Expression of p73, a p53 family 
member is important in the regulation of cell growth and apoptosis, and its expression is 
maintained at low levels in mammalian cells. NEDL2 binds p73 PY motifs, and is 
ubiquitinated and stabilized, reducing the degradation rate (Miyazaki, et al. 2003). NEDL2 
has been shown to be a substrate of APC/C-CDH1 complex as cells exit mitosis, regulating 
the metaphase to anaphase transition. CDH1 recognises the NEDL2 destruction box 
(R740GSL743) and targets it for degradation during mitotic exit. NEDL2 was shown to 
associate with the mitotic spindle, having a protein level maximum in mitosis, indicating it 
has an essential function in mitosis. This was supported by NEDL2 depletion which led to 
prolonged metaphase, and when overexpressed caused lagging chromosomes (Lu, et al. 
2013). 
G2E3 
G2E3, is a dual function E3 ligase, containing both a HECT domain and three PHD/RING 
domains, catalyses the conjugation of K48 polyubiquitin chains. Interestingly, the HECT 
domain of G2E3 is reported to be catalytically inactive (Brooks, et al. 2008). G2E3 was 
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shown to localise to the DNA in a DNA damage response dependent manner, and was 
reported to contain a nucleolar localisation signal (NLS) in its amino terminus and a nuclear 
export domain within the HECT domain (Brooks, et al. 2006). The nuclear export domain 
was shown to be regulated by another region of the HECT domain that has been shown to 
suppress the function of the NES, an NES inhibitor (Brooks, et al. 2006). This function of 
nuclear export within the HECT domain has not been previously reported and is atypical in 
HECT ligases. However, the cell cycle specific expression and its regulated nuclear 




Figure 1.10.  HECT ligases in cell cycle regulation. Summary of HECT ligases that have 
been characterised in cell cycle related functions. Where known the ubiquitin chain type has 
been included. Own figure.  
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1.6.3. Ubiquitin chain types and HECT function in cell cycle regulation 
The majority of the HECT E3 ligases involved in cell cycle regulation appear to mediate 
protein degradation by the UPS via K48-linked ubiquitin chains (Al-Hakim, et al. 2012). K63 
chains have also been shown to function in the cell cycle although in this case this ubiquitin 
signal would prevent degradation of MAD2 (Osmundson, et al. 2008). However, for the 
majority of the HECT E3 ligases shown to regulate the cell cycle, the chain type has not 
been defined. Recent work by the Rape lab has provided exciting insights into the role and 
function of branched/mixed chains in the cell cycle (see section 1.5.2) (Meyer, et al. 2014) 
and therefore identifying other linkages involved will improve our understanding on the role 




1.7. HECTD1 domain containing 1 (HECTD1) 
Preliminary data from the lab show that HECTD1 synthesises K29 and K48-linked ubiquitin 
chains. In addition, immunofluorescence studies suggested that HECTD1 might localise to 
the mitotic spindle, opening up the exciting possibility that a novel ubiquitin chain type might 
have a role in the cell cycle.  HECTD1 is located on chromosome 14 (14q2) and encodes a 
HECT domain containing E3 ubiquitin ligase (Zohn, et al. 2007). Human HECTD1 consists 
of 2610 amino acid residues, containing an ankyrin repeat domain, a central MIB/HERC2 







Figure 1.11. Annotated domains of HECTD1. HECTD1 contains an ankyrin repeat 
domain, Sad1/UNC domain, HERC domain and the HECT domain which contains a 
catalytic cysteine (shown), which is required for HECTD1 E3 ligase functionality. Adapted 





The C-terminal HECT domain of HECTD1 contains a conserved catalytic cysteine 
(Cys2579) that is required for ubiquitin conjugation to the substrate (Huibregtse, et al. 1995; 
Sarkar, et al. 2012). However, the function of the other domains of HECTD1 are less 
understood. The ankyrin repeat domain is a very common amino acid motif that has been 
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identified as a scaffold for protein-protein interactions (Mosavi, et al. 2004). Interestingly, 
the Sad1/UNC domain can be found in proteins that reside in the inner nuclear envelope 
forming a molecular bridge in the nuclear envelope despite HECTD1 being expressed 
throughout the cell, and not exclusively found at the nuclear envelope (own findings) (Zhou, 
et al. 2012). Finally, the MIB/HERC2 domain is not well characterised, and is so called as it 
is present in Mind bomb-2 (MIB2) and HECT- and RCC1-like domains 2 (HERC2) E3 ligase, 
suggesting that this domain is involved in protein interaction with HERC2, or has 
interactions similar to HERC2 (Stempin, et al. 2011; Cubillos-Rojas, et al. 2014).   
 
In mammals, HECTD1 has diverse functions within the cell, from the cytosol to the nucleus, 
as well as being important for development (Zohn, et al. 2007; Tran, et al. 2013; Li, et al. 
2013b; Sarkar, et al. 2014; Li, et al. 2015). HECTD1 was first shown to be involved in the 
process that leads to the closure of the dorsal neural tube. Hectd1 mutant mouse embryos 
display exencephaly, which is caused by the failure of the anterior neural tube to close 
completely during embryonic development (Zohn, et al. 2007). Investigation into the 
molecular basis of the abnormal behaviour of Hectd1 mutant cranial mesenchyme revealed 
heat shock protein 90 (HSP90) as one of HECTD1’s substrates (Sarkar, et al. 2012). HSP90 
is a chaperone protein, which is vital for maintaining the stability of its client proteins, such 
as the oncogenic tyrosine kinase, v-Src (Tsutsumi & Neckers. 2007). It was suggested that 
HECTD1-dependent K63 ubiquitination of HSP90 influences its intracellular localisation and 
negatively regulates its secretion, leading to the migration of the cranial mesenchyme and 
therefore the closure of the dorsal neural tube (Sarkar, et al. 2012).  
HECTD1 has also been implicated as a negative regulator in the Wnt signalling pathway, 
therefore playing a role in cell fate and cell homeostasis (Tran, et al. 2013). HECTD1 
associates with the OTU family DUB, TRABID, to modulate the K63 polyubiquitination of 
Adenomatous Polyposis Coli (APC) (Tran, et al. 2008; Tran, et al. 2013) as well as cell 
migration, where it functions in the regulation of the focal adhesion (FA) sites of cells (Li, et 
al. 2013b).  Recently, HECTD1 has also been implicated in the regulation of IQGAP1, a 
scaffold protein, regulating cell migration and the formation of FA sites, further 
demonstrating the role HECTD1 has in cell migration (Shen, et al. 2017).  
 
Finally, HECTD1 was shown to be involved in transcriptional activation, where, during 
interphase of human breast cancer cells, upon activation with oestrogen, HECTD1 recruits 
transcriptional coactivators by removing the corepressor, RIP40 (Li, et al. 2015). Condensin 
I and condensin II subunits, which play nonredundant differing roles in organising mitotic 
chromosomes, were found to be strongly recruited to oestrogen receptor α (ER-α)-bound 
functionally active enhancers (Green, et al. 2012; Li, et al. 2015). It was found that the 
condensins positively regulate ligand-dependent enhancer activation by recruiting 
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HECTD1. The degradation of RIP40 by the recruited HECTD1 allows for eRNA 
transcription, formation of enhancer:promoter looping, and therefore the activation of the 
coding gene (Li, et al. 2015).  
 
Biochemical data for HECTD1 are still lacking for these studies and although K63 chains 
have been suggested in previous functions of HECTD1, the evidence for HECTD1 
synthesising K63 remain weak. In these experiments, K63 has only been implicated by 
immunoprecipitation assays and an anti-K63 antibody in cell lysates (Sarkar, et al. 2012; 
Tran, et al. 2013). Interestingly, data from our lab support that, at least in vitro, HECTD1 
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1.8. Aims and objectives  
The HECT ligase HECTD1, has been shown to synthesise atypical ubiquitin chains linked 
via K29 and K48 (Licchesi JDF, unpublished data). Previous observations in our lab have 
suggested that HECTD1 might localise to the mitotic spindle. Therefore, the overall aim of 
this thesis was to determine whether HECTD1 regulates the cell cycle and to implicate 
heterotypic K29 and K48 for the first time in mitosis. The key objectives of this thesis were 
to: 
 
1. Determine the effect of transient depletion and knock out of HECTD1 in mammalian 
cells (HEK293ET, HEK293T, and HeLa) using cell proliferation and cell cycle 
assays. This was achieved using siRNA knockdown, CRISPR/Cas9 cells, rescue 
assays, cell synchronisation and protein densitometry of western blots. (Chapter1) 
 
2. Determine whether the effect of HECTD1 depletion on cell proliferation is through 
an effect of the cell cycle. This was explored by flow cytometry, immunofluorescence 
and confocal microscopy, time-lapse microscopy, and rescue assays using WT and 
catalytically mutant mHectd1 constructs. (Chapter 2) 
 
3. Further define the cell cycle phenotype associated with HECTD1 depletion using 
pHistone H3 and Cyclin B1 as established molecular markers of mitosis. This was 
achieved through cell synchronisation, immunofluorescence and confocal 
microscopy, as well as western blotting. In this chapter, it was also addressed 
whether the ubiquitin chains synthesised by HECTD1 are found in the cell cycle, in 
particular during mitosis. To this end, pull-down assays with a ubiquitin binding 
domain specific to K29 aimed to demonstrate, for the first time, the presence of 
these chains in mitosis. (Chapter 3) 
 
4. Examine the evidence that HECTD1 might be contributing to cancer development. 
This was determined by investigating HECTD1 expression in lung cancer cell lines, 
analysis of mutation and expression status from available databases including 
OncomineTM and CBioPortal. In addition, the effect of overexpression and 
knockdown of HECTD1 on glioblastoma cell proliferation was determined. Finally, 
HECTD1 expression in a small cohort of glioblastoma samples was assessed in 
order to explore the potential for this E3 ubiquitin ligase as a new diagnostic marker 
for brain tumours. (Chapter 4) 






































All general laboratory chemicals stated below were purchased from Sigma-Aldrich or Fisher 
Scientific unless otherwise stated.  
 
2.1.1 Buffers and solutions 
• Agar Plates (with ampicillin) 
LB Broth with Agar (Lennox) (Sigma-Aldrich, L2897), with 50μg/ml ampicillin 
(Sigma-Aldrich, A0166).  
• Agar Plates (with kanamycin) 
LB Broth with Agar (Lennox) (Sigma-Aldrich, L2897), with 30μg/ml kanamycin 
(Sigma-Aldrich, K1377). 
• Colony Formation Assay Fixing Solution  
0.27% (v/v) Formaldehyde 37% solution (Sigma-Aldrich, F15587), 1% (v/v) 
Methanol, 10% (v/v) 10X PBS, made up to 100ml with ddH2O. 
• Colony Formation Assay Staining Solution 
0.1g Crystal Violet (Sigma-Aldrich, C3886) in 1L ddH2O. 
• FACS Staining Buffer 
100mM Tris, pH7.4, 150mM NaCl, 1mM CaCl2, 0.5mM MgCl2, 0.1% Nonidet P-40 
(Sigma-Aldrich, 9016-45-9). 
• Immunofluorescence Blocking Buffer (BSA) 
3% Bovine Serum Albumin (BSA) (Sigma-Aldrich, A9418) (w/v) in PBS.  
• Lysogeny broth (LB) 
LB broth (Sigma-Aldrich, L3022) 
• Membrane Blocking Buffer (BSA) 
3% Bovine Serum Albumin (BSA) (Sigma-Aldrich, A9418) (w/v) in PBS-Tween. 
• Membrane Blocking Buffer (milk) 
5% OxoidTM skim milk powder (w/v) (Thermo Fisher, LP0013B) in PBS-Tween. 
• Phosphate-buffered saline (PBS) 
OxoidTM PBS Tablets (Thermo Fisher, BR0014). 
• PBS-Tween 
• Paraformaldehyde (PFA) 
4% PFA (Sigma-Aldrich, P6148) in ddH2O.  
• OxoidTM PBS Tablets (Thermo Fisher, BR0014) with 0.1% Tween-20. 
• RIPA Lysis Buffer 
150mM NaCl, 20mM Tris.Cl, pH7.5, 1mM Na2EDTA, 1mM EGTA, 1% (v/v) NP-40 
(Sigma-Aldrich, 9016-45-9), 1% (w/v) sodium deoxycholate.  
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• SDS-PAGE Running Buffer 
25mM Tris.Cl, pH6.3, 0.2M glycine, 0.1% (w/v) SDS.  
Dilute to 0.5X, plus 10% (v/v) Methanol to make Wet Transfer Buffer. 
• Triton Lysis Buffer 
150mM NaCl, 50mM Tris.Cl, pH8.0, 1% (v/v) Triton X-100. 
• 1X Tris-Acetate-EDTA (TAE) buffer 
40mM Tris.Cl, pH7.6, 20mM Acetic Acid, 1mM EDTA. 
• TRABID1-200 IP Lysis Buffer 
150mM NaCl, 50mM Tris.Cl, pH7.4, 5mM Dithiothreitol (Sigma-Aldrich, DTT-RO 
ROCHE), 2mM N-Ethylmaleimide (Sigma-Aldrich, E3876), 10mM Iodoacetimidine 
(Sigma-Aldrich, I6709), 1% (v/v) Triton X-100.  
• TRABID1-200 IP Pull-Down Buffer   
150mM NaCl, 50mM Tris.Cl, pH7.4, 5mM Dithiothreitol (Sigma-Aldrich, DTT-RO 
ROCHE), 2mM N-Ehthylmaleimide (Sigma-Aldrich, E3876), 10mM Iodoacetimidine 
(Sigma-Aldrich, I6709), 0.5mg/ml BSA (Sigma-Aldrich, A9418), 100μM ZnCl2, 0.1% 
(v/v) Nonidet P-40 (Sigma-Aldrich, 9016-45-9). 
• TRABID1-200 IP Wash Buffer   
250mM NaCl, 50mM Tris.Cl, pH7.4, 5mM Dithiothreitol (Sigma-Aldrich, DTT-RO 
ROCHE), 0.1% (v/v) Nonidet P-40 (Sigma-Aldrich, 9016-45-9). 
• Wet Transfer Buffer 
0.5X SDS-PAGE Running Buffer, 10% Methanol.  
 
  




Antibody suppliers, product code, species, and dilutions are summarised in Table 2.1 for 
primary antibodies and Table 2.2 for secondary antibodies. For immunoblotting, primary 
and secondary antibodies were diluted in either 3% (w/v) BSA in PBS-Tween or 5% (w/v) 
OxoidTM skim milk powder in PBS-Tween according to the manufacturer’s instructions. For 
immunofluorescence staining, primary and secondary antibodies were diluted in 3% (w/v) 
BSA in PBS.  
 
Table 2.1. Primary antibodies. Antibody name, supplier, product code, species, and the 
dilution of primary antibodies used. Abbreviations: WB = western blot, and IF = 
immunofluorescence, pAb = polyclonal antibody, mAb = monoclonal antibody. 
Antibody name Supplier Code Species Dilution Reference for 
use of antibody 
Anti-beta-actin Sigma-Aldrich A5441 Mouse mAb 1:10000 (WB) Fortungo, et al. 
(2002). 
Anti-BUB3 Abcam ab133699 Rabbit pAb 1:1000 (WB) n/a 
Anti-BUBR1 Abcam ab215351 Rabbit pAb 1:500 (IF) n/a 
Anti-Cyclin B1 Santa Cruz 
Biotechnology 
sc-245 Mouse mAb 1:1000 (WB) Vassilev, et al. 
(2006). 
Anti-GST Roche 27-4577-01 Goat pAb 1:5000 (WB) n/a 
Anti-HA Roche HA3F10 Rat pAb 1:1000 (WB) n/a 
Anti-HECTD1 (N 
terminus) 
Abcam  ab101992 Rabbit pAb 1:2500 (WB) 
1:200 (IF) 










Abcam  ab10543 Rat pAb 1:1000 (WB) 
1:200 (IF) 
Xu, et al. (2009). 




Abcam ab7254 Mouse mAb 1:1000 (WB) Castiel, et al. 
(2011).  
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Table 2.2. Secondary antibodies. Antibody name, supplier, product code, species, dilution 
of primary antibodies used, and application. Abbreviations: WB = western blot, and IF = 
immunofluorescence. 














sc-2005 Goat 1:5000 WB 




sc-2006 Goat 1:5000 WB 
Rabbit anti-goat 
IgG HRP 

























Plasmid DNA was stored at -20ºC.  
 
Table 2.3. Plasmids. Plasmid name and source.  
Plasmid name Source 
Mouse HA tagged full length 
Hectd1WT 
Dr M Bienz, LMB Cambridge, UK 
Mouse HA tagged full length 
Hectd1C2579G 
Dr M Bienz, LMB Cambridge, UK 
 
 
2.1.4. siRNA oligonucleotides 
All siRNA were resuspended in RNase-free 1x siRNA buffer (GE Dharmacon) at 100μM 
and the stock solution stored at -20ºC. A working solution of siRNA at 10μM was aliquoted 
and stored also at -20ºC. 
 
Table 2.4. siRNA oligonucleotide sequences. siRNA name, supplier, product code, and 
sequences used. Abbreviations: siRNA = small interfering RNA 
Name Supplier Catalogue Oligo sequence (5’ -> 3’) 
On-Target Plus Non 
Targeting Pool siRNA  




On-Target Plus HECTD1 
Individual #06 siRNA 
GE Dharmacon J-007188-06 GUUAAUAGCUGUACUAGAA 
On-Target Plus HECTD1 
Individual #07 siRNA 
GE Dharmacon J-007188-07 GCUCAUAGCUGCAUAUAAG 
On-Target Plus HECTD1 
Individual #08 siRNA 
GE Dharmacon J-007188-08 CAUAGAGGAUUUAGGUUUA 
On-Target Plus HECTD1 
Individual #09 siRNA 
GE Dharmacon J-007188-09 GAAAGGGACAUGCAACUAA 
On-Target Plus HECTD1 
SMARTPool siRNA 
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2.1.5. RT-PCR primers 
All primers were resuspended in DNase-free and RNase-free ddH2O at 100μM and the 




Table 2.5. RT-PCR primer sequences. Target, primer sequence, and product size. * = 
primer sequences previously reported in Valtente V, et al. 2009. 
Target 
(human) 
Primer sequence (5’ -> 3’) Product 
size (bp) 
HECTD1 














RNA Pol IIA Forward: TTGTGCAGGACACACTCACA 
Reverse: CAGGAGGTTCATCACTTCACC 
83 
GAPDH Forward: GAAGGTCGGAGTCAACGGATTT 
Reverse: ATGGGTGGAATCATATTGGAAC 
147 
RPS18 Forward: TGGACAACAAGCTCCGTGAA 
Reverse: GGGCCCGAATCTTCTTCAGT 
53 
HPRT1 * Forward: TGACACTGGCAAAACAATGCA 
Reverse: GGTCCTTTTCACCAGCAAGCT 
94 
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2.1.6. Cell cycle synchronisers 
All synchronisers were stored at -20ºC. Working concentrations of cell cycle synchronisers 
can be found in section 2.2.1 of Chapter 2.  
 









Aphidicolin DMSO 1mg/ml Pedrali-Noy, et al. (1980).  
Krokan, et al. (1981). 
2’-Deoxycytidine ddH2O 1M Thomas & Lingwood. (1975). 
Nocodazole DMSO 1mg/ml Zieve, et al. (1980). 
RO-3306 DMSO 5mg/ml Vassilev, et al. (2006). 
Thymidine ddH2O 100mM Xeros. (1962). 
 
  




2.2.1. Mammalian cell culture 
Human embryonic kidney (HEK) cells, HEK293T HECTD1 knock out cells (Dr Bienz, LMB 
Cambridge, UK) and HEK293ET cells (American Type Culture Collection, ATCC, USA) 
were cultured in Dulbecco’s modified minimum essential medium (DMEM) with GlutaMAX 
supplement (Life Technologies, 10566016), supplemented with 10% (v/v) Fetal Bovine 
Serum (Heat-inactivated FBS, 10270106) (Life Technologies) and 1% (v/v) 10,000 units 
Penicillin-10mg/ml Streptomycin (Sigma Aldrich, P4333), at 37°C in a humidified incubator 
with 5% CO2. Cells were passaged when confluent by incubating with sterile 0.05% EDTA-
PBS for 5mins at 37°C, followed by pelleting the cells at 150 x g for 3mins. Cells were then 
resuspended in supplemented DMEM (+GlutaMAX) and seeded (1/10) in a NunclonTM Delta 
surface-treated (NuncTM) 10cm dish (Thermo Scientific, 150350). Human embryonic kidney 
(HEK) cells, specifically HEK293ET, offers the possibility to obtain high levels of 
recombinant protein expression, as well as high transfection efficiency for future studies in 
this project, and has been used previously in cell cycle studies (Lu, et al. 2013). The high 
recombinant protein expression of HEK293ET is attributed to two stably transfected 
transgenes, EBNA-1 and the large T antigen, which promote plasmid replication (Durocher, 
et al. 2002). For experiments, HECTD1 knock out cells were cultured from passage 4 to 
passage 35. Both HEK293T HECTD1 KO1 and KO2 have been generated using the same 
gRNA and these are confirmed individual clones (and not pools). Sequencing carried out 
by Dr Bienz’s lab on HEK293T HECTD1 KO2 confirms that the mutation induces a frame 
shift and premature stop codon leading to nonsense mediated decay (Figure A.1). The 
gRNA is as published in (Flack, et al. 2017). 
 
HeLa cells (cervical cancer cell line) (American Type Culture Collection, ATCC, USA) were 
cultured in DMEM, supplemented with 10% (v/v) FBS and 1% (v/v) 10,000 units Penicillin-
10mg/ml Streptomycin. HeLa cells were passaged when confluent by washing with sterile 
PBS, incubating with sterile 0.05% Trypsin-EDTA (Life Technologies, 25300054) for 5mins 
at 37°C, followed by pelleting the cells at 150 x g for 3mins. Cells were resuspended in 
supplemented DMEM and seeded (1/5) in a NunclonTM Delta surface-treated (NuncTM) 
10cm dish. 
 
Glioblastoma cell lines U87 and U251 (Dr H Haynes, Bristol Southmead Hospital, University 
of Bristol) were cultured in Eagle’s Minimum Essential Media (EMEM) (Sigma, M2279), 
supplemented with 10% (v/v) Fetal Bovine Serum (Heat-inactivated FBS), 2mM L-glutamine 
(Thermo Fisher, 25030081), MEM 1% (v/v) non-essential amino acids (Thermo Fisher, 
11140050), 1mM sodium pyruvate (Thermo Fisher, 11360070), and 1%(v/v) 10,000 units 
Penicillin-10mg/ml Streptomycin, at 37°C in a humidified incubator with 5% CO2. U87 and 
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U251 cell lines were passaged when confluent by washing with sterile PBS, incubating with 
sterile 0.25% Trypsin-EDTA (Life Technologies, 25200056) for 5mins at 37°C, followed by 
pelleting the cells at 150 x g for 3mins. Cell were then resuspended in supplemented EMEM 
and seeded (1/5) in a NunclonTM Delta surface-treated (NuncTM) 10cm dish. U87 are of likely 
glioblastoma origin and U251 are glioblastoma astrocytoma cells. Finally, all cell lines were 
tested for Mycoplasma contamination, using the MycoAlertTM Mycoplasma Detection Kit 
(Lonza), as per manufacturer’s instructions.   
 
Cell synchronisation 
To synchronise the cells with RO-3306, cells were treated with 9µM RO-3306 (Caymen, 
872573-93-8) for 20hrs, washed three times in PBS, and released into fresh media for 
synchronous progression of the cell cycle from the G2/M transition. For synchronisation 
using Aphidicolin, cells were cultured in medium with reduced serum (0.5% FBS (v/v)), for 
48hrs before treatment with 11.8µM Aphidicolin (Fisher Scientific, 38966-21-1) for 15hrs. 
Cells were washed three times in PBS, and released in fresh media for synchronous 
progression of the cell cycle from the G1/S transition. For synchronisation with Nocodazole 
(Sigma-Aldrich, M1404), cells were treated with 50ng/ml Nocodazole for 20hrs, before 
collection of mitotic cells via mitotic shake off. The cells were centrifuged at 150 x g for 
3mins, washed with PBS three times, then released into fresh media and plated into a 6 
well plate, for synchronous progression of the cell cycle from metaphase. For a double 
thymidine block, cells were treated with 2mM thymidine (Sigma-Aldrich, T9250) for 18hrs, 
and then washed with PBS once, before adding fresh media containing 25µM 2’-
deoxycytidine (Sigma-Aldrich, D3897) for 9hrs. After 9hrs, 2mM thymidine was added for 
15hrs.  Cells were washed three times in PBS, and released in fresh media containing 25µM 
deoxycytidine for synchronous progression of the cell cycle from the G1/S transition. 
 
 
2.2.2. Transfection and gene silencing 
Transfection of siRNA oligonucleotides 
HEK293ET were seeded into an appropriately sized plate one day prior to transfection into 
DMEM + 10% (v/v) FBS, without antibiotics present. 24hrs later the knockdown mix was 
made by combining siRNA and LipofectamineÒ 2000 diluted in OptiMEM (Life 
Technologies, 31985062). For HEK293ET cells, in a 24-well plate, 20pmol of siRNA RNA 
and 1µl of LipofectamineÒ 2000 (Thermo Fisher, 11668027) was used, according to the 
manufacturer’s protocol (see Table 2.7 for more details). LipofectamineÒ 2000 was added 
to OptiMEM and left to incubate for 5mins, before being added to OptiMEM containing the 
appropriate siRNA and left to incubate for a further 20mins at room temperature. During this 
time, all media was removed from the wells, so that only the knock down mix covered the 
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cells. 4-6hrs later DMEM + 10% (v/v) FBS was added to each well to make it the appropriate 
total volume for each well.  
 
HeLa cells were seeded into an appropriately sized plate one day prior to transfection into 
DMEM + 10% (v/v) FBS, without antibiotics present. Again, 24hrs later the knockdown mix 
was made by combining siRNA and Lipofectamine 2000 diluted in OptiMEM. For HeLa cells, 
in a 24-well plate, 25pmol of siRNA RNA and 0.5µl of LipofectamineÒ 2000 was used, 
according to the manufacturer’s protocol (see Table 2.8 for more details). LipofectamineÒ 
2000 was added to OptiMEM and left to incubate for 15mins, before being added to 
OptiMEM containing the appropriate siRNA and left to incubate for a further 15mins at room 
temperature. Again, during this time all media was removed from the wells, so that only the 
knock down mix covered the cells. 4-6hrs later DMEM + 10% (v/v) FBS was added to each 
well to make it the appropriate total volume for each well.  
 
U87 and U251 cells were seeded into an appropriately sized plate one day prior to 
transfection into supplemented EMEM, without antibiotics present. 24hrs later, 
LipofectamineÒ  RNAiMAX (Thermo Fisher, 13778-075) was diluted in OptiMEM and 
incubated for 5mins before being added to the appropriate volume of siRNA (Table 2.9), 
and incubated for a further 5mins at room temperature. All media was removed from the 
wells, and then knock down mix was added. 4-6hrs later supplemented EMEM was added 
to each well to make it the appropriate total volume for each well. All samples were then 
harvested for the appropriate assay.  
 
Table 2.7. HEK293ET knockdown mix. Volumes of siRNA, LipofectamineÒ 2000, and 
OptiMEM provided for each size plate format. 
 24 well plate 12 well plate 6 well plate 
siRNA (20µM) 1µl 2µl 5µl 
LipofectamineÒ 2000 1µl 2µl 5µl 
OptiMEM 50µl of each (100µl in 
total) 
100µl of each (200µl in 
total) 




Table 2.8. HeLa knockdown mix. Volumes of siRNA, LipofectamineÒ 2000, and OptiMEM 
provided for each size plate format. 
 24 well plate 12 well plate 6 well plate 
siRNA (20µM) 1.25µl 2.5µl 6.25µl 
LipofectamineÒ 2000 0.5µl 1µl 2.5µl 
OptiMEM 50µl of each (100µl in 
total) 
100µl of each (200µl in 
total) 
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Table 2.9. U87 and U251 knockdown mix. Volumes of siRNA, LipofectamineÒ RNAiMAX, 
and OptiMEM provided for each size plate format. 
 24 well plate 12 well plate 6 well plate 
siRNA (20µM) 1µl 2µl 5µl 
LipofectamineÒ 
RNAiMAX 
1.5µl 3µl 7.5µl 
OptiMEM 50µl of each (100µl in 
total) 
100µl of each (200µl in 
total) 





HEK293ET and HEK293T cells were seeded into an appropriately sized plate one day prior 
to transfection into DMEM + 10% (v/v) FBS, without antibiotics present. 24hrs later, the 
transfection mix was made by combining branched PEI (MW ~25000) (Sigma, 408727) and 
DNA at a ratio of 3:1 diluted into 150mM NaCl. For example, in 24 well plate, 250ng of DNA 
was combined with 750ng of PEI (Table 2.10). The PEI and DNA were individually diluted 
in 150mM NaCl, left for 5mins before being combined and then incubated for 15mins at 
room temperature.  The mix was then added to cells that had been placed in OptiMEM, and 
left before a media change into DMEM + 10% (v/v) FBS 24hrs later (this step was optional 
depending on the assay).  
 
Table 2.10. HEK293ET and HEK293T knockdown mix. Volumes of DNA, PEI, and NaCl 
provided for each size plate format. Concentration (x) depends on the DNA.  
 24 well plate 12 well plate 6 well plate 
DNA  250ng 500ng 1-1.25µg 
PEI (1mg/ml) 3:1 3:1 3:1 
NaCl (150mM) 50µl per tube (100µl in 
total) 
100µl per tube (200µl in 
total) 







For confocal imaging, cells were plated at an experiment specific density onto Poly-L-Lysine 
(mol wt 30,000 – 70,000) (Sigma-Aldrich, 9155) coated NuncTM ThermanoxTM 13mm 
coverslips (Thermo Fisher, 1749500) in 12well plates (Corning, CLS3513). Asynchronous 
or synchronous cells were then fixed with 300μl/well 4% (w/v) paraformaldehyde, washed 
three times with 1ml PBS 100mM glycine, then permeabilised with 0.1% (v/v) Triton PBS 
for 5mins at room temperature. Cells were washed three times with 1ml PBS and then 
blocked with 3% (w/v) BSA in PBS for 1hr at room temperature. Cells were then incubated 
with 100μl/coverslip primary antibody for 1hr at room temperature. Cells were washed three 
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times with PBS and then incubated with 100μl/coverslip secondary antibody for 1hr at room 
temperature. Cells were washed twice with PBS and then counterstained with 
100μl/coverslip Hoechst 33342 (Thermo Fisher, H1399), 1µg/ml in PBS, followed by two 
more washes in PBS. VectaShield Antifade Mounting Medium (Vector Laboratories, H-
1000) was used as the mounting media. Samples were then imaged on the LSM Meta 510 
confocal microscope (Zeiss).  
 
Microtubule regrowth assay 
HEK293ET and HEK293T cells were seeded at 150,000 cells per well on Poly-Lysine 
coated coverslips before the addition of 300ng/ml of Nocodazole (Sigma M1404) in DMEM 
for 1hr at 37ºC. Cells were then shifted on ice for 30mins, followed by two 3min washes in 
ice cold PBS. The treated cells were released into DMEM at 37ºC before then fixing the 
cells in 4% (w/v) PFA at 15mins post-release. Cells were then stained for 
immunofluorescence with the microtubule marker, α-tubulin (to enable visualisation of 
microtubules at different time points), in addition to the DNA stain, Hoechst 33342 (Thermo 
Fisher, H1399), 1µg/ml in PBS. 
 
Spindle Assembly Checkpoint marker staining 
HEK293ET and HEK293T cells were seeded at 150,000 cells per well on Poly-Lysine 
coated coverslips before the addition of 9µM RO-3306 (Caymen, 872573-93-8) for 20hrs. 
After the incubation cells were washed three times with warm PBS for 5mins, and released 
into DMEM at 37ºC before then fixing the cells in 4% (w/v) PFA at 0, 10, 30, 60, and 120mins 
post-release. Cells were then stained for immunofluorescence with the spindle assembly 
checkpoint marker, BuBR1, and the microtubule marker, α-tubulin, in addition to the DNA 
stain Hoechst. 
 
Live cell imaging 
For live cell imaging, HEK293ET and HEK293T cells were seeded at 30,000 cells per ml 
onto Poly-L-Lysine (mol wt 30,000 – 70,000) (Sigma-Aldrich 9155) coated plastic Ibidi 8-
well chamber slides (Ibidi IB-80826). Cells were left overnight in 300μl/well DMEM + 10% 
(v/v) FBS, before exchanging the media the following day for Leibovitz’s L-15 media (no 
phenol red) (Life Technologies 21083027), with 10% (v/v) FBS. Cells were then filmed over 
the course of hours at either 2, 3, or 5min intervals using an Olympus IX81 microscope with 
a 40X oil immersion objective lens and Hammatsu ORCA-ET Camera for imaging at 37ºC. 
Micro-Manager (Edelstein, et al. 2014) was used to acquire and manage the images. Only 
the DIC channel was used for imaging. A binning of 2 was used for image acquisition, and 
images were acquired as a stacked TIFF format for downstream analysis. Images were 
then processed using ImageJ software (National Institutes of Health).  
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2.2.4. Flow Cytometry: cell cycle profiling 
HeLa cells were seeded at 300,000 cells per well and HEK293ET cells at 500,000 cells per 
well in a 6 well plate (Corning, 3516), cultured as normal, then treated with an appropriate 
cell synchroniser. At each time point samples were harvested in the following manner. The 
culture media was removed and saved in an eppendorf, the cells were then rinsed with 
PBS, before being treated with 300µl of 0.05% Trypsin-EDTA (Life Technologies, 
25200056). Once the cells were fully trypsinised the media was added back to generate a 
single cell suspension. Cells were pelleted at 500 x g for 5mins, supernatant discarded, 
then washed with PBS, by centrifugation and removing the supernatant. Cells were fixed in 
69% ethanol, 400µl ice-cold PBS with 900µl ice-cold 100% ethanol. Samples were then 
stored at 4ºC for at least 2hrs before staining. Samples were stained the same day as 
collecting the data. 2µg/ml Propidium Iodide (PI) (Life Technologies, P3566) and 100µg/ml 
RNase A (Life Technologies, EN0531) were diluted in 500µl FACS Staining Buffer. The 
samples were then incubated at 37ºC for 30mins before being placed on ice in the dark, 
just before running the samples on the BD FACSCanto (BD Biosciences). Data were 
analysed using BD FACSDIVATM software V.8.0.1. For cell cycle analysis, histograms were 
gated at 50 PI-A to calculate the percentage of cells in G1 and 100 PI-A to calculate the % 
of cells in G2.  
 
 
2.2.5. Cell proliferation assay 
Trypan Blue counting 
HEK293ET and HEK293T cells were seeded at 60,000 cells per well in a Poly-L-Lysine 
coated 24 well plate (Corning, 3524). At each time point cells were trypsinised and 
resuspended in DMEM + 10% (v/v) FBS, before being mixed in a 1:1 ratio with Trypan Blue 
solution 0.4% (Thermo Fisher, 15250061). Cells were then counted under a light 
microscope using a haemocytometer. Cells that are dead appear blue and cells that are 
living appear white. Counts were carried out in triplicate for each sample over three 
independent experiments. If appropriate some of the sample was kept and stored for 
Western Blot analysis. Total number of viable cells and percentage viability were calculated 
using the equations below.  
 
𝑉𝑖𝑎𝑏𝑙𝑒	𝐶𝑒𝑙𝑙𝑠 = 𝑁𝑢𝑚𝑏𝑒𝑟	𝑜𝑓	𝑏𝑙𝑢𝑒	𝑐𝑒𝑙𝑙𝑠 − 𝑇𝑜𝑡𝑎𝑙	𝑛𝑢𝑚𝑏𝑒𝑟	𝑜𝑓	𝑐𝑒𝑙𝑙𝑠 
 
%	𝑉𝑖𝑎𝑏𝑖𝑙𝑖𝑡𝑦 = 	 81 −	:
𝑁𝑢𝑚𝑏𝑒𝑟	𝑜𝑓	𝑏𝑙𝑢𝑒	𝑐𝑒𝑙𝑙𝑠
𝑇𝑜𝑡𝑎𝑙	𝑛𝑢𝑚𝑏𝑒𝑟	𝑜𝑓	𝑐𝑒𝑙𝑙𝑠
;< × 100 
 
 




HEK293T cells were seeded at 4000 cells per well into a Poly-L-Lysine coated 96 well clear-
bottomed white walled plate (Corning, 3903) in DMEM + 10% (v/v) without antibiotics. 48hrs 
later cells were transfected with either empty vector (eV), full length HA-HECTD1WT, or HA-
HECTD1C2579G vector (see 2.2.2 for transfection protocol), then left for 48hrs before 
measuring the ATP content using CellTiter-Glo assay kit (Promega, G7570). The assay was 
carried out according to the manufacturer’s protocol for a 96 well format, and measured in 
the GloMax Multi Plate Reader (Promega).  
 
Colony formation assay 
HEK293T cells were seeded at 500 cells per well in 5mL of DMEM + 10% (v/v) FBS of a 6 
well plate. The cells were left to grow over a period of 9 days before fixing in Colony 
Formation Assay Fixing Solution for 30mins at room temperature. The Colony Formation 
Assay Fixing Solution was removed and replaced with Colony Formation Assay Staining 
Solution for 1hr at room temperature. Cells were then washed with water and left to air dry 
before being imaged with a commercial camera (adapted from Haloom, et al. 2011).  
 
 
2.2.6. Western blotting  
Protein assays 
Control asynchronous or synchronised cells were grown in an appropriately sized plate 
depending on the assay type, then lysed in Triton X-100 lysis buffer with the addition of 
PierceTM Protease Inhibitor Mini Tablets (Thermo Fisher, 86665) and PierceTM Phosphatase 
Mini Tablets (Thermo Fisher, 88667). Cell lysates were clarified by centrifugation and total 
protein concentration was determined using PierceTM Coomassie Plus Bradford assay kit 
(Life Technologies, 23236), according to manufacturer’s instructions for 96 well format. For 
cells that were lysed in RIPA buffer, protein quantification had to be carried out by using the 
PierceTM Bicinchoninic Acid (BCA) protein assay kit (Thermo Fisher, 23225). A standard 
curve was generated according to the protocol and using the BSA protein standard provided 
(Thermo Fisher, 23236). A BCA working solution was prepared by mixing Reagent A and 
Reagent B together at a ratio of 50:1. In a 96 well plate, 10µl of each standard was plated 
in triplicate, followed by each sample in triplicate. 200µl of working solution was then added 
to each well before the plate was incubated at 37°C for 30mins. The absorbance at 565nm 
was taken using a Spectra Rainbow microplate spectrophotometer (Thermo Fisher). Protein 
concentrations were calculated from the BSA standard curve in Microsoft Excel. Protein 
values were normalised between samples based from the BCA assay by the addition of 
lysis buffer to yield the same protein concentration across the samples.  
 




Samples were prepared using NuPage 4X LDS sample buffer (Life Technologies, NP0007), 
reduced in 100mM Dithiothreitol (DTT) (Sigma-Aldrich, DTT-RO ROCHE) and denatured at 
95°C for 5mins. Samples were run on NuPAGE® Novex® 4-12% Bis-Tris Protein Gels, 
1.0mm gels (Life Technologies, NP0322BOX) for 100mins at 140V in 1X NuPAGE® MOPS 
SDS Running Buffer (Life Technologies, NP0001). Samples were run alongside the 
PageRulerTM Prestained Protein Ladder (Thermo Fisher, 26616).  
 
Wet transfer 
Samples were transferred from the protein gel to a Whatman® Westran® PVDF membrane 
0.45µm (Sigma-Aldrich, Z671088) using the Bio-Rad Mini Trans-Blot® Wet Transfer 
System (Bio-Rad), for 60mins at 100V in Wet Transfer Buffer (see section 2.1.1). 
 
Membrane boiling 
For detection of ubiquitin, samples were placed in sample buffer and were frozen without 
boiling. Prior to blocking membranes are boiled in the microwave for 10mins in ddH2O 
sandwiched between glass plates, to ensure even boiling (adapted from Emmerich, & 
Cohen. 2015).  
 
Immunoblotting 
PVDF membrane was blocked in 3% BSA-PBS-Tween (0.1%) for 1hr at room temperature. 
Primary antibody was diluted in 3% BSA-PBS-Tween (0.1%) as described in Table 2.2 and 
incubated either over-night at 4°C or for 1hr at room temperature. Membranes were then 
washed three times for 5mins in PBS-Tween (0.1%) before the addition of species-specific 
horseradish-peroxidase (HRP)-conjugated secondary antibody diluted as described in 
Table 2.2. in 3% BSA-PBS-Tween (0.1%) for 1hr at room temperature. Membranes were 
washed a further three times for 5mins before three quick washes with ddH20 to remove 
any excess Tween. Proteins were detected by incubating membranes for 1min using 
PierceTM ECL Western Blotting Substrate (Life Technologies, 32106). Chemiluminescence 
was detected using Fusion SL Chemiluminescence and Fluorescence Imager, Vilber 
Lourmat. Quantification of detected bands was carried out using ImageJ software (http:// 
rsb.info.nih.gov/ij/; W. Rasband, National Institutes of Health, Bethesda, USA).  
 
 
2.2.7. Pull-down assays  
NZF1 pull-down assay 
For the enrichment of K29/K33 ubiquitin chains, GST-TRABID1-200, GST-NZF1, and GST-
NZF1 LV/TY domains expressed in E. Coli were used (contributed by Dr Licchesi). For each 
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10cm3 dish, 100ug of trapping protein was used. 10μg of GST tagged protein was 
conjugated to PierceTM Glutathione Magnetic Agarose Beads (Thermo Fisher, 78602), for 
1hr at room temperature. Cells in 10cm3 dishes were lysed in 500μl of TRABID1-200 IP Lysis 
Buffer for 20mins, before being clarified by centrifugation (13,000 x g for 15mins at 4°C). 
60μl of lysate was collected for the input sample. 110μl of lysate was added to 50μl of 
conjugated beads in 500μl TRABID1-200 IP Pull-Down Buffer and left overnight at 4ºC. Beads 
were then washed four times in TRABID1-200 IP Wash Buffer for 5mins, before the addition 
of 2X LDS sample buffer with 100mM DTT.  
 
 
2.2.8. Molecular biology 
DNA agarose gel electrophoresis 
PCR products were combined with bromophenol blue loading buffer (1% v/v). Samples 
were then loaded onto 0.8 – 3% (w/v) agarose Tris-Acetate-EDTA (TAE) gels containing 
GelStarTM Nucleic Acid Stain 0.2X (Lonza, S9430), alongside 5µl of 1Kb Plus DNA Ladder 
(Invitrogen, 10787018). DNA gels were run at approximately 10V/cm of gel until the gel front 
approached the end of the gel. DNA on the gel was visualised using a non-UV Darker 
Reader Transilluminator (Clare Chemical Research). Gels were imaged using the UV filter 
in the GelDoc-ItTM Imaging System (UVP).  
 
Transformation of chemically competent cells 
One ShotTM TOP-10 Chemically Competent E. Coli (Thermo Fisher, C404010) were thawed 
on ice and dispensed into 25µl aliquots. 2µl of plasmid DNA was added to each aliquot and 
incubated on ice for 30mins. Negative, no DNA, and positive pUC19 vector control 
transformations were included according to the manufacturer’s instructions.  Samples were 
then heat-shocked at 42°C for 30secs and placed on ice for a further 2mins, before 250µl 
of pre-warmed S.O.C medium (2% tryptone, 0.5% yeast extract, 10mM NaCl, 2.5mM KCl, 
10mM MgCl2, 10mM MgSO4, and 20mM glucose) (Thermo Fisher, 15544034) was added. 
Samples were then left at 37°C with vigorous shaking for 1hr to allow outgrowth. Between 
20 and 200µl was then plated onto LB Agar selective plates and left at 37°C overnight to 
allow colony formation.  
 
Plasmid purification 
Colonies from the desired plasmid product were expanded by picking a single colony with 
a pipette tip and adding it to prewarmed selective media, 5ml for miniprep and 50ml for 
midiprep cultures. Cultures were grown overnight at 37°C with vigorous shaking. Plasmids 
were purified from overnight cultures using QIAGEN Midi/ Maxi-Prep Kits (Qiagen, 12163) 
according to the manufacturer’s instructions. DNA was eluted using Buffer EB.  




Lung cell line RNA was contributed by Dr Licchesi (University of Bath). Glioblastoma cDNA 
was contributed by Dr Kurian (University of Bristol).  Reverse transcription was performed 
using the High Capacity RNA-to-cDNA KitTM (Applied Biosystems, 4387406). 1μg of RNA 
was used per 20μl reaction, according to manufacturer’s instructions. The quality of the 
RNA was checked using an agarose gel and the RNA was quantified using a NanoDrop 
(Thermo Fisher).  
 
RT-PCR 
PCR reactions were set up with a total volume of 100μl, at a final concentration, containing 
1 X PCR buffer, 20μM dNTPs (each), 1.5mM MgCl2, 0.5μM Forward Primer, 0.5μM Reverse 
Primer, 1U Taq Polymerase (Thermo Fisher, EP0404), and 2μl cDNA. Reactions were 
carried out in a Bio-Rad Thermocycler (Bio-Rad) using the following cycling protocol: initial 
denaturation at 94ºC for 5mins, then 25 cycles of denaturation at 94ºC for 45secs, annealing 
at 55ºC for 30secs, and extension at 72ºC for 30secs, followed by a final extension at 72ºC 
for 10mins. A low number of PCR cycle was selected to provide semi-quantitative analysis 
of expression. For each reaction, a negative RT control with no reverse transcriptase 
present was used to confirm the absence of contaminating genomic DNA and water control 
were ran as negative controls on a 3% (w/v) agarose TAE gel containing GelStarTM Nucleic 
Acid Stain 0.2X, alongside 5µl of 1Kb Plus DNA Ladder, to assess HECTD1 expression in 
the cancer cell lines.  
 
Real time quantitative PCR (RT-qPCR) 
The standard reaction used in all the RT–PCR performed was as follows; 1X Power SYBR 
Green PCR Master Mix (Applied Biosystems, 4368577), 100nM reverse and forward primer, 
100ng cDNA and nuclease–free water made up to 20µl (according to the manufacturer’s 
instructions). Primers shown in Table 2.5. PCR reactions were loaded into MicroAmp fast 
96–well reaction plates (Applied Biosystems, 4349606) and the plates were sealed with 
MicroAmp Optical adhesive film (Applied Biosystems, 4311971). The cycling conditions for 
all reactions were as follows: initial denaturation at 95ºC for 10mins, then 40 cycles of 
denaturation at 95ºC for 15secs and annealing at 55ºC for 1min. Reactions were carried 
out using the StepOnePlus RealTime PCR System (Applied Biosystems) and threshold 
cycles (CT) were calculated using the instrument software. Control reactions without reverse 
transcriptase confirmed the absence of contaminating genomic DNA. Primer efficiency was 
validated by Dr Licchesi and amplified with an efficiency of 2. CT values were normalised to 
RNA Pol II and RPS18 housekeeping genes. These ΔCT values were used to calculate the 
relative change in mRNA expression as the ratio of mRNA expression in treated cells versus 
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mRNA expression in the control condition, using the Livak method (Livak & Schmittgen. 
2001).  
 
The final normalised ratio was calculated by the following formula:  
 




∆𝐶E = 𝐶E	(𝑡𝑎𝑟𝑔𝑒𝑡) −	𝐶E	(𝑟𝑒𝑓𝑒𝑟𝑒𝑛𝑐𝑒) 
 
 
∆∆𝐶E = ∆𝐶E	(𝑠𝑎𝑚𝑝𝑙𝑒) −	∆𝐶E	(𝑐𝑎𝑙𝑖𝑏𝑟𝑎𝑡𝑜𝑟) 
 
 
Data are presented as mean ratio values ±SEM from three biological repeats.  
  
 
2.2.10. Statistical analysis  
All data were analysed using GraphPad software (Prism, La Jolla, CA, USA), including 
mean, standard error values and statistical analysis. Standard error of the mean (S.E.M.) 
was calculated to quantify the precision of the mean and to compare differences in the 
means between conditions. S.E.M. was used to take into account both the value of the 
standard deviation and the sample size. Statistical analysis was carried out either using a 
one-way ANOVA with a Dunnett’s post-test, or a paired student’s t-test. A one-way ANOVA 
with a Dunnett’s post-test was used when comparing a series of conditions to a single 
control condition. A paired student’s t-test was used when comparing two conditions. 
Relevant p-values are indicated where relevant by * p < 0.05, ** p < 0.01 and *** p < 0.001. 





































HECTD1, a member of the class II family of HECT E3 ubiquitin ligases, was first 
demonstrated to function in dorsal neural tube closure in mice, where it is required for the 
migration of cranial mesenchyme migration (Zohn, et al. 2007; Sarkar, et al. 2012; Grau-
Bove, et al. 2013). The mechanism put forward suggested that HSP90 was ubiquitinated 
with K63-linked ubiquitin chains by HECTD1, although clear evidence on the chain type 
involved and the fate of ubiquitinated HSP90 are still lacking (Sarkar, et al. 2012). HECTD1 
also appears to function as a negative regulator of Wnt signalling, a key signal transduction 
pathway that regulates stem cell homeostasis (Tran, et al. 2013). Here, HECTD1 was 
reported to ubiquitinate APC with K63 chains and in doing so facilitate the binding of the 
APC to Axin, an inhibitor of the Wnt signalling pathway (Nakamura, et al. 1998; Tran, et al. 
2013). Therefore, HECTD1-mediated K63 ubiquitination might regulate the assembly of the 
β-catenin destruction complex (Tran, et al. 2013). Other roles for HECTD1 involve substrate 
degradation, for example, the regulation of focal adhesion sites where HECTD1 is 
responsible for the degradation of PIPKIg90, and its role in oestrogen-regulated enhancer 
activation mediated by the degradation of RIP40 (Li, et al. 2013b; Li, et al. 2015). 
Additionally, HECTD1 functions in placenta development, the mechanism by which this 
occurs is unknown (Chapter 1) (Sarkar, et al. 2014; Sarkar, et al. 2016; Shen, et al. 2017).  
 
Whilst synthesis of K63 chains by HECTD1 has been suggested in previous studies 
mentioned above, there are a lack of in vitro biochemical experiments to directly support 
this conclusion. Unpublished in vitro biochemical data from the lab, suggests that HECTD1 
synthesises mixed K29 and K48 ubiquitin chains (Figure 3.1A). Ubiquitin-absolute 
quantification (AQUA) mass spectrometry (Kettenbach, et al. 2011) was carried out on in 
vitro synthesised wild-type polyubiquitin ubiquitin to determine the abundance of different 
ubiquitin linkages. It was revealed that K29 and K48 linkages were the most abundant, and 
that K63 linkage only accounted for 13% of the ubiquitin synthesised by the catalytic domain 
of HECTD1 (Figure 3.1B) (Licchesi, unpublished data). HECTD1 is only the second 
ubiquitin ligase, in addition to UBE3C, to assemble mixed K29/K48 chains. However, the 
function of this chain type has not been investigated beyond the ubiquitin fusion degradation 
(UFD) pathway. Additionally, their role in signal transduction and in the regulation of cellular 
processes such as the cell cycle regulation remains unknown.  
 
Interestingly, mixed K29/K48 ubiquitin chains have been linked to proteasomal degradation 
via the UFD pathway. The UFD pathway is a proteolytic system that involves an uncleavable 
ubiquitin moiety fused to the N-terminus of a protein during translation, which serves to 
function as a degradation signal (Johnson, et al. 1995). Recently, it was shown in S. 
cerevisiae, that the HECTD1 orthologue, Ufd4p, has been demonstrated to be a UFD ligase. 
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Together with Ufd2p, Ufd4p is able to conjugate branched ubiquitin chains of K29 and K48 
that are synthesised on UFD substrates resulting in proteasome degradation (Liu, et al. 
2017). Therefore, this suggests that the atypical K29/K49 ubiquitin chains synthesised by 
HECTD1 may function in the UFD pathway in mammalian cells. Furthermore, data in 
multicellular organisms such as C.elegans also suggests that HECTD1 is a UFD pathway 
E3 ligase, where it functions to regulate mitochondrial proteins (Segref, et al. 2014). 
Nevertheless, the function of this chain type beyond the UFD pathway has until now not 
been investigated. It was initially considered that branched chains seem to be less effective 
at promoting proteasome degradation compared to a single linkage (Kim, et al. 2007; Kim, 
et al. 2009). However, a role for branched ubiquitin chains in protein degradation is starting 
to emerge. For instance, recent evidence suggests that K11/K48 branched chains, 
synthesised by the APC/C together with UBE2S and UBE2C, enhances UPS-mediated 
degradation (Meyer & Rape. 2014; Grice, et al. 2015; Yau, et al. 2017). Additionally, K48 
branching of K29-linked ubiquitin chains, has been identified as a better degradation signal 
than K29 alone  (Liu, et al. 2017). 
 
Indeed, mixed ubiquitin chains have been demonstrated as having an important role in cell 
cycle regulation. Using a K11/48 bispecific antibody, in cellulo, it was confirmed that APC/C 
substrates Cyclin A, CDC20, and NEK2A were indeed modified with branched K11/K48-
linked ubiquitin chains (Yau, et al. 2017). Furthermore, in synchronised cells, the abundance 
of these chains were measured by immunofluorescence using a specific antibody and this 
revealed that the abundance of K11/K48-linked ubiquitin chains increases during mitosis 
(Yau, et al. 2017). This further suggests that branched chains containing K48 are 
degradation signals.  
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Figure 3.1. HECTD1 synthesises atypical K29 and K48 ubiquitin chains in vitro. A) In 
vitro autoubiquitination assay using wild-type or mutant ubiquitin to assess the linkage 
specificity of HECTD1 conducted by Dr Licchesi. No E1, E2 and E3 controls, to show that 
ubiquitin conjugation requires E1, E2 and E3 activity. The methylated ubiquitin, UbMet, is 
unable to form polyubiquitin chains and can be used to visualise multi-monoubiquitination 
events. Ub-K0 is a mutant form of Ub, in which all Ks are replaced with Rs: Ub-K6R, K11R, 
K27R, K29R, K33R, K48R, and K63R are mutant forms of Ub with Lysines on residue 6, 
11, 27, 29, 33, 48, and 63, respectively, replaced with Arginine, so therefore is also not able 
to form polyubiquitin chains. The following ubiquitin mutants K6, K11, K27, K29, K33, K48, 
and K63- only ubiquitin prevent the formation of a ubiquitin chain through any lysine residue 
other than non-mutated residue named, so for example the K6 only mutant can only form 
K6 ubiquitin chains. Interestingly, other than the WT ubiquitin, only the K29-only and K48-
only mutants were able to produce a polyubiquitin smear. However, compared to the WT 
polyubiquitin smear both the K29 only and K48 only ubiquitin cannot fully constitute the 
signal of the WT ubiquitin. This suggests that HECTD1 conjugates mixed ubiquitin chains 
of K29 and K48. B) To confirm the presence of atypical chains, ubiquitin-AQUA Mass 
spectrometry was carried out on the polyubiquitin smear made with wild type ubiquitin. Left: 
western blot, showing the wild-type ubiquitin smear analysed by ubiquitin-AQUA, alongside 
a K29R ubiquitin mutant and a UbiCREST TRABID sample. The K29R ubiquitin mutant 
prevents ubiquitin linkages through K29, and therefore this sample shows the extent of 
chain formation without K29, again highlighting that K29 is required to recover the full 
ubiquitin smear of the wild type ubiquitin, but is not the only linkage present. Furthermore, 
the UbiCREST TRABID sample demonstrates that the wild-type smear can be digested by 
the K29/K33 specific DUB, however a small polyubiquitin smear remained. This further 
demonstrates that K29 linkages form part of the polyubiquitin conjugates that can be 
assembled by HECTD1. Right: pie chart showing the representation of the different lysine 
residue linkages present in the wild type ubiquitin smear. K48 and K29 are the most 
abundant chain types, again demonstrating that HECTD1 is a E3 ubiquitin ligase 
synthesising atypical ubiquitin chains assembled via K29 and K48. 
 
  




Unpublished data from the lab suggests that HECTD1 is a E3 ubiquitin ligase synthesising 
atypical ubiquitin chains assembled via K29 and K48. Furthermore, previous observations 
in our lab have suggested that HECTD1 might localise to the mitotic spindle. Therefore, the 
aim of this chapter was to search for a cell cycle-related phenotype upon HECTD1 depletion 
by initially focusing on cell proliferation, and then characterising the role that these atypical 
chains K29/K48 chains have in its cellular function. To achieve this the following objectives 
were addressed: 
 
1. To determine whether HECTD1 transient depletion or genetic knockout led to 
reduced cell proliferation in HEK293T, HEK293ET and HeLa cells. This was 
achieved using trypan blue cell counting and the CellTiter-Glo assay kit (Promega).    
 
2. To optimise the transient knock down of HECTD1 with the view to validate the cell 
proliferation findings using transient depletion and knockout of HECTD1. 
Optimisation was carried out in HEK293ET cells using both HECTD1 SMARTpool 
siRNA and individual HECTD1 siRNAs.  
 
3. To establish protocols for the cell synchronisation of different cell cycle populations 
using propidium iodide staining and flow cytometry, with the view to study HECTD1 
function in the cell cycle. Both HEK293ET and HeLa cells were synchronised with 
four different cell synchronisers (RO-3306, Nocodazole, Aphidicolin and double 
Thymidine block).  
 
4. To quantify HECTD1 expression at the protein level in the different stages of the cell 
cycle in HEK293ET and HeLa cells by densitometry using western blotting. Cells 
were synchronised and the levels of HECTD1 protein were quantified relative to beta 
actin (housekeeping protein) over the different stages of the cell cycle.   




3.2.1. Decrease in cell proliferation observed in HECTD1 knockout cell lines 
A previous observation in the Licchesi lab was that HECTD1 was shown by 
immunofluorescence to localise to the mitotic spindle during mitosis. Furthermore, a cellular 
function for the atypical K29/K48 ubiquitin chains synthesised by HECTD1 had not been 
established. Therefore, to establish a role for HECTD1 in the cell cycle, and to characterise 
a functional role for these atypical chains, the effect of HECTD1 depletion on cell 
proliferation was first characterised. The cell cycle and cell proliferation are directly linked 
(Duronio & Xiong. 2013), so it was deemed appropriate to first characterise the effect of 
HECTD1-depletion on cell proliferation as an simple read-out of any potential cell cycle 
function of HECTD1. The hypothesis being that if HECTD1 regulates the cell cycle, it may 
result in changes in overall cell proliferation.  
 
To this end, two CRISPR/Cas9 knockout clones were manually counted over 6 days using 
trypan blue staining and compared to wild type cells. Interestingly, trypan blue cell counting 
revealed a significant reduction in proliferation in HECTD1 KO1 and KO2 cell lines 
compared to the WT control (Figure 3.2A, C-D). By day 6 there was a 23.6% reduction in 
KO1 cells and a 24.9% reduction in KO2 cells. Furthermore, in both cell lines there was no 
observable change in viability between conditions (Figure 3.2B), indicating that the reduced 
cell number is due to cells proliferating slower compared to the wild type cells. Furthermore, 
this decrease in proliferation is observed in both HECTD1 knock out clones, indicating that 
this observation is not as a result of clonal selection. This decrease in cell proliferation was 
also visualised in the colony formation assay (Figure 3.1E), where the colonies formed by 
KO1 cells were fewer and smaller than the WT control. This was also observed with the 
KO2 cells but to a lesser extent. Taken together these results suggest that upon HECTD1 
knockout, cells proliferate at a slower rate, with no change in viability over time in culture.  
  
















































Figure 3.2. Reduced cell proliferation in HECTD1 knock out cells but no effect on cell 
viability. A) Viable cell count (x104) for HEK293T WT compared with HECTD1 KO1. B) 
Viable cell count (x104) for HEK293T WT compared with HECTD1 KO2. C) Viability (%) for 
HEK293T WT, HECTD1 KO1 and HECTD1 KO2. Cells were counted using trypan blue to 
assess the viability of the cells. Data plotted as mean with error bars that represent ±S.E.M., 
over three independent experiments (n=3). ****p<0.001, ***p<0.001, **p<0.01, *p<0.05 by 
paired student’s t-test. D) Colony formation assay comparing WT with HECTD1 KO1 and 
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3.2.2. Decrease in cell proliferation observed in HECTD1-depleted cells 
To confirm the observations seen in the HECTD1 CRISPR/Cas9 knockout cells, HECTD1 
was transiently depleted in HEK293ET cells and HeLa cells. To this end, HECTD1 transient 
depletion was optimised using small-interfering RNAs (siRNA) oligomers (Fire, et al. 1998) 
and Lipofectamine 2000 in HEK293ET cells. In order to transiently deplete HECTD1, 4 
individual siRNAs that target 6 of the 8 protein encoding isoforms of HECTD1 (Appendix 
Table A.1), and a SMARTpool (Dharmacon) that contains a combination of the 4 individual 
siRNAs  were screened in HEK293ET cells (Figure 3.3). The SMARTpool and all individual 
siRNAs were able to knock down HECTD1, but the efficiency of the knock down varied. The 
HECTD1 SMARTpool showed a 60% knockdown efficiency and HECTD1 #06 gave the best 
knockdown efficiency out of the individual siRNAs at around 80%. HECTD1 #07, #08, #09, 
gave a 65%, 70%, and 25% knockdown efficiency, respectively. Based on this preliminary 
data, SMARTpool and individual HECTD1 oligomers #06 and #08 were used for 
downstream experiments. In particular, SMARTpool oligomers were used in most 
experiments while the individual siRNAs were used alongside whenever appropriate to 
discount any off-target effects and provide more confidence when characterising the cellular 
phenotype. In addition, the amount of siRNA was optimised in order to establish the lowest 
concentration with the most efficient HECTD1 knockdown (Figure 3.4). For this optimisation 
experiment, HEK293ET cells were treated with varying amounts of HECTD1 SMARTpool 
siRNA, maintaining the same concentration of Lipofectamine 2000 for each condition. This 
revealed that the 20pmol condition of siRNA produced around a 75% knockdown efficiency 
compared to the control. Therefore, the 20pmol condition was selected since it also showed 
no obvious cell toxicity in contrast to the 40pmol condition.  
 
Given that HECTD1 was successfully depleted using siRNA, HECTD1-depleted HEK293ET 
and HeLa cells were counted over 4 days post knockdown to assess proliferation and 
viability over time in culture (Figure 3.5). Similar to the knockout cell lines, transient 
depletion of HECTD1 with HECTD1 SMARTpool siRNA in HEK293ET and HeLa cells 
resulted in reduced cell proliferation over time in culture. In HECTD1 transiently depleted 
HEK293ET cells, by day 4 there was a 26.9% reduction in viable cell number (Figure 3.5A). 
Again, there was no observable change in viability between conditions (Figure 3.5B), 
suggesting slower proliferation compared to the control. Strikingly, this was again observed 
in HECTD1 transiently depleted HeLa cells where by day 4 there was a 43.6% reduction in 
viable cell number (Figure 3.5C). The reduction in the number viable cells was to a greater 
extent to those seen in both HEK293T and HEK293ET cells (Figure 3.2A and Figure 3.5A). 
Consistently, the statistically significant reduction in cell number was associated with no 
observable change in viability (Figure 3.5D). Interestingly, in both HECTD1 knockout cells 
and HECTD1 depleted cells there was a decrease in proliferation with no change in viability. 
Chapter 3: Is HECTD1 a novel cell cycle regulator? 
 
 68 
Taken together this suggests that HECTD1 has a role in cell proliferation, although it is not 
essential as HECTD1-depleted cells are viable. 
 
Throughout the project HECTD1 was depleted using HECTD1 SMARTpool siRNA, and two 
individual siRNA #06 and #08 as per the optimisation. This was carried out to ensure that 
any observations made were not as a result of an off-target effect of one of the individual 
siRNAs. However, despite the optimisation, the knockdown efficiency was variable and 
therefore experiments were also carried out using a knockout system to observe any 
phenotype without questioning the extent of HECTD1 depletion. Use of a CRISPR/Cas9 
system (Cong, et al. 2013; Mali, et al. 2013) for studying the role of HECTD1 does have 
drawbacks in that any observations in the phenotype could be related to clonal selection as 
opposed to HECTD1 knockout (Graham & Root. 2015). Clonal selection occurs in the 
process of generating the CRISPR/Cas9 genome-edited cell lines, where cells undergo 
phenotypic changes. To overcome this, and where possible, two knockout clones (KO1 and 
KO2) were used for future assays (contributed by Mariann Bienz, MRC-LMB, Cambridge 
UK).   
  
























Figure 3.3. Efficiency of HECTD1 knockdown by SMARTpool and individual 
oligonucleotides.  HEK293ET cells were transiently transfected using 20pmol of HECTD1 
SMARTpool (smart pool) siRNA and individual HECTD1 siRNA with Lipofectamine 2000. 
Following 72hrs incubation, cells were harvested, lysed in RIPA buffer and HECTD1 
proteins levels were analysed on a 4-12% SDS PAGE. Following western blotting on PVDF, 
the membrane was blocked in 3%-BSA-PBST and incubated overnight with anti-HECTD1 
antibody (ab101992) followed by detection with a secondary HRP antibody. Anti-beta-actin 
(A5441) was used as loading control. For validation of HECTD1 (ab101992) antibody see 
Figure 4.4 (Chapter 4). A) Western blot of HECTD1 and loading control beta actin. Molecular 
weight markers are superimposed on the left-hand side of the immunoblot.  B) quantification 
















































































































































Figure 3.4. Efficiency of HECTD1 knockdown by different concentrations of 
SMARTpool oligonucleotides. HEK293ET cells were transiently transfected using 0pmol, 
10pmol, 20pmol, and 40pmol siRNA with Lipofectamine 2000. Following 72hrs incubation, 
cells were harvested, lysed in RIPA buffer and HECTD1 proteins levels were analysed on 
a 4-12% SDS PAGE. Following western blotting on PVDF, the membrane was blocked in 
3%-BSA-PBST and incubated overnight with anti-HECTD1 antibody (ab101992) followed 
by detection with a secondary HRP antibody. Anti-beta-actin (A5441) was used as loading 
control. A) Western blot of HECTD1 and loading control beta actin. Molecular weight 
markers are superimposed on the left-hand side of the immunoblot.  B) quantification of 



























































































Figure 3.5. Reduced cell proliferation upon HECTD1 transient depletion but no effect 
on cell viability. HEK293ET and HeLa cells knocked down with 20pmol HECTD1 
SMARTpool (smart pool) siRNA and Lipofectamine 2000/ RNAiMAX, on day 0. Viable cell 
count (x104) for HEK293ET A) and HeLa C) and cell viability (%) for HEK293ET B) and 
HeLa D), which have been treated with non-targeting siRNA and HECTD1 SMARTpool 
(smart pool) siRNA. E) Western blot showing HeLa knockdown with 20pmol HECTD1 
SMARTpool (smart pool) siRNA and RNAiMAX. Cells were counted using trypan blue to 
assess the viability of the cells. Molecular weight markers are superimposed on the left-
hand side of the immunoblot. Data plotted as mean with error bars that represent ±S.E.M., 
over three independent experiments (n=3) defined as three separate transfections. 
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3.2.3. The E3 ligase activity of HECTD1 is needed to rescue the decrease in cell 
proliferation 
To further demonstrate the requirement of HECTD1 ubiquitin ligase activity in the decrease 
in proliferation phenotype, rescue assays were performed (Figure 3.6-7).  To understand 
the role HECTD1 plays in the decrease in proliferation observed in Figure 3.2 in HECTD1 
CRISPR/Cas9 knock out cells were transfected with HA-FL-mHectd1WT and the 
catalytically-dead version of this construct, HA-FL-mHectd1C2579G. In Figure 3.6A HEK293T 
HECTD1 KO1 cells were transfected with empty vector (eV), HA-FL-mHectd1WT, and HA-
FL-Hectd1C2579G, then viable cell number was calculated by counting cells in the presence 
of trypan blue. It can be seen that 48hrs post-transfection HEK293T HECTD1 KO1 cells 
transfected with HA-FL-mHectd1WT showed a 19.9% increase compared to cells transfected 
with eV. However, this increase was not comparable to the proliferation observed in the 
HEK293T WT cells. By day 5, the increase in viable cells in HEK293T HECTD1 KO1 
transfected with HA-FL-mHectd1WT was comparable to the number of viable cells seen in 
HEK293T WT cells (Figure 3.6A), showing rescue of the reduced proliferation phenotype. 
In HEK293T HECTD1 KO1 cells transfected with HA-FL-mHectd1C2579G, there was a 21.4% 
reduction in viable cells compared to HEK293 WT cells. This indicates that the catalytic 
mutant was not able to rescue the proliferation defect. Confirmation of expression of HA-
FL-mHectd1 was carried out by western blot (Figure 3.6B).  
 
Furthermore, the rescue of the phenotype seen with cell counting was confirmed using an 
alternative assay, an ATP-assay, for both knock out clones; KO1 and KO2. ATP-assays are 
regularly used as an alternative to MTT assays (a colorimetric assay using 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) as a more sensitive method to 
assess cell viability and proliferation (Maehara, et al. 1987; Petty, et al. 1995). CellTiter-Glo 
assay (Promega) was used for both HEK293T KO1 and HEK293T KO2 at 48hrs post-
transfection, to see if in both clones the phenotype could be rescued. It can be seen that in 
both HEK293T KO1 and HEK293T KO2 the phenotype could be significantly rescued by 
HA-FL-mHectd1WT but not HA-FL-mHectd1CM (Figure 3.7). Indeed, in KO1 cells transfected 
with HA-FL-mHectd1WT, the relative luminescence was comparable to the parental 
HEK293T cells (98.8% KO1 + WT; 100% WT), indicating rescue. Similar data were also 
observed for the KO2 cells, which showed cells transfected with HA-FL-mHectd1C2579G, 
growing at a similar rate to the KO2 cells transfected with the empty vector (78.0% KO2 + 
CM; 85.7% KO2 + eV). In agreement with this, KO2 cells transfected with HA-FL-
mHectd1WT showed a higher relative luminescence than that of the WT cells (121.5% KO2 
+ CM; 100% WT), suggesting that whilst wild type mHectd1 was able to rescue the decrease 
in proliferation seen in both knockout cells. In summary, the growth defects observed in 
both of the KO cell lines can be rescued by HA-FL-mHectd1WT but not HA-FL-
Chapter 3: Is HECTD1 a novel cell cycle regulator? 
 
 73 
mHectd1C2579G. Further demonstrating that the E3 ubiquitin ligase activity of HECTD1 is 
needed for optimum cell proliferation. Therefore, HECTD1 may regulate cell proliferation by 
regulating the cell cycle. For example, depletion of the cell cycle regulator NuMA, was 
associated with a decreased proliferation phenotype (Haren, et al. 2009). In NuMA-depleted 
HeLa cells, an enrichment of cells in early mitosis coincided with a decrease in proliferation 
compared to non-targeting controls (Haren, et al. 2009). Therefore, this may indicate that 
































Figure 3.6. HA-FL-mHectd1WT but not HA-FL-mHectd1CM rescues the decrease in 
proliferation phenotype. HEK293T KO1 cells were transfected with empty vector (eV), 
HA-FL-mHectd1WT (Hectd1WT on figure) and HA-FL-mHectd1CM (Hectd1CM on figure) 
vectors with PEI. Samples were harvested at 1, 2, 3, 4, and 5 days post-transfection and 
lysed in RIPA buffer. A) Cell proliferation count (Viable cells) measured by trypan blue 
staining. B) Western blot showing HA-FL-mHectd1 expression in HEK293T KO1 cells. 
Samples were analysed on a 4-12% SDS PAGE, followed by western blotting on PVDF, the 
membrane was blocked in 3%-BSA-PBST and incubated overnight with anti-HA antibody 
(HA3F10) followed by detection with a secondary HRP antibody. Anti-beta-actin (A5441) 
was used as loading control. SE = short exposure and LE = long exposure. Molecular weight 
markers are superimposed on the left-hand side of the immunoblot. Data plotted as mean 
with error bars that represent ±S.E.M., over three independent experiments (n=3) defined 
as three separate transfections, **p<0.01, *p<0.05 by a one-way ANOVA with Dunnett’s 























































































Figure 3.7. HA-FL-mHectd1WT but not HA-FL-mHectd1CM can rescue the decrease in 
proliferation in HEK293T KO2 at 48hrs post-transfection. HEK293T KO1 and KO2 cells 
were transfected with empty vector (eV), HA-FL-mHectd1WT (mHectd1WT on figure), or HA-
FL-mHectd1C2579G (mHectd1CM on figure) vectors. Samples were taken at 48hrs post- 
transfection. Cell proliferation count (relative luminescence) measured by CellTiter-Glo 
assay. Data plotted as mean with error bars that represent ±S.E.M., over three independent 
experiments (n=3) defined as three separate transfections, *p<0.05 by a one-way ANOVA 
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3.2.4. Characterisation of cell synchronisers 
Having established that HECTD1 is required for optimum cell proliferation, protocols for cell 
cycle synchronisation were optimised in order to help determine whether the phenotype 
observed is due to a defect in the cell cycle. Cell synchronisers are chemical compounds 
that inhibit the progression of the cell cycle at a specific stage, therefore allowing enrichment 
of stage-specific cell populations. To this end, four synchronisation agents (i.e. RO-3306, 
nocodazole, aphidicolin, and thymidine) were used (Figure 3.8). RO-3306, a quinolinyl 
thiazolinone derivative, is a selective small-molecule inhibitor of human cyclin dependent 
kinase 1 (CDK1), which arrests cells at the G2/M border (Vassilev, et al. 2006). CDK1 is 
non-redundant in the cell cycle, and together with Cyclin B1 minimally forms the mitosis 
promoting factor, which allows for mitotic onset (Draetta & Beach. 1988; Sherr & Roberts. 
2004; Vassilev, et al. 2006). Nocodazole binds to a-tubulin and inhibits the assembly of 
microtubules, the main constituent of the mitotic spindle (Hoebeke, et al. 1976; Kline-Smith 
& Walczak. 2004). Nocodazole is therefore, a mitotic spindle poison that reversibly arrests 
cells in M-phase (Zieve, et al. 1980). Aphidicolin synchronises cells in G1, preventing cells 
from entering S phase by the inhibition of DNA polymerase α (Pedrali-Noy, et al. 1980; 
Krokan, et al. 1981). Finally, treatment of cells with excess thymidine prevents DNA 
synthesis by the inhibition of the formation of deoxycytidine, arresting cells in S phase 
(Xeros. 1962). To achieve greater synchronisation, a double thymidine block can be used, 
which includes two treatments of thymidine to accumulate cells at the G1/S boundary prior 
to the final release (Puck. 1964; Bootsma, et al. 1964). The arrested cells are released by 
multiple washes to remove the synchroniser, then they are replaced in fresh media. Release 
from the thymidine block is aided by the addition of deoxycytidine, which replenishes the 
depleted pools (Thomas & Lingwood. 1975). The released cells are then harvested at time 
points post-release to capture synchronous cells.  
 




Figure 3.8. Diagram illustrating where RO-3306, nocodazole, aphidicolin, and 
thymidine block cell cycle progression. RO-3306 blocks cells at the G2/M transition, 





The efficacy of RO-3306, nocodazole, aphidicolin and thymidine in enriching specific cell 
populations was determined by cell cycle profiles generated by using propidium iodide 
staining and flow cytometry (Figures 3.9-12). PI is a nucleic acid stain, which is used to label 
the DNA content of each cell (Pollack & Ciancio. 1990). Although, a limitation when using 
PI staining and flow cytometry is that the G2 and M populations cannot be separated, it is 
the simplest method to assess the cell cycle profile (Ormerod & Kubbies. 1992). Human 
epithelial cervical cancer cells, HeLa cells, were used for synchroniser characterisation 
because they are extensively used for cell cycle assays, for example, in the characterisation 
of the APC/C in human cells (Geley, et al. 2001; Sudakin, et al. 2001).  
 
Synchronisation of cells at the G2/M boundary was achieved using the CDK1 inhibitor RO-
3306 for 20 hours (t=0). This led to an enrichment of cells at the G2/M stage (42.2% HeLa; 
67.9% HEK293ET) compared to asynchronous untreated cells (14.3% HeLa; 21.8% 
HEK293ET). Cells were then released into mitosis through washes and a media change. 
As expected, G2/M population was enriched at 30mins (54.2% HeLa; 61.6% HEK293ET) 
and 1hr post-release (54.1% HeLa; 66.8% HEK293ET). In HEK239ET cells samples 
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collected 6hrs post-release show that most cells had exited mitosis (26.0% HEK293ET), 
however a large proportion of HeLa cells were still in mitosis (33.8% HeLa) (Figure 3.9). 
The extent of synchronisation seen in the HeLa cells was not to the same extent as seen in 
Vassilev, et al. (2006), where most cells are in the G2/M peak after treatment with RO-3306 
for 20hrs (t=0).  
 
In order to test whether greater synchronisation of the G2/M population could be obtained 
in both cell lines, nocodazole was used. Synchronisation of HeLa and HEK293ET following 
treatment with 50ng/ml of nocodazole for 20hrs (t=0), led to an enrichment of cells in the 
G2/M population (79.0% Hela; 44.2% HEK293ET). In contrast to RO-3306, after 30mins 
most HeLa cells had exited mitosis, unlike HEK293ET cells (27.4% HeLa; 36.9% 
HEK293ET), which were seen to exit mitosis after 1hr (28.7% HEK293ET) (Figure 3.10). 
RO-3306 synchronises cells at the G2/M border, whereas nocodazole synchronises cells in 
metaphase, therefore it is expected that cells synchronised with nocodazole will exit mitosis 
before those synchronised with RO-3306. In addition, the extent of synchronisation 
achieved using nocodazole in HeLa cells was comparable to that seen in Neganova, et al. 
(2009), where 67.5% of hESCs (human embryonic stem cells) were synchronised using 
nocodazole.  
 
In contrast to RO-3306 and nocodazole, aphidicolin is often used to arrest cells in G1, 
preventing them from entering S phase (Pedrali-Noy, et al. 1980; Krokan, et al. 1981). In 
agreement with this both HeLa and HEK293ET cells were synchronised in G1 after 48hrs 
serum starvation, followed by 15hrs of treatment with 4µg/ml aphidicolin (74.5% HeLa; 
69.3% HEK293ET), compared to the asynchronous population (70.8% HeLa; 67.6% 
HEK293ET). HeLa cells around 4hrs post-release were seen to enter S phase, in contrast 
to HEK293ET, which entered S phase at 6hrs post-release. This complements the HeLa 
synchronisation with aphidicolin seen in Pedrali-Noy, et al. (1980), where after 4.5hrs post-
release, cells were in S phase. 12hrs post-release, cells were present in the G2/M 
population (53.7% HeLa; 39.1% HEK293ET) (Figure 3.11), although this enrichment in 
G2/M was not to the same extent of RO-3306 and nocodazole, aphidicolin could be used 
to track cells from G1 through to G2/M phase.  
 
Double thymidine block, as a method of synchronisation, has already been used for the 
characterisation of HECT ligases in the cell cycle (Osmundson, et al. 2008; Lu, et al. 2013). 
Two rounds of treatment with 2mM thymidine arrest cells at the G1/S boundary (Puck. 1964; 
Bootsma, et al. 1964), as seen in HeLa and HEK293ET (Figure 3.12).  At t=0, HeLa cells 
were in G1, whereas HEK293ET cells entered S phase, as seen in the G1 peak (68.0% 
HeLa; 31.3% HEK293ET) at 0hrs compared to the asynchronous G1 peak (72.8% HeLa; 
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63.8% HEK293ET). In accordance with Lu, et al. (2013), HeLa cells were seen to be in S 
phase at 4hrs post-release, before entering G2/M at 8hrs post-release from the double 
thymidine block (65.7% HeLa; 39.3% HEK293ET). By contrast, the largest G2/M peak 
observed in HEK293ET cells was seen at 4hrs post-release (42.4% HeLa; 52.3% 
HEK293ET). 12hrs post-release most cells have exited mitosis with the G2 peak returning 
to near asynchronous levels (28.4% HeLa; 11.2% HEK293ET). In comparison to 
aphidicolin, cells synchronised using a double thymidine block, entered S phase earlier 
post- release, resulting in mitotic entry and exit being captured. However, like aphidicolin, 
the enrichment of cells in G2/M was not as efficient as using RO-3306 or nocodazole. 




HeLa Time points G1 population (P3) G2/M population (P4) 
Asynchronous 75.2% 14.3% 
0h 34.5% 42.2% 
30min 25.1% 54.2% 
1h 21.4% 54.1% 
6h 53.1% 33.8% 
24h 51.4% 27.2% 
 
HEK293ET Time points G1 population (P3) G2/M population (P4) 
Asynchronous 61.5% 21,8% 
0h 14.0% 67.9% 
30min 17.6% 61.6% 
1h 14.7% 68.8% 
6h 55.69% 26.0% 
24h 61.9% 18.9% 
 
 
Figure 3.9. Synchronisation of HeLa and HEK293ET with RO-3306. HeLa and 
HEK293ET cells were treated with 9µM RO-3306 for 20hrs, before releasing and harvesting 
time points. 0hrs time point was taken before releasing the cells. Cells were fixed using 70% 
ethanol, cells were stained using 2µg/ml PI, with 100µg/ml RNase A, for 30mins at room 
temperature. Stained samples were then analysed immediately by flow cytometry. 
Histograms for each time point, A) HeLa and C) HEK293ET. Gated population percentages 
shown in tables B) Hela and D) HEK293ET. PI-A of 50 is equivalent to 2N (G1 population), 









HeLa Time points G1 population (P3) G2/M population (P4) 
0h 6.8% 79.0% 
30min 60.1% 27.4% 
1h 66.3% 21,7% 
6h 73.7% 17.2% 
24h 63.1% 25.7% 
 
 
HEK293ET Time points G1 population (P3) G2/M population (P4) 
0h 39.7% 44.2% 
30min 50.2% 36.9% 
1h 57.4% 28,7% 
6h 59.0% 27.6% 
24h 59.8% 26.8% 
 
 
Figure 3.10. Synchronisation of HeLa and HEK293ET with nocodazole. HeLa and 
HEK293ET cells were treated with 50ng/ml nocodazole for 20hrs, before releasing and 
harvesting time points. 0hrs time point was taken before releasing the cells. Cells were fixed 
using 70% ethanol, cells were stained using 2µg/ml PI, with 100µg/ml RNase A, for 30mins 
at room temperature. Stained samples were then analysed immediately by flow cytometry. 
Histograms for each time point, A) HeLa and C) HEK293ET. Gated population percentages 
shown in tables B) Hela and D) HEK293ET. PI-A of 50 is equivalent to 2N (G1 population), 









HeLa Time points G1 population (P3) G2/M population (P4) 
Asynchronous 70.8% 15.3% 
0h 74.5% 10.0% 
2h 70.3% 9.4% 
4h 23.6% 14.3% 
8h 19.6% 42.5% 
12h 27.8% 53.7% 
 
HEK293ET Time points G1 population (P3) G2/M population (P4) 
Asynchronous 67.6% 16.8% 
0h 69.3% 13.8% 
2h 68.6% 15.0% 
4h 62.4% 16.1% 
8h 30.8% 27.0% 
12h 31.6% 39.1% 
 
Figure 3.11. Synchronisation of HeLa and HEK293ET with aphidicolin. HeLa and 
HEK293ET cells were treated with 48hrs of serum starvation, followed by 4µg/ml aphidicolin 
for 15hrs, before releasing and harvesting time points. 0hrs time point was taken before 
releasing the cells. Cells were fixed using 70% ethanol, cells were stained using 2µg/ml PI, 
with 100µg/ml RNase A, for 30mins at room temperature. Stained samples were then 
analysed immediately by flow cytometry. Histograms for each time point, A) HeLa and C) 
HEK293ET. Gated population percentages shown in tables B) Hela and D) HEK293ET.PI-










HeLa Time points G1 population (P3) G2/M population (P4) 
Asynchronous 72.8% 17.0% 
0h 68.0% 5.5% 
2h 63.7% 4.1% 
4h 23.9% 43.4% 
8h 20.1% 65.7% 
12h 65.6% 28.4% 
 
HEK293ET Time points G1 population (P3) G2/M population (P4) 
Asynchronous 63.8% 19.9% 
0h 31.3% 18.6% 
2h 21.2% 28.0% 
4h 21.5% 52.3% 
8h 53.4% 39.3% 
12h 77.2% 11.2% 
 
Figure 3.12. Synchronisation of HeLa and HEK293ET with double thymidine block. 
HeLa and HEK293ET cells were treated with 2mM thymidine for 18hrs, followed by a 9hrs 
release. Then an additional 2mM thymidine for 15hrs, before releasing and harvesting time 
points. 0hrs time point was taken before releasing the cells. Cells were fixed using 70% 
ethanol, cells were stained using 2µg/ml PI, with 100µg/ml RNase A, for 30mins at room 
temperature. Stained samples were then analysed immediately by flow cytometry. 
Histograms for each time point, A) HeLa and C) HEK293ET. Gated population percentages 
shown in tables B) Hela and D) HEK293ET. PI-A of 50 is equivalent to 2N (G1 population), 
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3.2.5. HECTD1 protein levels throughout the cell cycle  
To establish a link between the cell proliferation phenotype and the cell cycle, it was next 
established whether HECTD1 itself is regulated by the cell cycle. Interestingly, sequence 
analysis revealed that HECTD1 has a predicted KEN box and 10 potential D boxes based 
on the RxxL motif (none following the RxxLxxxxN motif) (data in Appendix Figure A.3). 
Therefore, making HECTD1 a potential APC/C substrate. The hypothesis was that HECTD1 
may be a target of the APC/C, as both the D box and KEN are well established degradation 
motifs in APC/C substrates (Glozter, et al. 1991; Pfleger & Kirschner. 2000). Interestingly, 
NEDL2, a HECT E3 ligase was found to be degraded by the APC/CCDH1 upon mitotic exit 
(Lu, et al. 2013).  Therefore, to establish whether HECTD1 is cell cycle regulated given the 
cell proliferation phenotype, HeLa and HEK293ET cells were synchronised in M-phase and 
in G1 and HECTD1 protein levels were determined. 
 
To establish whether HECTD1 is degraded during mitosis or mitotic exit, HeLa cells were 
synchronised using 50ng/ml nocodazole for 20hrs (Figure 3.12A) (Zieve, et al. 1980). From 
the characterisation of the synchronisers (Figure 3.10), the greatest enrichment of G2/M 
phase HeLa cells was achieved using nocodazole. However, both visually and from the 
quantification of HECTD1 protein from the western blot (Figure 3.13B), the relative HECTD1 
levels remained constant throughout the cell cycle. Taking into consideration the large 
variability between replicates, there appeared to be no overall loss of HECTD1 protein level 
between metaphase and mitotic exit (60secs and 90secs time points) or subsequent G1 
phase (3hrs and 5hrs time points). However, nocodazole synchronises cells in metaphase 
and therefore does not allow for mitotic entry to be monitored (Zieve, et al. 1980). To 
overcome this, HEK293ET cells were synchronised in G2/M phase by RO-3306 (Figure 
3.13C). HEK293ET cells were synchronised using our optimised and also published 
conditions of 9µM RO-3306 for 20hrs (Vassilev, et al. 2006). Again, synchronisation using 
RO-3306 revealed no overall consistent change in HECTD1 levels in the 28hrs following 
release. The quantification of HECTD1 shows that upon mitotic exit (5hrs time point), there 
was no loss of HECTD1 (Figure 3.13D). However, because RO-3306 synchronises cells at 
the G2/M transition by CDK1 inhibition (Vassilev, et al. 2006), the later time points did not 
capture G1 phase. In addition, as shown in the synchroniser characterisation (Figure 3.9-
10), the degree of synchronisation was lost over time.  
 
To overcome the limitations of using nocodazole and RO-3306 to capture cells in G1, both 
HeLa and HEK293ET cells were synchronised using aphidicolin. From the synchronisation 
characterisation (Figure 3.11), use of aphidicolin resulted in the greatest enrichment of cells 
in G1. HEK293ET and HeLa cells (Figure 3.14) were synchronised using serum starvation 
followed by aphidicolin treatment and released into the G1/S transition (Pedrali-Noy, et al. 
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1980; Krokan, et al. 1981). In agreement with Figure 3.13, there was no consistent and 
repeated observable change in HECTD1 protein levels in HeLa relative to beta actin during 
cell cycle progression. Due to the fact that the data did was not consistent between repeats, 
this experiment should be repeated using additional APC/C substrates to rule out that 
HECTD1 is an APC/C substrate. The data currently are inconclusive and therefore, it is not 




















































Figure 3.13. HECTD1 protein levels in G2/M phase synchronised cells. A) 
Representative western blot of HeLa cells synchronised with 50ng/ml Nocodazole for 20hrs. 
B) Quantification of HECTD1 expression relative to the loading control, beta actin (n=2). C) 
Representative western blot of HEK293ET cells synchronised with 9µM RO-3306 for 20hrs. 
D) Quantification of HECTD1 expression relative to the loading control, beta actin (n=2). 
HeLa and HEK293ET cells were synchronised then harvested and lysed in RIPA buffer at 
the following time points collected at 0hrs, 10secs, 30secs, 60secs, 90secs, 3hrs, 5hrs, 
18hrs, 20hrs, 22hrs, 24hrs, and 28hrs post release. Samples were analysed on a 4-12% 
SDS PAGE and following western blotting on PVDF, the membrane was blocked in 3%-
BSA-PBST and incubated overnight with anti-HECTD1 antibody (ab101992) and anti-Cyclin 
B1 (sc-245), followed by detection with a secondary HRP antibody. Anti-beta-actin (A5441) 
was used as loading control. Molecular weight markers are superimposed on the left-hand 

















































































































Figure 3.14. HECTD1 protein levels in G1 phase synchronised cells. A) Representative 
western blot of HeLa cells synchronised by serum starvation for 48hrs before treatment with 
4µg/ml Aphidicolin for 15hrs. B) Quantification of HECTD1 expression relative to the loading 
control, beta actin (n=2). C) Representative western blot of HEK293ET cells synchronised 
by serum starvation for 48hrs before treatment with 4µg/ml Aphidicolin for 15hrs. D) 
Quantification of HECTD1 expression relative to the loading control, beta actin (n=1). HeLa 
and HEK293ET cells were synchronised then harvested and lysed in RIPA buffer at the 
following time points collected at 0, 2, 4, 6, 7, 8, 10, 11, 12, 13, 15 and 25hrs post-release. 
Samples were analysed on a 4-12% SDS PAGE and following western blotting on PVDF, 
the membrane was blocked in 3%-BSA-PBST and incubated overnight with anti-HECTD1 
antibody (ab101992) and anti-Cyclin B1 (sc-245), followed by detection with a secondary 
HRP antibody. Anti-beta-actin (A5441) was used as loading control. Molecular weight 











































































In this chapter, HECTD1 has been identified as a regulator of cell proliferation. The 
decrease in cell proliferation seen in HEK293T HECTD1 knock out cells was also seen in 
HECTD1-depelted HEK293ET and HeLa cell lines. Furthermore, this decrease in 
proliferation can only be rescued by wild type mHectd1 and not the catalytic mutant. This 
strongly indicates that the ubiquitin ligase activity of HECTD1 is required for optimum cell 
proliferation. To investigate the mechanisms involved, and given that many proteins 
involved in the cell cycle are cell-cycle regulated at the protein level, HECTD1 levels were 
assessed. To this end, synchronising agents were fully characterised across two cell lines 
allowing the enrichment of specific cell cycle populations. HECTD1 protein levels were 
assessed in synchronised cell population, however the data is inconclusive at this stage 
and would require further work to demonstrate whether HECTD1 is cell cycle regulated.  
 
 
3.3.1.  Decrease in proliferation as a result of HECTD1-depletion or knockout 
In an attempt to determine the cellular functions of HECTD1 more rigorously, it was 
determined whether HECTD1 depletion resulted in any obvious cellular phenotype. 
Specifically, cell proliferation was assessed to determine if it was affected in HECTD1 
knockout or HECTD1-depleted cells using trypan blue and cell counting as a readout. It was 
observed that over time, the number of proliferating cells were reduced in the knockout 
compared to the wild type cells. Furthermore, this was also observed in cells treated with 
HECTD1 siRNA in both HEK293ET and HeLa, indicating that the robustness of this effect. 
Transient overexpression of HA-FL-mHectd1WT resulted in the rescue of the reduced 
proliferation observed in the KO cell lines indicating that indeed HECTD1 was required for 
cell proliferation. In contrast, overexpression of HA-FL-mHectd1C2579G was not able to 
rescue this decreased proliferation suggesting that the E3 ligase activity is required for 
optimum cell proliferation. Therefore, this suggests that the atypical activity of HECTD1 in 
synthesising K29/K48 ubiquitin chains may function in regulating cell proliferation. This is a 
novel and exciting observation because to date, depletion of HECTD1 has not been shown 
to result in a reduced cell proliferation phenotype. This regulation of cell proliferation 
alongside the previous observation that HECTD1 colocalises to the mitotic spindle, may 
together indicate the HECTD1 has a role in cell cycle regulation, this will be explored at a 
greater depth in Chapter 4.  
 
An important consideration is that the cell proliferation phenotype associated with HECTD1-
depletion may not be linked to a role the cell cycle. For example, HECTD1 has been 
previously reported to function in the Wnt signalling pathway however, it acts as a negative 
regulator (Tran, et al. 2013). In this scenario, increased HECTD1 leads to reduced Wnt 
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signalling, which results in reduced proliferation. Therefore,  reduced HECTD1 would result 
in increased cell proliferation and so, the observed phenotype of reduced proliferation upon 
HECTD1-depletion is not due to the role HECTD1 has in Wnt signalling. Furthermore, 
HECD-1, the HECTD1 orthologue, has been implicated in mitochondrial metabolism in C. 
elegans (Segref, et al. 2014). Therefore, aberrant regulation of the mitochondria by 
HECTD1-depletion may result in reduced proliferation as a result of reduced metabolic 
output. Dysregulation of the mitochondria often results in cell death through ATP depletion 
and Ca2+ dysregulation (Di Lisa, & Bernardi. 1998). The viability of HECTD1 depleted or 
knockout cells did not reduce over time in culture, therefore suggesting that the reduction 
in cell proliferation was not as a result of cell death, suggesting that changes in proliferation 
were not as a result of mitochondrial regulation. Therefore, the observed reduction in 
proliferating cells may be as a result of cell cycle regulation associated with HECTD1 and 
not a previously published role of HECTD1. To implicate HECTD1 in the cell cycle, further 
work will be needed to see if the phenotype is cell cycle related (Chapter 4).  
 
 
3.3.2. Optimisation of cell synchronisation protocol to study HECTD1 in the cell cycle  
In contrast to nocodazole, RO-3306 is able to capture the whole of mitosis due the inhibition 
at the G2/M transition (Zieve, et al. 1980; Vassilev, et al. 2006). For HeLa cells synchronised 
with nocodazole, 79.0% of cells were in G2/M and HEK293ET cell synchronised with RO-
3306 yielded a comparable 67.9%. However, HEK293ET cells synchronised with 
nocodazole, and HeLa synchronised with RO-3306 enriched less than 45% of cells in G2/M. 
The poor synchronisation of HEK293ET cells synchronised with nocodazole may be 
explained by the semi-adherent nature of the cells. The harvesting of mitotic cells 
synchronised with nocodazole, included a mitotic shake-off, therefore, non-mitotic cells may 
be collected additionally. HeLa in comparison are much more adherent, making the mitotic 
shake-off less likely to include non-mitotic cells. The poor enrichment of HeLa cells using 
RO-3306 is unexpected given that the synchroniser was initially characterised using HeLa 
cells, and in their data, shows greater enrichment in G2/M (Vassilev, et al. 2006). This may 
be as a result of the characterisation only being carried out once, therefore for future 
experiments the extent of synchronisation should be measured. Synchronisation using 
aphidicolin releases cells into G1, therefore allowing G1 to be monitored up to (4hrs-6hrs) 
post-release. However, when synchronised using a double thymidine block, HEK293ET are 
released straight into S phase and HeLa cells enter S phase 1 hr post-release. Therefore, 
when selecting which synchroniser to use for future experiments, this characterisation will 
help in experimental design to ensure that the cells are enriched in the desired cell cycle 
phase.  
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Chemical synchronisation reagents such as RO-3306, nocodazole, aphidicolin, and 
thymidine do have important drawbacks and limitations to consider. For instance, their 
mechanism of action is not fully understood, with possible pleiotropic side effects such as 
stress, and apoptosis. In contrast to chemical synchronisation, mitotic shake-off, counter-
current centrifugal elutriation, and cell sorting via flow cytometry all provide a physical way 
of enriching for cells in a distinct cell cycle phase, potentially negating the side effects seen 
with chemical synchronisers. Mitotic shake-off, the simplest method of synchronisation, 
relies on the detachment of rounded mitotic cells under agitation. Chemical synchronisation 
before mitotic shake-off functions to enrich the mitotic population prior to agitation, however 
this is not necessary (Elvin, et al. 1983). The main limitation of this method being that only 
M-phase cells can be synchronised. Cell synchronisation by way of cell sorting separates 
cells according to antibody-, ligand-, and dye-mediated fluorescence in a flow cytometer, 
the benefit of which allows cells to be sorted on a single-cell basis (Rosner, et al. 2013). 
However, this method tends to be limited by the inability of cell cycle profiling by DNA 
staining to distinguish G2 phase from M phase (Ormerod & Kubbies. 1992). Finally, cells 
can be synchronised by separation by their physical size, by counter-current centrifugal 
elutriation. This method separates cells in 12 fractions by their sedimentation velocity in a 
gravitational field, which yields cells in each stage of the cell cycle. The liquid containing the 
cells flows against the centrifugal force, resulting in the sedimentation rate of the cells being 
proportional to their size (Lindahl. 1948). Importantly, this method ensures that cells are not 
metabolically perturbed, however the cells as a result of the elutriation process can enter 
quiescence, G0 (Kauffman, et al. 1990; Zickert, et al. 1993).  
 
 
3.3.3. HECTD1 protein levels during cell cycle progression 
Given the presence of both a KEN box and several D boxes predicted in the sequence of 
HECTD1 (data in Appendix Figure A.3), it was hypothesised that it may be a substrate of 
the APC/C. Using nocodazole, RO-3306, and aphidicolin, mitotic exit and G1 phase were 
captured, where APC/CCDH1 is active (Wei, et al. 2004; Lu, et al. 2013). Furthermore, early 
mitosis was captured by synchronisation using RO-3306 where APC/CCDC20 is active 
(Kramer, et al. 2000). However, both cell lines, synchronised in G2/M and G1, showed large 
variability in the protein levels of HECTD1 both visually and by quantification. Therefore, it 
was not possible to conclude whether HECTD1 protein levels are cell cycle regulated. This 
experiment would need to be repeated, and for completeness blotted for APC/C substrate 
other than Cyclin B1, such as Cyclin A, NEK2A, securin, and PLK1. If HECTD1 was 
degraded by the APC/C, one would expect to see a visible loss of the HECTD1 protein band 
as seen in western blots of other E3 ligases,  NEDL2, SKP2, and SMURF1 (Wei, et al. 
2004; Kannan, et al. 2012; Lu, et al. 2013). The HECT E3 ligase, EDD, involved in SAC 
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regulation, was shown not to be cell cycle regulated in the 180mins following release from 
nocodazole (Scialpi, et al. 2014). Therefore, not all regulators of the cell cycle are cell cycle 
regulated and therefore it is possible that HECTD1 enzymatic activity, rather than HECTD1 
protein levels might be regulated during the cell cycle. Indeed, recent data indicate that 
some HECT ligases are constitutively inactive and regulated by complex intra- and 
intermolecular mechanisms. For example, the NEDD4 family of HECT ligases have an auto-
inhibitory C2 domain which can be released upon binding to Ca2+ or small PY-containing 
membrane proteins, NDFIP1 and NDFIP2 (Mund & Pelham. 2009; Wang, et al. 2010). In 
addition, the HECT ligase HUWE1 has been described as being regulated by the formation 
of an auto-inhibitory dimer that is stabilised by the tumour suppressor p14ARF (Sander, et 
al. 2017). Recently it was found that peptide linkers between the WW domains found in 
NEDD4 family proteins, such as WWP1, WWP2, and ITCH are important for their catalytic 
regulation. These linkers were found to function to lock the ligase in an inactive conformation 
and that tyrosine phosphorylation was found to relieve this autoinhibition (Chen, et al. 2017). 
However, it is currently unknown how the ligase activity of endogenous HECTD1 is 
regulated. 
 
A potential solution to studying the ligase activity of endogenous HECTD1 is by using 
Activity-Based Probes (ABP). ABPs are chemical probes that direct the active site of 
enzymes, to profile their activity within complex mixtures of proteins (Love, et al. 2007). To 
specifically target E3 ligases, novel E2-based ABPs have been recently developed in order 
to monitor ubiquitin ligase activity (Pao, et al. 2016). E2-based ABPs, mimic a ubiquitin-
charged E2 with a C-terminal electrophilic warhead that is able to label RBR and HECT E3 
ubiquitin ligases. This allows for specific labelling of RBR and HECT ligases, as only active 
sites with an E2 binding site will result in covalent modification of the cysteine, thus 
excluding labelling of deubiquitinases (Pao, et al. 2016). These C-terminal warheads 
comprise aldehyde, vinyl sulfone, vinylmethylester (VME), and propargylamide (PA) 
(Hershko & Rose. 1987; Palmer, et al. 1995; Borodovsky, et al. 2001; Borodovsky, et al. 
2002; Ekkebus, et al. 2013). The use of novel ABPs could therefore help decipher whether 
HECTD1 ligase activity changes during cell cycle progression and how loss of this activity 
can impact on cell proliferation (Further discussed in 3.4. Future Work). 
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3.4. Future work: 
The use of trypan blue to count the number of viable cells for growth curves, is a simple 
experiment, however is subject to human error or bias when counting. Therefore, to 
overcome this, cellular assays, such as MTT or ATP assays can be used to calculate cell 
viability, and the number of viable cells, which are not subject to bias (Riss, et al. 2004). 
Only one of the cell proliferation analyses was carried out using an ATP proliferation assay, 
which largely repeated the observation seen with manual cell counting. However, for future 
work this metabolic readout should be used as a more reliable and high-throughput method 
to assay cell proliferation and viability. 
 
The use of propidium iodide staining to assess the cell cycle profile is a quick and simple 
method. However, due to the nature of the technique whereby the DNA content is 
measured, it is not possible to quantify the proportion of cells in S-phase, or separate out 
the G2 population from the M population (Ormerod & Kubbies. 1992). The S-phase 
population is assumed to be the population of cells that exists between G1 and M phase 
populations. However, a more accurate way of measuring this is using BrdU 
(bromodeoxyuridine) staining. BrdU, a synthetic nucleoside that is an analogue of 
thymidine, is incorporated into newly synthesised DNA. S-phase cells are detected by using 
an antibody against BrdU (Gratzner. 1982), and this can be adapted to flow cytometry or 
high-content microscopy to quantify this population (Ormerod & Kubbies. 1992; Massey A. 
2015). In addition, the use of mitotic specific antibodies such as cyclin B1 and pHistone H3 
(ser28) can be used for flow cytometry or high content microscopy to visualise the mitotic 
population (Chapter 4).  
 
One limitation of using western blotting to characterise HECTD1 protein levels throughout 
the cell cycle, is that the technique is exposed to uneven loading of the sample, and that it 
is only ever semi-quantitative. Therefore, any subtle change in protein levels would be 
difficult to detect. To overcome hits, endogenous GFP-tagged HECTD1 signal could be 
measured and tracked over time in synchronised cells transfected with the GFP-tagged 
protein. This measurement and tracking of the localisation could be carried out using high-
content microscopy. For example, Liberali, et al. 2014, used high-content microscopy to 
conduct an RNAi screen on single-cells to measure endocytic tracking, where fluorescently 
labelled cargo were tracked and measured quantitatively. Another limitation to be 
considered is the use of only one cell cycle maker, Cyclin B1, which only identifies cells that 
are in G2/M (Pines & Hunt. 1987; Murray & Kirschner. 1989). To identify cell cycle 
populations, flow cytometry or high-content microscopy, as discussed, could be used to 
show the cell cycle stage at each time point alongside the western blot.  
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Finally, expanding on the idea that HECTD1 ligase activity rather than the stability of the 
ligase might be regulated during cell cycle progression, synchronised cell lysates could be 
treated with an E2-Ub-ABP (Byrne, et al. 2017). Previously, using ABPs our laboratory 
showed that in unstimulated HeLa and HEK cells, HECTD1 is either inactive or that its 
activity is below the threshold of detection for the assay, in experiments carried out in 
asynchronised cells (Byrne, et al. 2017). Preliminary data using ABPs on frozen cell lysates 
obtained from synchronised cells did not result in the labelling of endogenous HECTD1. 
Since frozen samples might be an issue for labelling, cells have been lysed by sonication 
as described in Pao, et al. (2016). This was also unsuccessful at labelling HECTD1 in RO-
3306 synchronised cell lysates at 0hrs, 20mins, 2hrs and 20hrs post-release. However, this 
was only carried out once, and by western blot the cell lysis appears to be incomplete, 
suggesting that an initial optimisation of this experiment would be to improve the lysis 
protocol. Based on optimisation from previous experiments, the ABP probe is always in 
excess, therefore the availability of HECTD1 may be a limiting factor. The anticipated results 
would be that whilst the ABP would not covalently label HECTD1 in basal unstimulated 
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Transient and genetic depletion of HECTD1 resulted in a reduction in cell proliferation in 
HEK293T, HEK293ET and Hela cells (Chapter 3). The cell cycle and cell proliferation are 
tightly and directly connected and reduced cell proliferation phenotypes have been 
observed for cell cycle regulators such as NuMA (Haren, et al. 2009). Therefore, it was 
hypothesised that the observed reduction in proliferating cells may be due to a novel role of 
HECTD1 in the cell cycle. The control of cell proliferation is regulated in late G1, where, 
activation of G1/S- and S-CDKs triggers an irreversible commitment to a new cell cycle. 
This point of commitment is known as the restriction point (Zetterberg, et al. 1995; Johnson 
& Skotheim. 2013). The activation of G1/S- and S-CDKs is regulated by extracellular factors 
known as mitogens, which ensure that cells proliferate only when needed (Zetterberg, et al. 
1995; Hengstschläger, et al. 1999). Interestingly, it has been observed that cells, which 
undergo prolonged prometaphase, result in the inhibition of daughter cell proliferation 
despite normal completion of mitosis (Uetake & Sluder. 2010). It was subsequently revealed 
that a mechanism exists that senses prometaphase duration in cells. For instance, a delay 
in prometaphase for more than 1.5hrs triggered a durable p38- and p53- dependent G1 
arrest of the daughter cells despite normal division of the parent cell (Uetake & Sluder. 
2010).  
 
Most of what is known about ubiquitin signalling in the cell cycle relates to RING E3 ligases 
such as the APC/C and the SCF complexes, where the mechanisms, substrates, and 
ubiquitin chain types have been studied over the last 15 years, by many different research 
groups (Vordermaier. 2004; Petroski, et al. 2005; Jin, et al. 2008). In contrast, HECT E3 
ligases have diverse roles in cell cycle regulation and for the majority of ligases, their 
substrates and chain type are yet to be fully characterised (Table 1.3). These proposed 
roles include, regulation of DNA replication, centrosome amplification, and regulation of the 
spindle assembly checkpoint. HUWE1 the human ortholog of the yeast Tom1, was shown 
to be responsible for the degradation of CDC6, a cell cycle protein responsible for DNA 
replication (Hall, et al. 2007; Kim, et al. 2012b). HERC2, together with NEURL4 and CP110, 
was identified as a regulator of centrosome amplification (Al-Hakim, et al. 2012). 
Interestingly, both SMURF2 and EDD, have been implicated in the regulation of the spindle 
assembly checkpoint. SMURF2 prevents ubiquitination and degradation of MAD2, a SAC 
component, permitting the checkpoint to be active. Therefore, depletion of SMURF2 
resulted in premature anaphase onset, a phenotype associated with a defective SAC 
(Osmundson, et al. 2008). Finally, EDD was shown to physically interact with the SAC 
components BUB3 and BUBR1, although its precise mechanism of regulation is unknown 
(Scialpi, et al. 2015). 
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Importantly, the cell proliferation defect observed upon HECTD1 depletion was rescued by 
expression of HA-FL-mHectd1WT but not HA-FL-mHectd1C2579G (Chapter 3). This suggests 
that the E3 ligase activity of HECTD1 is required for cell proliferation. Therefore, the atypical 
ubiquitin ligase activity of HECTD1 in synthesising K29/K48 ubiquitin chains, (Licchesi, 
personal communication), may function as a novel signal in cell proliferation and perhaps 
the cell cycle. To date, the best characterised chain type in cell cycle regulation is K11-
linked ubiquitin chains, which are conjugated onto substrates by the APC/C (Jin, et al. 
2008). More recently, branched K11 ubiquitin chains synthesised by the APC/C and 
UBE2S, have been shown to enhance proteasomal degradation of the cell cycle substrates 
NEK2A and p21 (Meyer & Rape. 2014).  Furthermore, the APC/C was also recently shown 
to synthesise K11/K48 ubiquitin chains on similar mitotic substrates (NEK2A and Cyclin A) 
(Yau, et al. 2017). The HECT E3 ligase HERC2 has been shown to conjugate K48 onto 
NEURL4 in its role in regulating centrosome duplication (Al-Hakim, et al. 2012). In mitosis, 
the HECT ligase SMURF2 conjugates K63 in the regulation of the mitotic protein MAD2, 
however there is currently no biochemical evidence to support this chain type specificity 
(Osmundson, et al. 2008). Together these studies emphasise that the type of ubiquitin 
chains synthesised by HECT ligases in the context of the cell cycle is still poorly understood. 
Therefore, the discovery that HECTD1, which in vitro appears to synthesise K29/K48 
chains, is important for optimum cell proliferation is exciting. Indeed, this suggests that a 
novel type of ubiquitin chain might be implicated in cell cycle regulation, through HECTD1 









Given that HECTD1 depletion leads to reduced cell proliferation, this next chapter aims to 
identify the cellular process affected by the loss of HECTD1 function. Since, the cell cycle 
is tightly connected to cell proliferation (Duronio & Xiong. 2013), the aim was to determine 
whether HECTD1 depletion affects cell cycle progression. Therefore, the following 
objectives were to: 
 
1. Measure DNA content by flow cytometry as a readout for cell cycle stage, to 
determine the effect of HECTD1 depletion on the cell cycle in HeLa and HEK293ET 
cells.  
 
2. Use immunofluorescence and confocal microscopy to determine the localisation of 
HA-FL-mHectd1 during the cell cycle in HEK293ET cells.  
 
3. Use immunofluorescence and confocal microscopy to quantify the number of cells 
in each stage of mitosis, to determine the effect of  HECTD1-depletion in both HeLa 
and HEK293ET cells. Mitotic and nuclear defects were also quantified. 
 
4. Compare the length of mitosis in both wild-type and HECTD1-depeleted cells by 
synchronising cells and probing western blots for cell cycle markers. Additionally, by 
measuring the DNA content by flow cytometry as a readout for cell cycle stage in 
synchronised cells. Finally, by measuring the time taken from Nuclear Envelope 
Breakdown (NEBD) to anaphase onset by using time lapse microscopy. 
 
5. Determine whether the observed phenotypes are due to HECTD1 ubiquitin ligase 
activity through rescue assays using plasmids encoding HA-FL-mHectd1WT, HA-FL-
mHectd1C2579G, and an empty vector control. 
  




4.2.1. HECTD1 depletion results in no change in the G2/M population  
In Chapter 3, HECTD1 depletion was shown to result in a decrease in cell proliferation and 
interestingly this phenotype was rescued by HA-FL-mHectd1WT. Therefore, it was 
hypothesised that this decrease in proliferation could be mediated by an effect on the cell 
cycle. Flow cytometry alongside propidium iodide staining is a useful technique to determine 
the cell cycle stages of individual cells in an asynchronous population, with the limitation 
that it is not possible to quantify the proportion of cells in S phase, or separate out the G2 
population from the M population (Ormerod & Kubbies. 1992). However, propidium iodide 
staining was used here to determine whether HECTD1-depleted cells may show any 
obvious defects in their ability to cycle through the different stages of the cell cycle.  
 
The cell cycle profiles shown in Figure 4.1, show similar sized G1 peaks, and similar G2/M 
peaks. This therefore suggests that there is no change in G2/M population in cells depleted 
of HECTD1. PI staining and flow cytometry can be used to assess the presence of 8N 
populations as a result of cells being unable to complete mitosis, as seen with the ligase 
SMURF2 (Osmundson, et al. 2008). Therefore, PI staining was used to establish whether 
HECTD1-depleted cells could induce chromosomal instability. However, there were no 8N 
cells present (data not shown), indicating that cells were successful in completing mitosis.  
  
































Figure 4.1. No change in G2/M population upon HECTD1-depletion in HEK293ET and 
HeLa cells. Cell cycle profile was characterised by using flow cytometry and propidium 
iodide staining. HEK293ET and HeLa cells were knocked down with either 20pmol Non-
targeting siRNA (NT) or HECTD1 SMARTpool siRNA (HECTD1) and Lipofectamine 2000/ 
RNAiMAX, then analysed asynchronously after 72hrs. Cells were fixed using 70% ethanol 
and stained using 2µg/ml PI, with 100µg/ml RNase A, for 30mins at room temperature prior 
to analysis. Histograms for HEK293ET and HeLa, gate P3 = G1 population and gate P4 = 
G2/M population to quantify cell populations (HEK293ET, n=3 and HeLa, n=3). PI-A of 50 
is equivalent to 2N (G1 population), and PI-A of 100 is equivalent to 4N (G2/M population). 
  
HEK293ET NT siRNA HEK293ET HECTD1 siRNA 
HeLa NT siRNA HeLa HECTD1 siRNA 
HEK293ET NT siRNA HEK293ET HECTD1 siRNA 
HeLa NT siRNA HeLa HECTD1 siRNA 
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4.2.2. HA-FL-mHectd1 localises to the mitotic spindle during mitosis 
To characterise the previously observed mitotic spindle staining, the localisation of HECTD1 
throughout the cell cycle was explored. To this end, two HECTD1 antibodies were tested 
for their ability to detect endogenous HECTD1 by immunofluorescence in HEK293ET cells 
and two HECTD1 CRISPR/Cas9 KO cell lines (kindly contributed by Mariann Bienz, MRC-
LMB, Cambridge) (Figure 4.2). The antibody ab101992 was raised against the N-terminal 
amino acids 1-50 of hHECTD1 while ab101993, also from Abcam, was raised against the 
C-terminal region of hHECTD1 (AA2100-2150). Staining with the N-terminal HECTD1 
antibody revealed a strong signal, almost exclusively cytosolic in interphase cells and at the 
mitotic spindle of mitotic HEK293T cells (Figure 4.2A). However, this signal was also 
present in two CRISPR/Cas9 clones derived from HEK293T cells suggesting that the 
observed staining is non-specific (Figure 4.2B). In contrast, the C-terminal specific HECTD1 
antibody showed a dissimilar staining pattern in interphase cells, where a nuclear staining 
was observed, and a weak signal was observed in mitotic cells (Figure 4.2A). In addition, 
with this antibody the signal was reduced in HECTD1 KO cell lines, suggesting that the 
epitope was more specific towards endogenous HECTD1 (Figure 4.2B). However, the 
signal in cells stained with ab101993 was overall weak compared to the background signal, 
making this antibody unsuitable. Therefore, neither antibody was suitable for 
immunofluorescent staining of mitotic cells. In contrast, both antibodies could be used to 
detect full-length HECTD1 by western blotting, with ab101992 yielding fewer background 
bands compared to ab101993 (Figure 4.3). This validates and confirms the previous 
observations carried out in Chapter 3 using ab101992, therefore, ab101992 was deemed 
appropriate for further western blotting experiments.  
 
The limitation of using the endogenous HECTD1 antibodies for immunofluorescence was 
overcome by the use of an overexpression assay. Although overexpression can lead to 
artefacts, expression of HECTD1 labelled with a HA- epitope tag, allows for more specific 
detection of the protein compared to antibodies raised against the endogenous protein. 
HEK293ET cells were transiently transfected with HA-FL-mHectd1 (kindly contributed by 
Mariann Bienz, MRC-LMB, Cambridge) and cells were imaged by IF detection using anti-
HA antibody in interphase and mitotic cells. Both HA-FL-mHectd1WT and HA-FL-
mHectd1C2579G during interphase showed diffuse staining in the cytoplasm and exclusion 
from the nucleus (Figure 4.4). Interestingly, HA-FL-mHectd1WT was found to localise with 
the mitotic spindle marker, a-tubulin (Mandelkow & Mandelkow. 1989), in prometaphase 
and metaphase, suggesting that HECTD1 may function in mitosis.  Furthermore, as cells 
progress from anaphase I to telophase, the staining of HA-FL-mHectd1 at the mitotic spindle 
(a-tubulin), became gradually weaker and more diffuse until no colocalisation was observed 
in anaphase II and telophase (Figure 4.5). To elucidate whether the E3 ligase activity of 
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HECTD1 was required for its mitotic localisation, the catalytic mutant of HECTD1 (C2579G) 
(Sarkar, et al. 2012) was overexpressed in HEK293ET cells, and imaged throughout 
mitosis. HA-FL-mHectd1C2579G was seen to localise to the mitotic spindle (a-tubulin) during 
prometaphase and metaphase, as seen with the wild-type protein. Again, the localisation, 
and potentially the staining for HECTD1, was reduced as cells progressed from anaphase 
I to telophase (Figure 4.6). This indicates that the E3 ligase activity of the HECTD1 is not 
required for its localisation during mitosis.  Importantly, to validate this assay, an empty 
vector control was also carried out and showed absence of staining, including spindle 
staining, suggesting that the observed staining was not due to non-specific binding of the 
anti-HA antibody (Figure 4.4-6). Taken together, this suggests a potential function for 
HECTD1 during M phase and not G2 phase.  
  















































Figure 4.2. Validation of HECTD1 antibodies for immunofluorescent staining. A) 
Confocal images of HEK293ET mitotic cells stained with ab101992 or ab101993 (1 in 200 
dilution). Cells were fixed using 4% PFA, and imaged using the LSM 510 Meta Confocal 
Microscope. Scale bar represents 10µm. White arrow indicates weak mitotic spindle 
staining using C terminal antibody. B) HEK293T HECTD1 knockout cells were stained with 
either a HECTD1 N-terminal antibody (ab101992) or a HECTD1 C-terminal antibody 
(ab101993), at a 1 in 200 dilution. Cells were fixed using 4% PFA, and imaged using the 









































































Figure 4.3. Validation of HECTD1 antibodies for western blotting. A) Western blot 
showing the antibody staining for ab101992 and ab101993 in HEK239T HECTD1 knockout 
cells, labelled with the molecular weight marker on the left-hand side. Based on the 
molecular weight, the band indicated by *1 represents full length HECTD1 and *2 represents 
HECTD1 005, *3, *4, and *5 do not correspond to known splice variants of HECTD1. Cells 
were lysed in RIPA buffer and samples were analysed on a 4-12% SDS PAGE. Following 
western blotting on PVDF, the membrane was blocked in 3%-BSA-PBST and incubated 
overnight with anti-HECTD1 antibody (ab101992) and anti-pHistone H3 (ser28) (ab10543), 
followed by detection with a secondary HRP antibody. Anti-beta-actin (A5441) was used as 
loading control. B) Predicted molecular weights of protein coding variants of hHECTD1, 
using Ensembl Gene Browser 90, https://www.ensembl.org, (accessed 09/10/17). 
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Figure 4.4. Diffuse localisation of mHectd1WT and mHectd1C2579G in human cell lines 
during interphase. Representative images of HA-FL-mHectd1WT and HA-FL-
mHectd1C2579G staining in interphase HEK cells. HEK293ET cells were transfected with 
500ng of HA-FL-mHectd1WT, HA-FL-mHectd1C2579G and an HA-tagged empty vector (EV) 
using PEI, in a 12 well format. 24hrs post-transfection cells were fixed using 4% PFA, then 
stained with anti-HA, anti-α-tubulin and Hoechst. Images were taken using the LSM Meta 





















































Figure 4.5. HA-FL-mHectd1WT is localised to the mitotic spindle in HEK293ET cells 
during mitosis. Representative images of HA-FL-mHectd1WT in mitotic HEK cells. 
HEK293ET cells were transfected with 500ng of HA-mHectd1WT and an HA-tagged empty 
vector (EV) using PEI, in a 12 well format. 24hrs post-transfection cells were fixed using 4% 
PFA, then stained with anti-HA, anti-α-tubulin and Hoechst. Images were taken using the 
LSM Meta 510 Confocal Microscope. Scale bar represents 10µm. Images were taken of 
cells in prometaphase, metaphase, anaphase I, anaphase II, and telophase. Anaphase was 
subdivided into anaphase I, and anaphase II; anaphase I denotes early anaphase, where 
the sister chromatids begins to segregate to opposite poles of the spindle, and anaphase II 
denotes late anaphase where elongation of the spindle occurs (Pines. 2006). White arrows 
indicate cells with the strongest colocalisation to α-tubulin, seen during prometaphase and 
metaphase. 
 












































Figure 4.6. HA-FL-mHectd1C2579G is localised to the mitotic spindle in HEK293ET cells 
during mitosis. Representative images of HA-FL-mHectd1C2579G in mitotic HEK cells. 
HEK293ET cells were transfected with 500ng HA-mHectd1C2579G and an HA-tagged empty 
vector (EV) using PEI, in a 12-well format. 24hrs post-transfection cells were fixed using 4% 
PFA, then stained with anti-HA, anti-α-tubulin and Hoechst. Images were taken using the 
LSM Meta 510 Confocal Microscope Scale bar represents 10µm. Images were taken of 
cells in prometaphase, metaphase, anaphase I, anaphase II, and telophase. Anaphase was 
subdivided into anaphase I, and anaphase II; anaphase I denotes early anaphase, where 
the sister chromatids begins to segregate to opposite poles of the spindle, and anaphase II 
denotes late anaphase where elongation of the spindle occurs (Pines. 2006). White arrows 
indicate cells with the strongest colocalisation to α tubulin, seen during prometaphase and 
metaphase.  
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4.2.3. HECTD1 depletion results in an enrichment of metaphase cells 
Given the limitation of the PI staining in reporting a change in the G2/M population of cells 
upon HECTD1 depletion, and the apparent localisation of HECTD1 during mitosis, cells 
were scored based on their mitotic stage following confocal imaging. This is an established 
phenotypic assay successfully used to identify JMJD5 and NuMA as mitotic regulators 
(Haren, et al. 2009; He, et al. 2015). Here, HECTD1 was transiently depleted in HEK293ET 
and HeLa cells, and stained with anti-α-tubulin antibody and Hoechst. Cells were scored at 
prophase, prometaphase, metaphase, anaphase, and telophase based on the morphology 
of the microtubules and the DNA. Cells in prophase were defined as cells with condensed 
chromosomes (Sager, et al. 1986; Strunnikov. 2003) and cells in prometaphase were 
defined by centrosomes at each pole, with chromosomes that begin to align into the centre 
of the cell (Aubin, et al. 1980; Beaudouin, et al. 2002). Metaphase cells were defined by 
chromosomes aligned along the equatorial plane (Rieder & Alexander. 1990), followed by 
anaphase cells where sister chromatids begin to segregate to opposite poles (Baskin, & 
Cande. 1990; Pines. 2006), and finally telophase cells where the nuclear envelope forms 
around each set of chromosomes in the daughter cells, and the chromosomes uncoil 
(Chaudhary, & Courvalin. 1993; Schwalm. 1969). A representative image of each stage of 
mitosis scored is shown in Figure 4.7C.  
 
In HEK293ET that were transiently depleted of HECTD1, there was a significant increase 
in the number of metaphase cells compared to control. Specifically, 40% of cells in the non-
targeting control were in metaphase, compared to 58.1% seen with cells treated with 
HECTD1 siRNA #06, and 57.7% for the HECTD1 SMARTpool (SP) siRNA (Figure 4.7A). 
Similarly, this effect was also observed in Hela cells, where 35.7% of cells in the non-
targeting condition were scored as being in metaphase, compared to 50.4% (SMARTPool), 
48.8% (#06), and 51.7% (#08). (Figure 4.7B). In summary, cells depleted for HECTD1 
showed an 18% increase in HEK239ET and a 15% increase in HeLa of cells in metaphase 
compared to the non-targeting siRNA control. This therefore indicates that HECTD1 
depletion results in an enrichment of cells in metaphase.  














Figure 4.7. Scored mitotic stage upon HECTD1 depletion in HEK293ET and HeLa 
cells. Asynchronous A) HEK293ET cells and B) HeLa cells were scored according to 
chromatin morphology or spindle morphology based on Hoechst (blue) and α-tubulin 
(green) staining following knockdown using NT (non-targeting), HECTD1 SMARTpool 
(smart pool), #06, and #08 siRNA, and Lipofectamine-2000 or -RNAiMAX for 48hrs. Data 
plotted as mean with error bars that represent ±S.E.M., over 6 biological repeats (individual 
transfections). **p<0.01, ***p<0.001, and ****p<0.0001 using a one-way ANOVA with a 
Dunnett’s post-test. Each HECTD1 siRNA condition was significant when compared to the 
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4.2.4. HECTD1 depletion does not induce mitotic spindle or nuclear defects 
Having shown that HECTD1 depletion resulted in a significant enrichment of metaphase 
cells. The next question was to establish whether this could be due to an increase in 
abnormal mitosis and perhaps increased defects including multipolar spindles, misaligned 
metaphase plates or lagging chromosomes. For instance, cells depleted of NuMA were 
found to be enriched in early mitosis coinciding with chromosome alignment defects and 
spindle abnormalities (Haren, et al. 2009). Multipolar spindles are defined by cells that have 
more than two spindle poles (Yan, et al. 2015) and cells with a misaligned metaphase plate 
are cells that have a number of unattached kinetochores (Haren, et al. 2009; Chapard, et 
al. 2014; Yan, et al. 2015) (Figure 4.8C). Cells with lagging chromosomes exhibit 
chromosomes that do not move at the same rate as the other chromosomes during 
anaphase (Chapard, et al. 2014; Yan, et al. 2015).  Finally, normal mitotic cells are cells 
that have no observable mitotic defects. Again, HECTD1 was transiently knocked down in 
HEK293ET and HeLa cells and stained with anti-α-tubulin antibody and Hoechst, to score 
their morphologies. In both cell lines, there was no change in the number of cells with 
multipolar spindles, misaligned metaphase plates, and lagging chromosomes (Figure 4.8). 
Taken together this suggests that the observed enrichment of metaphase cells in HECTD1-
depleted cells does not translate into mitotic defects for most cells. 
 
Nuclear defect phenotypes generally refer to cells with abnormal spindles. For example, 
depletion of MISU, identified as being required for mitotic spindle stability, results in 
unstructured and multipolar spindles, resulting in chromosome missegregation and 
therefore leading to multinucleated cells (Hussain, et al 2009). To establish whether 
HECTD1 depletion resulted chromosome missegregation, and therefore abnormal nuclei, 
interphase cells were scored based on their nuclear morphology to identify any abnormal 
nuclear phenotypes. Multinucleated cells were defined as cells with more than one nuclei, 
cells with enlarged nuclei were defined as possessing 2X the mean diameter of nuclei, 
14.5µm, at the widest point, and finally multilobed nuclei were nuclei that had an irregular 
shape comprising 2 or more defined lobes (Hussain, et al 2009; Jevtić, et al. 2015) (Figure 
4.9C). In both cell types, there were no differences in the number of multinucleated cells, 
cells with enlarged nuclei, multilobed nuclei in the compared to the control (Figure 4.9) 
(Hussain, et al 2009; Jevtić, et al. 2015). Therefore, indicating that HECTD1 depletion does 
not lead to large increases in nuclear defects.   















































Figure 4.8. Scored mitotic defects upon HECTD1 depletion in HEK293ET and HeLa 
cells. Asynchronous A) HEK293ET cells and B) HeLa cells were scored according to 
chromatin morphology or spindle morphology based on Hoechst (blue or white) and α-
tubulin (green) staining following knockdown using NT (non-targeting), HECTD1 
SMARTpool (smart pool), #06, and #08 siRNA, and Lipofectamine-2000 or -RNAiMAX for 
48hrs. Cells were categorised into three mitotic defect phenotypes: multipolar spindle, 
misaligned metaphase plate, or lagging chromosomes. Cells with no observable mitotic 
defects were scored as cells that were in normal mitosis. Data plotted as mean with error 
bars that represent ±S.E.M., over 6 biological repeats. Average increase in multipolar 
spindle = HECTD1 siRNA of 8.0% HEK293ET; 4.1% HeLa. Average misaligned metaphase 
plate = HECTD1 siRNA of 7.1% HEK293ET; 6.2% HeLa. C) Representative images of each 
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Figure 4.9. Scored nuclear morphology upon HECTD1 depletion in HEK293ET and 
HeLa cells. A) HEK293ET cells and B) HeLa cells were scored according to nuclear 
morphology based on Hoechst (blue) staining of interphase cells following knockdown using 
NT (non-targeting), HECTD1 SMARTpool (smart pool), #06, and #08 siRNA, and 
Lipofectamine-2000 or -RNAiMAX for 48hrs. Cells were categorised into three nuclear 
defect phenotypes: multinucleated cells, enlarged nuclei, or multilobed nuclei. Data plotted 
as mean with error bars that represent ±S.E.M., over 6 biological repeats. HEK293ET 
HECTD1 08 siRNA represents one independent experiment. C) Representative images of 
each nuclear defect scored, cells were stained with Hoechst (blue) and α-tubulin (green). 
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4.2.5. Mitotic delay observed in HECTD1-depleted and knockout cells 
Given the enrichment of metaphase cells observed in Figure 4.7, it was hypothesised that 
this enrichment may lead to an increase in the time taken for cells to progress through 
mitosis. For example, with depletion of JMJD5, the enrichment of cells in early mitosis 
coincided with an increase in the length of mitosis (He, et al. 2015). Therefore, expression 
of pHistone H3 (Ser28) was used as a molecular marker to track mitotic entry and anaphase 
onset in order to time the length of mitosis in synchronised cells either WT or depleted for 
HECTD1. 
 
Cells synchronised with a double thymidine block and released into fresh media were 
harvested at 0hrs, 3hrs, 6hrs, 8hrs, 10hrs, 12hrs, and 14hrs post-release to capture mitotic 
entry and exit. As seen by the presence of a 15kDa band on the western blot, mitotic entry 
occurred at 8hrs for both the non-targeting and HECTD1 SMARTpool siRNA treated 
samples, indicating that there was no delay in mitotic entry (Figure 4.10A). At the 12hr time-
point, a strong signal for pHistone H3 (ser28) was present in HECTD1-depleted cells but 
not in the non-targeting control samples. Similarly, this was also seen at the 14hr time-point, 
suggesting that HECTD1-depletion leads to mitotic delay. A similar mitotic delay was also 
observed in HEK293T KO1 knock out cells, which further strengthen the data obtained by 
transient siRNA knock down. 
 
To confirm this mitotic delay observed by western blotting, HEK293T KO1 and parental (i.e. 
WT) cells were synchronised using the CDK1 inhibitor RO-3306. Cells were released and 
the cell cycle profile was determined at time-points post-release by PI staining using the 
optimised conditions determined in Figure 3.8. RO-3306, a CDK1 inhibitor was used 
because of the ability to synchronise cells in G2/M, therefore allowing observation of mitosis 
from the G2/M border to mitotic exit (Vassilev, et al. 2006). At 0hrs, both samples showed 
a strong degree of synchronisation with RO-3306, with 90.2% synchronised in the WT 
condition (Figure 4.11A) and 88.8% of the KO1 cells (Figure 4.11B) in the G2/M peak (P4). 
At 2hrs post-release, 78.5% of KO1 cells were in the G2/M peak compared to 53.7% of  
HEK293T WT cells, further suggesting a delay in the completion of mitosis. Furthermore, at 
4hrs, 66.0% of KO1 cells were in G2/M compared to 36.7% of WT cells. This therefore 










Figure 4.10.  Delay in mitosis observed by a delay in pHistone H3 turnover. HEK293ET 
cells knocked down with 20pmol HECTD1 SMARTpool (smartpool) siRNA and 
Lipofectamine 2000. 24hrs later cells were then synchronised using a double thymidine 
block. Knockout cells were also synchronised using a double thymidine block. A) 
Representative blot showing HEK293ET cells treated with non-targeting and HECTD1 
SMARTpool (smart pool) siRNA (n=2; independent transfections). B) Blot showing 
HEK293T WT compared with HEK293T KO1 cells (n=2).  For the double thymidine block, 
cells were treated with 2mM Thymidine for 18hrs, followed by a 9hrs release. Then an 
additional 2mM Thymidine for 15hrs, before being released and harvested at 0hrs, 3hrs, 
6hrs, 8hrs, 10hrs, 12hrs, and 14hrs post-release. Cells were lysed in RIPA buffer and 
samples were analysed on a 4-12% SDS PAGE. Following western blotting on PVDF, the 
membrane was blocked in 3%-BSA-PBST and incubated overnight with anti-HECTD1 
antibody (ab101992) and anti-pHistone H3 (ser28) (ab10543), followed by detection with a 
secondary HRP antibody. Anti-beta-actin (A5441) was used as loading control. Molecular 













































Figure 4.11. Delay in G2/M population observed in HEK293T knockout cells 
synchronised with RO-3306. HECTD1 knockout cells were treated with 9µM RO-3306 for 
20hrs before being fixed using 70% ethanol. Cells were stained using 2µg/ml PI, with 
100µg/ml RNase A, for 30mins at room temperature. A) Histograms for HEK293T WT cell 
line, B) histograms for HEK293T KO1 cell line. C) Graph showing quantification of G1 and 
G2/M populations in HEK293T WT and KO1 cell lines at each time point post RO-3306 
release. Data from one independent experiment. PI-A of 50 is equivalent to 2N (G1 
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4.2.6. Increase in NEBD to anaphase onset in HECTD1-depleted and knockout cells 
To understand whether the mitotic delay observed in cells depleted with HECTD1 and 
HECTD1 knock out cells is associated with the enrichment of metaphase cells, 
asynchronous HEK293T CRISPR/Cas9 knockout cells were filmed by time-lapse 
microscopy (Figure 4.12). The time taken for cells to progress from NEBD to anaphase 
onset is an established read out to measure mitotic progression and has been used to show 
the requirement of post translational modifications in regulation of CDC20 (Uzunova, et al. 
2012; Hein, et al. 2017). Mitotic progression was analysed in HEK293T KO1 and KO2 
HECTD1 knock out cell lines and the parental control cell line HEK293T. NEBD and 
anaphase onset were defined by visible loss of the nuclear membrane and the separation 
of chromosomes respectively by Differential Interference Contrast (DIC) (Beaudouin, et al. 
2002; Pines. 2006) (Figure 4.12C). There was a significant delay in the time taken for cells 
to progress from NEBD to anaphase onset in HEK283T KO1 cells when compared to the 
WT control and this trend was also observed in KO2 cells (Figure 4.12A). Specifically, KO1 
cells showed a mean delay of around 15.5mins and KO2 cells a mean delay of around 
9mins compared to the WT control cell line. This indicates that the enrichment of metaphase 
cells seen in Figure 4.7, is due to a delayed NEBD to anaphase onset. Furthermore, cells 
can be observed with chromosomes aligned along the equatorial plane for longer before 
anaphase onset (Figure 4.12C), indicating that cells may be held by the spindle assembly 
checkpoint for longer.  
 
To validate the data obtained with the knock out cells, mitotic progression was also analysed 
following transient HECTD1 knock down. HEK293ET cells were treated with non-targeting, 
HECTD1 SMARTpool (SP) HECTD1 #06, and #08 siRNA. Cells were visualised at 48hrs 
and 72hrs post knockdown. At 48hrs it can be seen that both HECTD1 SMARTpool and 
HECTD1 #08 showed a delay in the length of NEBD to anaphase onset compared to the 
non-targeting control (Figure 4.13A). HEK293T treated with HECTD1 SMARTpool siRNA 
showed a mean delay of around 28.3mins and 22.8mins for HECTD1 #08 siRNA compared 
to the non-targeting control (Figure 4.13B). At 72hrs the HECTD1 SMARTpool showed a 
mean delay of 21.6mins, and HECTD1 #06 siRNA showed a significant delay of 39.3mins 
compared to the non-targeting control. In contrast, the HECTD1 #08 treated sample was 
slightly faster than the non-targeting control in the time taken to progress from NEBD to 
anaphase onset. This is most likely due to the difficulty of targeting all cells transiently using 
siRNA. An important consideration is that the mean is only representative and in reality the 
data show that only a subset of cells are delayed for a long time (>200mins). Taken together, 
these results suggest that HECTD1 knockout or transient depletion results in a mitotic delay 
of around 15-30min on average, representing a 30-60 % increase in the length of mitosis in 
HEK293T and HEK293ET cells, which in our hands is around 50mins.   

















































Figure 4.12. Delay in NEBD to anaphase onset in HECTD1 knockout cells. Duration of 
NEBD to anaphase onset was timed in asynchronous HEK293T WT and two HECTD1 
CRISPR/Cas9 knockout cell lines. A) Vertical scatter plot showing the time taken for each 
cell to progress from NEBD to anaphase onset.  B) Mean time taken for cells to progress 
from NEBD to anaphase onset. C) Representative images of cells scored in A). Error bars 
represent ±S.E.M., ***p<0.001, using a one-way ANOVA with a Dunnett’s post-test. Number 
of cells filmed are as follows, WT = 116, KO1 = 136, and KO2 = 161, filmed over 4 
independent experiments. Cells were imaged using an Olympus IX81 microscope with a 
40X oil immersion objective lens and Hammatsu ORCA-ET Camera at 37ºC. Micro-


















































































































Figure 4.13. Delay in NEBD to anaphase onset in HECTD1-depleted HEK293ET cells. 
Duration of NEBD to anaphase onset was timed in HEK293ET cells treated with either NT 
(non-targeting), HECTD1 SP (SMARTpool), HECTD1 #06, and HECTD1 #08 siRNA, and 
Lipofectamine 2000 for either 48hrs and 72hrs.  A) Vertical scatter plot showing the time 
taken for each cell to progress from NEBD to anaphase onset 48hrs post knockdown.  B) 
Mean time taken for cells to progress from NEBD to anaphase onset for data shown in A). 
C) Vertical scatter plot showing the time taken for each cell to progress from NEBD to 
anaphase onset 72hrs post knockdown.  D) Mean time taken for cells to progress from 
NEBD to anaphase onset for data shown in C). Error bars represent ±S.E.M., ***p<0.001, 
**p<0.01 by using a one-way ANOVA with a Dunnett’s post-test. Number of cells filmed are 
as follows, NT (48h) = 60, HECTD1 SP (48h) = 64, HECTD1 #06 (48h) = 38, HECTD1 #08 
(48h) = 41, NT (72h) = 18, HECTD1 SP (72h) = 57, HECTD1 #06 (72h) = 39, and HECTD1 
#08 (72h) = 45, filmed over 3 independent experiments. Cells were imaged using an 
Olympus IX81 microscope with a 40X oil immersion objective lens and Hammatsu ORCA-
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4.2.7. The E3 ligase activity of HECTD1 is needed to rescue the NEBD to anaphase 
onset delay 
To determine whether the mitotic delay phenotype associated with HECTD1 results from 
loss of its E3 ligases activity, asynchronous HEK293T KO1 cells transfected with either HA-
FL-mHectd1WT or HA-FL-mHectd1C2579G were filmed by time-lapse microscopy (Figure 
4.14). Interestingly, for most HECT ligases involved in cell cycle regulation the ligase activity 
is critical to their function (Chapter 1, Section 1.9.2). Although the HECT ligase G2E3, has 
been reported to contain a catalytically inactive HECT domain, the PHD/RING domains are 
able to catalyse the conjugation of Lys48-linked ubiquitin chains (Brooks, et al. 2006; 
Brooks, et al. 2008). In contrast, the HECT ligase EDD has been shown to regulate p53 
independent of its ligase activity (Ling & Lin. 2011; Smits. 2012). For instance, EDD has 
been reported to regulate miRNA-mediated gene silencing independent of its E3 ligase 
activity (Su, et al. 2011). This demonstrates the ability of these HECT ligases to behave as 
multifunctional proteins, behaving in an E3 ligase-dependent or –independent manner. 
Therefore, the aim was to establish whether the role of HECTD1 in the cell cycle was 
dependent on its E3 ligase activity.  
 
To assess whether the ligase activity of HECTD1 was needed to rescue the mitotic delay 
seen in Figure 4.14, the time taken for cells to progress from NEBD to anaphase onset was 
measured. This was compared between the parental HEK293T WT cell line and the two 
HECTD1 knock out cell lines transfected with either wild type mHectd1 (HA-FL-mHectd1WT) 
or the catalytic mutant of mHectd1 (HA-FL-mHectd1c2579) (Figure 4.14). As seen in Figure 
14.4A, only HA-FL-mHectd1WT was able to rescue the mitotic delay phenotype in both cell 
lines. Again, there was a significant delay in NEBD to anaphase onset in HECTD1 KO1 
compared to WT, which was also seen with HECTD1 KO2 cells. The WT cells took on 
average 37.1mins to progress from NEBD to anaphase onset (Figure 4.14B). In 
comparison, both KO1 and KO2 cells showed an increase in the time taken to progress 
NEBD to anaphase onset, at 52.6mins and 52.9mins (on average) respectively. HA-FL-
mHectd1WT rescued the delay observed in HECTD1 KO1 and KO2 cells, reducing the time 
taken by around 14mins on average in both cell lines. Taken together this suggests that the 
E3 ligase activity of HECTD1 is required to rescue the observed delay in the progression 
from NEBD to anaphase onset, and positions the role of HECTD1 in the cell cycle 














































Figure 4.14. Rescue of delay in NEBD to anaphase onset in HEK293T knockout cells. 
Duration of NEBD to anaphase onset was timed in HEK293T knockout cells transfected 
with either HA-FL-mHectd1WT (mHectd1WT on figure), or HA-FL-mHectd1C2579G (mHectd1CM 
on figure) DNA and PEI.  A) Vertical scatter plot showing the time taken for each cell to 
progress from NEBD to anaphase onset 48hrs post transfection. B) Mean time taken for 
cells to progress from NEBD to anaphase onset for data shown in A). Error bars represent 
±S.E.M., ***p<0.001, **p<0.01 by a one-way ANOVA with a Dunnet’s post-test. Number of 
cell filmed are as follows, WT = 127, KO1 = 97, KO1 + mHectd1WT = 48, KO1 + mHectd1CM 
= 108, KO2 = 153, KO2 + mHectd1WT = 46, and KO2 + mHectd1CM = 19, filmed over 3 
independent experiments. Cells were imaged using an Olympus IX81 microscope with a 
40X oil immersion objective lens and Hammatsu ORCA-ET Camera at 37ºC. Micro-
Manager (Edelstein et al. 2014) was used to acquire and analyse the images. C) Western 
blot showing transfection of HECTD1 constructs in the knockout cells. Cells were lysed in 
RIPA buffer and samples were analysed on a 4-12% SDS PAGE. Following western blotting 
on PVDF, the membrane was blocked in 3%-BSA-PBST and incubated overnight with anti-
HECTD1 antibody (ab101992) and anti-pHistone H3 (ser28) (ab10543), followed by 
detection with a secondary HRP antibody. Anti-beta-actin (A5441) was used as loading 
control. Molecular weight markers are superimposed on the left-hand side of the 
immunoblot. 
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In this chapter, using both transient HECTD1-depletion and HECTD1 knockout cells, 
HECTD1 has been shown to be required for the timely progression through mitosis. No 
change in the G2/M population in HECTD1 depleted cells was initially observed by flow 
cytometry. However, HA-FL-mHectd1 was expressed in HEK293ET cells to confirmed 
localisation to the mitotic spindle during metaphase. Interestingly, in HECTD1 transiently 
depleted cells, which were scored for different stages of mitosis, there was a significant 
enrichment of metaphase cells. Additionally, both HECTD1 knock down and knockout cells 
were shown to have a delayed mitotic exit by western blot compared to the control. This 
was further supported by the use of flow cytometry in the knockout cells, again revealing a 
prolonged mitosis. To understand how enrichment of metaphase cells and mitotic delay 
coincided, cells were filmed from NEBD to anaphase onset, to establish if the delay was 
occurring in early stages of mitosis. Indeed, in both HECTD1-depleted and HECTD1 
knockout cells there was an increase in the time taken to progress from NEBD to anaphase 
onset. This therefore, indicates that HECTD1 is required for mitotic progression, and it is 
hypothesised that it functions specifically in metaphase to enable the timely progression 
through mitosis. Importantly, this phenotype was rescued using wild type full-length 
mHectd1, but not the catalytic inactive mutant. This strongly suggests that the ubiquitin 
ligase activity of HECTD1 is required for this cell cycle function. Taken together, data 
presented in this chapter are consistent with the observed reduced growth in HECTD1-
depleted cells reported in Chapter 3.  
 
 
4.3.1. No change in G2/M population upon HECTD1 depletion in HeLa and HEK293ET 
cells.  
HECTD1-depleted HeLa and HEK293ET cells were first screened using flow cytometry to 
probe for a cell cycle associated phenotype. No change in the G2/M population in 
asynchronous cells was observed with HECTD1 depletion. This result is in stark contrast 
with, for example, cell depleted of CDH1 which resulted in a large increase in G2/M cells as 
well as chromosomal abnormalities (Wei, et al. 2004). This suggests, that the cell cycle 
related phenotype associated with HECTD1 is subtle. In addition, HECTD1 depletion did 
not yield 8N, tetraploid, cells suggesting that that the SAC checkpoint itself is not 
compromised in HECTD1 depleted cells. For example, SMURF2 depletion resulted in 8N 
cell populations, which is in line with its role as part of the SAC where it recruits MAD2 to 
unattached kinetochores (Osmundson, et al. 2008). Therefore, HECTD1 does not appear 
to be required for proper SAC function, and instead is associated with a prolonged SAC 
activation phenotype as seen with JMJD5, which will be discussed in Chapter 5.  
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An important consideration when using cell cycle profiling to study the phenotype 
associated with HECTD1 depletion is that it may be masked by an inability to distinguish 
between G2 and M populations. Propidium iodide staining is used to assess the cycle profile 
(as discussed in Chapter 3), by separating cells based on their DNA content. Indeed, G2 
cells and M phase cells both have double the amount (4N) of DNA compared to G1 cells 
(2N), and therefore these different populations of cells with similar DNA content cannot be 
distinguished using flow cytometry and PI staining. Therefore, if the phenotype is subtle, as 
seen in further experiments, this may not be very apparent from looking at cell cycle profile 




4.3.2. HA-FL-mHectd1 localises to the mitotic spindle in cells during prometaphase 
and metaphase 
HA-FL-mHectd1 was shown to colocalise with the mitotic spindle during mitosis, however 
the staining became more diffuse as cells progressed through the later stages of the cell 
cycle. This mitotic spindle staining confirms the previous observation that HECTD1 
colocalised to the mitotic spindle. Additionally, these results indicate that the association to 
the spindle is metaphase specific, which implies that HECTD1 may only have a specific role 
during metaphase. Interestingly, cell cycle proteins such as JMJD5 and NuMA, show mitotic 
spindle staining and both function in spindle formation and orientation (Wong, et al. 2006; 
He, et al. 2016). JMJD5, was reported to regulate microtubule stability via a-tubulin 
acetylation. Depletion of the protein resulted in loss of inter-kinetochore tension, and failure 
to satisfy the SAC (He, et al. 2016).  NuMA has been associated with the assembly and 
orientation of the spindle (Wong, et al. 2006; Haren, et al. 2009; Gallini, et al. 2016). This 
demonstrates a link between spindle localisation and mitotic spindle regulation. NEDL2 also 
colocalises to the spindle during mitosis, where it is speculated that the HECT ligase may 
regulate the SAC or activation of the APC/C, however no direct evidence was provided to 
show this (Lu, et al. 2013). Interestingly, SMURF2 and EDD which are known to regulate 
the SAC do not appear to show the same spindle localisation (Osmundson, et al. 2008; 
Scialpi, et al. 2015). This could potentially indicate that HECTD1 might regulate mitotic 
spindle formation rather than the SAC directly. Furthermore, two of the proposed substrates 
of HECTD1, Adenomatous Polyposis Coli (APC) and HSP90, have also been associated 
with the mitotic spindle (Sarkar, et al. 2012; Tran, et al. 2013). APC is a conventional 
microtubule associated protein, where it functions to stabilise microtubules, and together 
with EB1, has been implicated in spindle regulation (Berrueta, et al. 1998; Mimori-Kiyosue 
& Tsukita. 2003). Whilst the chaperone HSP90, has been shown to be required for Cyclin 
B1 localisation to the mitotic spindle (Basto, et al. 2007).  
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The catalytically-dead HA-FL-mHectd1C2579G also localised to the mitotic spindle, suggesting 
that the ligase activity is not involved in the spindle localisation. HECTD1 has a number of 
predicted ankyrin repeats, and similar domains have been shown to be important for protein 
binding and substrate recognition (Mosavi, et al. 2004). It is therefore likely that HECTD1 
ankyrin repeats direct the relocalisation of HECTD1 to the spindle during mitosis. An 
example of an ankyrin repeat domain protein is protein phosphatase 6 (PP6), an essential 
Ser/Thr phosphatase whose regulatory subunits are composed of ankyrin repeats 
(Stefansson, et al. 2008). PP6 has been implicated in the regulation of mitotic spindle 
formation and the ankyrin repeats were shown to be involved in its function (Zeng, et al. 
2010). However, further work would be needed to understand the region of the HECTD1 
responsible for localisation.  
 
 
4.3.3. Enrichment of metaphase cells upon HECTD1 depletion and knockout 
Having demonstrated that full-length HECTD1 localises to the mitotic spindle during 
metaphase, and that its depletion in cells results in enrichment of a G2/M population, 
HECTD1-depleted cells were next scored to see whether cells were enriched in a mitotic 
stage. To this end, HECTD1 transiently depleted HeLa and HEK293ET cells were scored 
in each mitotic stage, based on their morphology, using immunofluorescence. There was a 
significant increase of HeLa and HEK293ET cells in metaphase upon HECTD1 depletion 
using HECTD1 siRNA compared to the non-targeting control, indicating an enrichment of 
metaphase cells. Interestingly, at the metaphase to anaphase transition the mitotic 
checkpoint, known as the SAC functions to regulate mitotic progression (Murray. 1994). The 
SAC prevents the separation of sister chromatids until all of the chromosomes are attached 
to the mitotic spindle; only upon the checkpoint satisfaction can cell progress through to 
anaphase (Hagting, et al. 2002; Nilsson, et al. 2008). It is therefore possible that HECTD1 
regulates the formation of the mitotic spindle, rather than regulating the SAC itself. Depletion 
of proteins that are involved in maintenance of the SAC result in a phenotype of increased 
progression through mitosis because of the checkpoint being compromised and therefore it 
cannot be “switched on” and prevent anaphase onset. This translates into no increase in 
the proportion of metaphase cells, because cells can progress to anaphase unmonitored. 
This is in contrast to the observed increase of G2/M cells, specifically metaphase cells, in 
HECTD1 knockout or transiently depleted cells. In addition, this may explain why there were 
no nuclear defect cells observed, because cells are not progressing through the checkpoint 
unmonitored they are accumulating at the checkpoint. This again complements the 
observation that no 8N populations are observed when using PI staining and flow cytometry. 
Through extensive microscopy, scoring, and analysis there was no change in the number 
of cells with mitotic defects, namely multipolar spindle and misaligned metaphase plate. 
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This observation may imply that HECTD1 does not regulate the SAC directly, or it may be 
due to a limitation of the assay, which is discussed in Section 4.4. Future Work.  
 
 
4.3.4. Mitotic delay observed upon HECTD1 depletion or knockout 
There are two main possible implications for the observed accumulation of mitotic cells upon 
HECTD1 depletion or knockout: shortening of premitotic processes (G1 phase, S phase or 
G2 phase) or prolongation of mitosis (He, et al. 2015). Interestingly, a recent study reported 
that the C. elegans ortholog of HECTD1, Hecd-1, cooperates with Ufd2 and Atx3, in 
response to DNA damage to activate apoptosis (Ackermann, et al. 2016), potentially 
implicating HECTD1 in the regulation of S phase. HECTD1 may regulate the DNA damage 
checkpoint, which may have knock-on effects in mitosis (Lawrence, et al. 2015). The 
western blot on HECTD1-depleted synchronised cells, showed that cells enter mitosis at 
the same time and the delay occurs in mitotic cells. Therefore, this suggests that the cells 
are not delayed in a premitotic process. When knockout cells were synchronised using the 
CKD1 inhibitor RO-3306, synchronising them at the G2/M transition, there was a delay in 
the decrease of the G2/M peak, further indicating that the delay was specific to mitosis and 
not premitotic. However, to confirm that the mitotic delay is not a results of HECTD1 
regulation of DNA damage, further experiments would be required that induce DNA damage 
in cells and monitor their cell cycle progression.  
 
To further demonstrate the second scenario, of prolongation of mitosis, the time taken from 
NEBD to anaphase onset was measured using live cell imaging. In both HECTD1-depleted 
cells and HECTD1 knockout cells, there was a delay in the time taken for the cells to 
progress from NEBD to anaphase onset. This period in mitosis was filmed based on the 
previous observation that HECTD1 depletion or knockout resulted in an enrichment of 
metaphase cells, and the implication that this may encompass the spindle assembly 
checkpoint. Therefore, any observed delay in NEBD to anaphase onset would further 
suggest that the phenotype is a result of the delayed SAC satisfaction, and not regulation 
of the checkpoint directly. As mentioned previously, this is in line with the observed 
phenotypes of mitotic spindle regulators, namely JMJD5 and BRISC, where depletion of 
either of these proteins results in an increased time taken for cells to progress from NEBD 
to anaphase onset (Yan, et al. 2015; He, et al. 2016). In contrast, cells depleted of the E3 
ligase involved in SAC regulation, TRAIP, showed a decreased length of time to progress 
through NEBD to anaphase onset. Despite a deficient checkpoint, cells were able to 
progress through mitosis unchallenged resulting in a decrease in the length of time taken 
(Chapard, et al. 2014). This further suggests that HECTD1 is involved in mitotic spindle 
regulation, resulting in delayed spindle assembly checkpoint satisfaction.  
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Interestingly, no phenotype was associated with HECTD1 depletion in Homo Sapiens, in 
the Cellular Phenotype database (https://www.ebi.ac.uk/fg/sym, accessed 05/12/17), which 
provides phenotypic data derived from high throughput screening. Phenotypes screened 
included the mitocheck study, where by RNAi screens, mitotic proteins have been screened 
by microscopy to visualise their sub-cellular localisation at different stages of the cell cycle 
(Neumann, et al. 2010). The fact that HECTD1 RNAi did not correlate with a cellular 
phenotype, specifically a mitotic phenotype in these large high throughput screens, is not 
surprising based on the subtlety of the phenotype identified. In a large phenotype screen 
based on microscopy, a delay in mitotic progression that does not result in sustained cell 
cycle arrest or cell death may not be readily identifiable. In addition, the extent of HECTD1 
depletion achieved in these screens cannot be readily assessed. The yeast orthologue of 
HECTD1, SPAC12B10.01c, was not identified in a systematic screen of new elements 
regulating at the G2/M control (Navarro & Nurse. 2012), indicating that the role of HECTD1 
in cell cycle regulation might not be conserved in S. pombe.  
 
 
4.3.5. HECTD1 catalytic activity is required to rescue the delay in NEBD to anaphase 
onset. 
To implicate the novel activity of HECTD1 in synthesising K29/K48 ubiquitin chains in the 
delay observed when NEBD to anaphase onset was measured, HECTD1 KO1 cells were 
transfected with either HA-FL-mHectd1WT or HA-FL-mHectd1C2579G. Only HA-FL-mHectd1WT 
was able to rescue the delay in NEBD to anaphase onset, which aligns with the rescue of 
the cell proliferation assay presented in Chapter 3. Therefore, this suggests that the E3 
ligase activity of HECTD1 is also required for its function in mitosis. Additionally, this may 
implicate,  for the first time, K29/K48 ubiquitin chains in mitosis. HERC2 has been shown to 
conjugate K48 ubiquitin chains in its role in centrosome amplification (Al-Hakim, et al. 2012). 
Furthermore, K63 has also been implicated with no direct evidence, in signalling and 
prevention of degradation in SAC regulation by SMURF2 (Osmundson, et al. 2008). 
Nevertheless, the composition and topology of the ubiquitin chain types through which these 
ligases may exert their effect in the cell cycle, specifically mitosis, remain poorly understood. 
Therefore, and given that the E3 ligase activity of HECTD1 is required to rescue the cell 
proliferation and mitotic phenotype identified, further work was carried out to try and 
establish whether the K29/K48 ubiquitin chains represent a novel signal in mitotic regulation 
(Chapter 5). 
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4.4. Future work: 
To fully understand the localisation of HECTD1 during the cell cycle, experiments using 
endogenous GFP-tagged constructs of HECTD1 could be used. This would indeed facilitate 
characterisation by immunofluorescence and could limit the possibilities of artefacts 
associated with overexpression. Recent advances in genome editing have enabled the use 
of CRISPR/Cas9 genome editing, to generate a GFP knock-in cell line to produce GFP-
tagged HECTD1 under the endogenous promoter thereby preventing any off-target effects 
usually associated with over-expression (Lackner, et al. 2015; Ratz, et al. 2015). Using fixed 
cells or live cell imaging, GFP-tagged HECTD1 localisation can be monitored during the cell 
cycle. Work conducted by Ratz, et al. 2015, generated CRISPR/Cas9 knock-in proteins and 
compared their expression to plasmid transfected cells, it was revealed that the knock-ins 
resulted in less variability in expression and localisation, and therefore less artefacts. Given 
that the E3 ligase activity has been shown to not be required for the localisation of HECTD1 
to the spindle, the localisation of deletion constructs of HECTD1 protein could also be 
studied by immunofluorescence. This would help identify the region of the protein required 
for localisation to the mitotic spindle.  
 
For a more high-throughput quantifiable method of showing mitotic enrichment, cell cycle 
staging of individual cells could be achieved by high-content microscopy and DAPI staining 
(Roukos, et al. 2015). This used in combination with fluorescent ubiquitin based cell cycle 
indicator (FUCCI) probes would provide a faster way of scoring cells that were enriched in 
certain phases of the cell cycle. The FUCCI method relies on proteasomal degradation of 
two fluorescently tagged cell cycle regulatory proteins: CDT1 and geminin (Sakaue-
Sawano, et al. 2008). These proteins are fused to either a GFP or a RFP tag. Temporally 
regulated E3 ligases, APC/CCDH1 and SCFSKP2 are involved in degrading these proteins, 
which results in the inverse biphasic cycling of CDT1 and geminin. In G1, GFP-tagged 
geminin is degraded by ACP/C mediated ubiquitination leaving RFP-tagged CDT1 at the 
nuclei (McGarry & Kirschner. 1998). In S, G2, and M phases RFP-tagged CDT1 is degraded 
by SCF mediated ubiquitination resulting in GFP-geminin labelled cells (Li, et al. 2003). 
However, during the G1/S transition, when CDT1 levels are decreasing and geminin levels 
are increasing, both proteins are present, resulting in yellow cells, where the GFP and RFP 
signals are overlaid. These colour changes result in live tracking of cells in the cell cycle. 
However, a significant drawback to this technique and specifically to this project is that M 
phase is not easily defined in this method. Cells in mitosis are visualised as green as well 
as cells in S/G2 and G2 cells (Sakaue-Sawano, et al. 2008). One way to overcome the 
difficulty in identifying M phase cells it that because the GFP signal is visualised in the 
nucleus, upon NEBD the whole cell is visualised as green in accordance with a non-
compartmentalised GFP signal, as demonstrated in the characterisation of the cell cycle in 
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HT1080 FUCCI cells (Marcus, et al. 2015). Therefore, the GFP signal could be measured 
using live cell imaging and quantified using software such as ImageJ, or high content 
microscopy to monitor enrichment of mitotic cells and length of mitosis.  
 
Finally, to characterise abnormalities and defects in mitotic spindle formation, spindle 
dynamics in HECTD1 depleted cells could be measured and quantified by live cell imaging. 
Cell lines that stably express GFP-tagged a-tubulin could be imaged throughout the course 
of mitosis to visualise in unfixed cells the formation of the mitotic spindle (Rusan, et al. 
2001). Furthermore, as outlined in the protocol by Decarreau, et al. (2014), the orientation 
of the mitotic spindle can be measured using MATLABâ in fixed cells by confocal 
microscopy. As part of the characterisation of the phenotype associated with NuMA 
phosphorylation by Aurora A, the orientation of the mitotic spindle was measured (Gallini, 
et al. 2016). This revealed that NuMA phosphorylation by Aurora A regulates spindle 
orientation, and therefore such studies could easily be applied to HECTD1 to determine 
whether it also has a role in mitotic spindle orientation. Additionally, recent advances in 
microscopy now mean that there are multiple types of super high-resolution microscopy 
available (Wegel, et al. 2016). For example, structured illumination microscopy (SIM), 
stimulated emission depletion (STED), and single molecule localisation microscopy (SMLM; 
also known as STORM microscopy). These different types of super high-resolution all have 
their advantages and drawbacks when imaging different cellular components, therefore it is 
important to consider, which type is the most appropriate for each experiment (Wegel, et al. 
2016). Thus, to assess spindle defects using super high-resolution microscopy, either SIM 
or SMLM microscopy, would be the most appropriate, in comparison to STED, which gave 
a poor signal and lowest image contrast when imaging microtubules (Wegel, et al. 2016).   
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Chapter 4 demonstrated that HECTD1 depletion resulted in a mitotic phenotype, specifically 
the enrichment of cells in metaphase, which was due to a delay in mitotic exit. Mitotic 
progression is monitored by the SAC. The SAC functions as a mitotic checkpoint to inhibit 
cells progressing from metaphase to anaphase until each kinetochore is attached to the 
mitotic spindle, safeguarding proper chromosome segregation (Murray. 1994; Stern & 
Murray. 2001). The accurate formation and orientation of mitotic spindle during 
prometaphase, is essential to enable cells to progress through the SAC (Stern & Murray. 
2001; Uchida, et al. 2009; Tauchman, et al. 2015). Therefore, the mitotic phenotype 
associated with HECTD1 may be as a result of prolonged activation of the SAC. This 
chapter will investigate this hypothesis by looking at the effect of HECTD1 depletion on the 
SAC and spindle formation, as well as explore using TRABID1-200 to identify mitotic proteins 
modified by K29-K48-linked ubiquitin chains, since our laboratory has shown that HECTD1 
synthesises this chain type, at least in vitro. 
  
 
5.1.1. Mitotic spindle formation 
The mitotic spindle, composed of microtubules (MTs), is the macromolecular machinery 
responsible for the segregation of chromosomes into two daughter cells (Walczak & Heald. 
2008). The mitotic spindle is thought to comprise three categories of microtubule, these are: 
kinetochore microtubules (K-MTs), non-kinetochore microtubules (nK-MTs), and astral 
microtubules (A-MTs) (Dumont & Mitchison. 2009). K-MTs are responsible for the 
attachment of the chromosomes to the poles where they have their plus-ends embedded in 
kinetochores and their minus-ends at or near poles (McDonald, et al. 1992; Dumont & 
Mitchison. 2009; Prosser & Pelletier. 2017). K fibres form by the attachment and 
stabilisation of K-MTs into morphologically distinct bundles at the kinetochore (Rieder & 
Salmon. 1998; Prosser & Pelletier. 2017). Correct attachment of K-MTs to the kinetochores 
is monitored by the SAC, and results in its satisfaction once all of the kinetochores are 
attached to the spindle (Tauchman, et al. 2015). nK-MTs, also known as interpolar 
microtubules, span the region from one spindle pole to the other, and help to stabilise K-
MTs and separate the poles (Mastronarde, et al. 1993; Dumont & Mitchison. 2009). Finally, 
A-MTs radiate from spindle poles, which have their minus-ends attached to centrosomes 
and their plus-ends extending towards the cell cortex, are responsible for spindle positioning 
(Grill & Hyman. 2005; McNally. 2013).  
 
Three pathways for spindle formation are used to explain how the mitotic spindle attaches 
to the chromosomes, these are centrosome-mediated MT nucleation, chromatin-mediated 
MT nucleation, and microtubule-mediated MT nucleation (Prosser & Pelletier. 2017). 




Importantly, each pathway relies on gTuRC to initiate nucleation and MT motor proteins to 
aid the organisation of spindle formation (Gaglio, et al. 1996; Walczak, et al. 1998; Lüders, 
et al. 2005). The “search and capture” model stems from the principle of microtubules 
dynamic instability, where microtubules grow and shrink from centrosomes to “search” for 
chromosomes and upon “capture” this dynamic instability is suppressed, to facilitate 
attachment (Mitchison & Kirschner. 1984; Heald & Khodjakov. 2015). However, a limitation 
demonstrated by mathematic modelling, is that without any bias toward chromosomes, 
search and capture would not happen on the same time scale as prometaphase, and would 
take considerably more time (Wollman, et al. 2005). Chromatin facilitates spindle formation 
by the generation of a RanGTP gradient, which functions to promote spindle assembly 
directly around chromosomes by the local discharge of cargoes important in microtubule 
dynamics and organisation (Kalab, et al. 2002). RanGTP is also required for MT nucleation 
directly from kinetochores, where MTs grow from kinetochores forming K-fibres, which are 
then incorporated into the forming spindle (Maiato, et al. 2004; Meunier & Vernos. 2011). In 
addition, MTs nucleating from chromosomes can form independently of RanGTP by the 
formation of the chromosome passenger complex (CPC) (Carmena, et al. 2012). The CPC 
consists of Aurora B, INCENP, borealin, and survivin and functions to create an Aurora B 
gradient responsible for the inactivation of microtubule destabilising proteins; mitotic 
centromere-associated kinesin (MCAK) and stathmin 1 (STM1) (Lan, et al. 2004; Sampath, 
et al. 2004). Finally, in early prometaphase both centrosome and chromatin-mediated 
pathways drive MT nucleation facilitating the capture of chromosomes in the formation of a 
common spindle (Prosser & Pelletier. 2017). In late prometaphase, Augmin is recruited to 
MTs in an Aurora A and PLK1 dependent manner, and has been implicated in the nucleation 
of MTs from pre-existing MTs to further support spindle formation by K fibre formation and 
formation of a common spindle (Goshima, et al. 2008; Wainman, et al. 2009). This therefore 




TRABID is a DUB of the OTU family (Evans, et al. 2003), with roles suggested in Wnt 
signalling (Tran, et al. 2008) and innate immunity (Fernando, et al. 2014). The ovarian 
tumour (OTU) family of DUBs contain a papain-like catalytic core of around 180 amino acids 
(Komander, et al. 2009). TRABID was initially reported to cleave K63 linked-ubiquitin chains 
(Tran, et al. 2008), however more recent work identified TRABID as a K29-specific DUB, 
that could cleave K29 linked diubiquitin with a 40-fold higher efficiency compared to K63 
linked diubiquitin (Virdee, et al. 2010). Furthermore, it was demonstrated by Licchesi, et al. 
(2012), that TRABID preferentially cleaved K29 and K33 over K63 linked ubiquitin chains, 
and cleaved no other chain type. This study also revealed that TRABID contains a UBD 




based on an ankyrin-repeat fold (AnkUBD), which functions as a novel ubiquitin binding 
fold, which was essential for full DUB activity. The AnkUBD enables the positioning of the 
ubiquitin linkage connecting two ubiquitin molecules across the active site of the OTU 
domain and this restricts the linkage specificity of the TRABID OTU domain towards the 
cleavage of K29 and K33 linked ubiquitin chains. In addition to the AnkUBD domain, 
TRABID contains three NPL4 zinc finger (NZF) domains, which provide additional ubiquitin 
binding sites (Alam, et al. 2004; Licchesi, et al. 2012; Kristariyanto, et al. 2015a; Michel, et 
al. 2015) (Figure 5.1).   
 
To study how NZF domains help to contribute to the specificity of TRABID, free K29 and 
K33 chains were synthesised using UBE3C and AREL1 E3 ubiquitin ligases, which have 
known activity for assembling K29/K48 and K29/K33 linked chains respectively, in 
combination with DUBs such a vOTU (Wang & Pickart. 2005; Kristariyanto, et al. 2015a; 
Kristariyanto, et al. 2015b; Michel, et al. 2015). Solution structures of both K29 and K33 
revealed that these chains adopt open and dynamic conformations (Michel, et al. 2015). 
Furthermore, the crystal structure of K29 linked diubiquitin revealed an open extended 
conformation, with exposed hydrophobic patches on both ubiquitin moieties that were 
available for binding (Kristariyanto, et al. 2015a). The TRABID N-terminus, which contains 
three NZF UBDs was reported to specifically bind K29 and K33 linked diUb (Michel, et al. 
2015; Kristariyanto, et al. 2015a). Pull-down experiments with individual NZF domains 
showed that K29/K33 specificity could be attributed entirely to the N-terminal NZF1 domain 
(aa 1–33) suggesting that NZF1 is the minimal module required for K29 binding (Michel, et 
al. 2015; Kristariyanto, et al. 2015a). The crystal structure of the NZF1 domain of TRABID 
in complex with K29 revealed that binding occurred through the hydrophobic patch of only 
one of the ubiquitin moieties and exploited the flexibility of the K29 chains to achieve linkage 
selective binding (Kristariyanto, et al. 2015a). These studies further support the possibility 
that ubiquitin binding domains such as NZF1 could be used to pulldown K29 and K33 linked 
polyubiquitin which might be relevant in specific cellular context, including the cell cycle 
(Kristariyanto, et al. 2015a).   
 
The use of ubiquitin-binding domains and ubiquitin-associated domains as tools to capture 
(poly)ubiquitinated proteins has been widely reported (Scott, et al. 2015). For example, the 
ubiquitin-association domain (P2UBA) from ubiquilin-2, was used to capture total 
polyubiquitin chains from Huntington’s disease models and patient samples (Bennett, et al. 
2007). Furthermore, Tandem-repeated ubiquitin-binding entities (TUBEs) have been 
designed based on UBA domains to enhance that capture of polyubiquitinated proteins 
(Hjerpe, et al. 2009). These are designed with multiple UBAs to provide a higher affinity for 




polyubiquitin providing an increased capture of polyubiquitin within cell lysates (Hjerpe, et 
al. 2009). Many TUBEs are now commercially available such as the NZF1 TUBE (UBPBio). 
 
Figure 5.1. Domains of TRABID. Domains of full legnth TRABID and TRABID1-200 (1-200 
amino acids). Full length TRABID comprises three NZF domains, an AnkUBD and OTU 
domain. TRABID1-200 comprises three NZF domains.  
  





The mitotic phenotype associated with HECTD1 was characterised using cellular based 
techniques (Chapter 4). In this chapter molecular markers were used to validate this 
phenotype at the molecular level and to attempt to elucidate the mechanism by which 
HECTD1 regulates mitotic progression. In addition, TRABID1-200 domain was used in 
synchronised cell lysates in an attempt to identify cell cycle proteins that have been modified 
with K29 ubiquitin chains, potentially representing HECTD1 substrates. This was achieved 
by the following objectives: 
 
1. Validate the role of HECTD1 in mitosis by evaluating expression levels of early 
mitotic markers in cells transiently depleted of HECTD1 and HECTD1 knockout cells 
by western blot and immunofluorescence.  
 
2. Establish whether HECTD1 is required for microtubule formation in HEK293T and 
HEK293ET cells through a microtubule regrowth assay in HECTD1-depleted and 
knockout cells. 
 
3. Score HECTD1 knockout cells based on the spindle assembly checkpoint marker, 
BUBR1, to assess whether there is a delay in checkpoint satisfaction.  
 
4. Optimise the use of GST-TRABID1-200 to enrich for K29/K33 ubiquitin chains in 
HEK293T cell lysates.   
 
5. Using GST-TRABID1-200 to determine the presence of K29/K33 ubiquitin chains 









5.2.1. HECTD1 depletion results in increase of an early mitotic marker 
To confirm the increase in metaphase cells observed in the microscopy study (Chapter 4) 
using molecular markers, early mitotic markers were selected including Cyclin B1 and 
pHistone H3 (Ser28). Cyclin B1 levels increase during G2, before peaking in early mitosis, 
followed by the degradation of the protein at anaphase onset (Pines & Hunt. 1987; Murray 
& Kirschner. 1989). In contrast, pHistone H3 (ser28) was found to be phosphorylated during 
prophase, and dephosphorylated during exit from anaphase (Gurley, et al. 1978) (Figure 
5.15), making them both suitable markers of early mitosis. 
 
First, HECTD1 was transiently depleted in HEK293ET cells that were stained post-fixation 
with anti-Cyclin B1, anti-pHistone H3 (ser28) antibodies, and Hoechst. The number of Cyclin 
B1 positive cells (Figure 5.2) and pHistone H3 (ser28) (Figure 5.3) relative to the total 
number of cells was determined. The number of Cyclin B1 positive cells in HEK293ET 
showed no increase in cells treated with HECTD1 SMARTpool siRNA compared to the non-
targeting control (Figure 5.2B). However, there was a significant increase in the proportion 
of pHistone H3 (ser28) positively stained cells between the non-targeting control and cells 
depleted of HECTD1 using HECTD1 SMARTpool siRNA in HEK293ET cells (Figure 5.3B), 
indicating an enrichment of cells in early mitosis. Here, the percentage of positive cells 
increased from 2.5% (±0.2%) in the non-targeting to 3.3% (±0.3%) in the HECTD1-treated 
condition. This was also seen in the image panel for HEK293ET cells (Figure 5.3A).  
 
Cyclin B1 and pHistone H3 (ser28) were also scored in HEK293T knockout cells, however 
there was no increase in either Cyclin B1 or pHistone H3 (ser28) (Figure 5.4). The lack of 
an increase in pHistone H3 in the knockout cells compared to the transiently depleted cells 
may be because the knockout cells may have become adapted to the lack of HECTD1 
protein, whereas the HECTD1-depleted cells do not have this adaptation. Another 
consideration is that the increase in pHistone H3 seen with HECTD1-depletion was carried 
out using only HECTD1 SMARTpool siRNA, therefore this result could be as a result of off-
target effects. It is important in the future to repeat these experiments using individual 
siRNA.  
 
Finally, the increase in pHistone H3 (ser28) seen by immunofluorescence in the transiently 
depleted cells was also determined by western blot (Figure 5.5). Figure 5.5A showed an 
increase in pHistone H3 (ser28) seen when HEK293ET cells were treated HECTD1 
SMARTpool siRNA. Quantification, over three independent experiments, showed a 52% 
increase in signal compared to the control (Figure 5.5B). This indicates that the levels of 
pHistone H3 (ser28) significantly increased when HECTD1 is depleted. This was repeated 




in the HEK293T knockout cells and a representative western blot shows that in both the 
KO1 and KO2 cell lines there was an increase in pHistone H3 (ser28) staining (Figure 5.5C). 
Taken together, this data suggest that there is an enrichment of cells in early mitosis 
following HECTD1 knockout. The use of molecular markers, rather than morphology, 
























Figure 5.2. No change in Cyclin B1 positive cells in HEK293ET cells depleted with 
HECTD1. HEK293ET cells with HECTD1 knocked down using 20pmol HECTD1 
SMARTpool (smart pool) siRNA and Lipofectamine-2000, then fixed with 4% PFA after 
48hrs. 4% PFA, Cells were permeabilised with Triton X-100, and stained for Cyclin B1 and 
imaged using the EVOS FL Cell Imaging System. A) HEK293ET cells immunofluorescence 
images showing a representative field of view per condition. Cyclin B1 (green) and Hoechst 
(Blue). Scale bar represents 400µm. B) Quantification of Cyclin B1 positive cells in 
HEK293ET (n=3). For quantification 15 fields of view were imaged. Data plotted as mean 
with error bars that represent ±S.E.M., independent experiments, n, defined by number of 



















Figure 5.3. Increase in pHistone H3 (ser28) positive cells in HEK293ET cells depleted 
with HECTD1. HEK293ET cells with HECTD1 knocked down using 20pmol HECTD1 
SMARTpool (smart pool) siRNA and Lipofectamine-2000, then fixed with 4% PFA after 
48hrs. Cells were permeabilised with Triton X-100, and stained for pHistone H3 (ser28) and 
imaged using the EVOS FL Cell Imaging System. A) HEK293ET cells immunofluorescence 
images showing a representative field of view per condition. pHistone H3 (red) and Hoechst 
(Blue). Scale bar represents 400µm.  B) Quantification of pHistone H3 (Ser28) positive cells 
in HEK293ET (n=3). For quantification 15 fields of view were imaged. Data plotted as mean 
with error bars that represent ±S.E.M., *p<0.05 by paired student’s t-test. Independent 
experiments, n, defined by number of separate transfections. 
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Figure 5.4. No change in the number of Cyclin B1 and pHistone H3 (ser28) positive 
cells in HECTD1 knockout cell lines. Asynchronous HECTD1 CRISPR/Cas9 knockout 
cells were fixed with 4% PFA, permeabilised with Triton X-100, and stained for Cyclin B1 
and pHistone H3 and imaged using the EVOS FL Cell Imaging System. A) Quantification of 
pHistone H3 (Ser28) positive cells in HEK293T (n=3). B) Quantification of pHistone H3 
(Ser28) positive cells in HEK293T (n=3). For quantification 15 fields of view were imaged, 
over three independent experiments, defined as separate seeding and staining of cells. 



































































































































Figure 5.5. pHistone H3 (ser28) protein levels are increased in HECTD1-depleted 
cells. HEK293ET cells with HECTD1 knocked down using 20pmol HECTD1 SMARTpool 
(smart pool on figure) siRNA and Lipofectamine 2000, then analysed asynchronously after 
72hrs. Knockout cells were harvested asynchronously. Cells were lysed in RIPA buffer and 
proteins levels were analysed on a 4-12% SDS PAGE. Following western blotting on PVDF, 
the membrane was blocked in 3%-BSA-PBST and incubated overnight with anti-HECTD1 
(ab101992) and anti-pHistone H3 (ser28) followed by detection with an appropriate 
secondary HRP antibody. Anti-beta-actin (A5441) was used as loading control. A) Western 
blot of HEK293ET cells with HECTD1 transiently depleted compared to non-targeting 
control. B) Quantification of pHistone H3 intensity normalised to beta actin, n=3, data plotted 
as mean with error bars that represent ±S.E.M., **p<0.01 by paired student’s t-test. C) 
Representative western blot of HEK293T knockout cells compared to wild type control 










































































































5.2.2. BUBR1 staining in HECTD1 knockout cells 
A hypothesis based on Chapter 4 was that HECTD1 may regulate microtubules or mitotic 
spindle formation, and therefore the resultant phenotype might be caused by prolonged 
SAC activation. To try to elucidate whether the observed delayed mitotic phenotype 
associated with HECTD1 depletion is as a result of prolonged SAC activation, cells were 
scored based on the presence of the SAC component, BUBR1 (Sudakin, et al. 2001). 
BUBR1 is present at unattached kinetochores, and its localisation is required for recruitment 
of other checkpoint proteins (Chen. 2002). To this end, cells were synchronised using the 
CDK1 inhibitor, RO-3306, and fixed at 10, 30, 60, 90, and 120mins post-release to monitor 
SAC activation during mitosis (Figure 5.6). It can be seen at 10mins post-release from RO-
3306 that BUBR1 stained cells at unattached kinetochores (Figure 5.6A), as suggested by 
Chen. (2002). The BUBR1 positive foci were seen to decorate the chromosomes (Hoechst), 
which are assumed to be unattached. However, due to time constraints it was not possible 
to characterise whether the SAC is persistent in HECTD1 knockout cells. Further work 
would be required to establish whether there is an enrichment of SAC markers upon  
HECTD1 depletion or knockout.  
  







Figure 5.6. BUBR1 staining in HECTD1 knockout cells. Representative images of 
endogenous BUBR1 foci in HEK293T WT and HECTD1 KO1 cells. HEK293T cells were 
synchronised using 9µM RO-3306 for 20hrs, released, then fixed using 4% PFA at 10mins 
post-release. Cells were then stained using antibodies against BUBR1 (red) and α-tubulin 
(green), and DNA stained using DAPI (blue).  
  




5.2.3. HECTD1 and mitotic spindle formation 
Next, the possibility that HECTD1 may be involved in mitotic spindle regulation was 
explored. This could explain the phenotype seen in Chapter 4, which may be as a result 
prolonged SAC activation. For example, depletion of the mitotic spindle factor, NuMA, was 
associated with delayed microtubule regrowth, and reduced inter-kinetochore tension 
(Haren, et al. 2009). HECTD1 depletion and knockout display similar growth defects and 
enrichment of mitotic cells to NuMA depleted cells, which could suggest that HECTD1 
depletion may result in similar microtubule defects.  
 
To test whether HECTD1 was required for microtubule polymerisation, microtubule re-
growth was studied in both HECTD1 siRNA depleted HEK293ET and knockout HEK293T 
cells. Cells were treated with 300ng/ml nocodazole for 1hr, followed by 30mins cold 
treatment to completely depolymerise the microtubules (Jordan, et al. 1992). Cells were 
then placed back at 37°C into fresh media to allow the microtubules to reform, permitting 
testing of the requirement of HECTD1 in spindle formation (Haren, et al. 2009).  In HECTD1-
depleted cells and knockout cells, there appeared to be no effect on mitotic spindle 
formation compared to control cells after 15mins recovery (Figure 5.7), however more work 
would be required to extensively image mitotic spindle formation. Therefore, it is not 
possible to determine whether HECTD1 is involved in mitotic spindle regulation. An 
additional consideration is that the phenotype may be subtle and may not be detected using 

















































Figure 5.7. Mitotic spindle formation in HECTD1 depleted or knockout cells. A) 
Representative images of HEK293ET treated with 20pmol NT or HECTD1 SP siRNA, at 
15mins post recovery from microtubule depolymerisation. B) Representative images of 
HEK293T WT and KO1 cells, at 15mins post recovery from microtubule depolymerisation. 
Cells were treated with 300ng/ml nocodazole for 1hr at 37ºC, followed by cold treatment on 
ice for 30mins, cells were released into DMEM at 37ºC before then fixing the cells in 4% 
PFA at 15mins post-release. Cells were stained for either α-tubulin (green) or Hoechst. 
Images are representative of two independent experiments. Images were taken using the 
LSM Meta 510 Confocal Microscope. Scale bar represents 10µm. White arrows indicate 








5.2.4. TRABID1-200 can be used to trap K29/K33 ubiquitin chains and HECTD1 
As a parallel approach to identify a HECTD1 putative mitotic function, an alternative 
strategy, which aimed at developing an assay to enrich for HECTD1 substrates was used. 
To characterise the E3 ligase activity of HECTD1 in the cell cycle phenotype demonstrated 
in Chapter 4, GST-TRABID1-200 was used to demonstrate the ability to trap K29/K33 
ubiquitin chains in asynchronous and synchronised cell lysates.  TRABID1-200 is able to pull 
down K29 chains only, K33 chains only and mixed K29/K33 chains (Kristariyanto, et al. 
2015a; Michel MA, et al. 2015). Here, both HEK293T WT and HECTD1 KO1 cell lysates 
were used in the GST-TRABID1-200 pull down, to establish whether the amount of ubiquitin 
pulled down in the HECTD1 KO1 cell lysates was different to the WT cells, therefore 
indicating that the polyubiquitin captured was as a result of the activity of HECTD1. HECTD1 
like UBE3C, is a E3 ubiquitin ligase that can synthesise atypical ubiquitin chains assembled 
via K29 and K48 (Figure 3.1). Recently, it has been shown that the NZF1 domains within 
TRABID enrich for branched K29/K48 ubiquitin chains (Crowe, et al. 2017). Therefore, in 
order to detect K29 in the cell cycle, bacterially expressed GST-TRABID1-200 was used in 
pull down experiments using lysates from synchronised cells (Figure 5.1).  
 
First to establish that the pull-down was specific to the binding domain, the TRABID1-200 TY/LV 
mutant was used. This mutant comprises the 3 NZF binding domains that each have been 
mutated at the ubiquitin binding Thr and Tyr residues, which are responsible for interacting 
with the Ile44 patch on ubiquitin (Alam, et al. 2004). Mutation of each of the Thr and Tyr 
residues to Leu and Val, prevents ubiquitin binding in each of the NZF domains (Alam, et 
al. 2004). As seen in Figure 5.8, GST-TRABID1-200 was able to pull down ubiquitin in the 
HEK293T WT cells, furthermore, HECTD1 was pulled down with ubiquitin. Importantly, 
neither the GST only nor the GST-TRABID1-200 TY/LV mutant were able to pull down ubiquitin 
or HECTD1. Indicating that the association with HECTD1 is via K29/K33 polyubiquitin, and 
not through binding the TRABID1-200 or GST-only. Therefore, this demonstrates that 
TRABID1-200 can be used as a UBD to enrich for substrates modified with K29/ K33 chains 
in cell lysates. However, it is important to consider that the loading of the GST-TRABID1-200 
TY/LV mutant was less than GST-TRABID1-200. This would reduce the HECTD1 and 
polyubiquitin signal seen in the western blot. A Coomassie gel with each protein loaded at 
5µg, based on the protein concentration used for this assay, showed even loading of the 
protein (Appendix Figure A.4). Therefore, it is likely that this was an experimental issue that 
would be overcome by repeating the assay. HECTD1 KO1 cells were used as a control to 
determine the level of K29-containing polyubiquitin ubiquitin chains in cells without 
HECTD1. Interestingly, in the HEK293T HECTD1 KO1 cells, there were still K29 and K33 
containing ubiquitin chains present, however as expected there were no HECTD1 in the 
pull-down or in the input. This suggests that these chain types are still synthesised without 




the presence of HECTD1, this is expected given the activity of UBE3C in conjugating 
K29/K48 ubiquitin chains (Wang & Pickart. 2005). Additionally, the polyubiquitin smear 
appeared to be less intense than in the WT cells, suggesting that there may be fewer of 
these atypical polyubiquitin chains in HECTD1 KO1 cells and that HECTD1 activity 
contributes to the synthesis of these chains.  
 
In addition, it also determined whether K29 and K33 chains were responsive to proteasomal 
inhibition using MG132 (Vinitsky, et al. 1992; Tsubuki, et al. 1993). This revealed that 
proteasome inhibition did indeed increase the amount of ubiquitin entities pulled down by 
TRABID1-200 suggesting that K29 and or K33 are proteasomal signals (Figure 5.9). The GST 
only IP in both the DMSO and MG132 treated cells showed no ubiquitin signal, indicating 
that the increase in signal was specific to the TRABID1-200. Based on this data and to 
increase the chance that the ubiquitin entities pull down by TRABID1-200 are due to HECTD1 
ligase activity, subsequent experiments were carried out in the absence of MG132. 
Interestingly, inhibition of the proteasome has been shown to result in increased activity of 
UBE3C, which would lead to enrichment of K29/K48 (Besche, et al. 2014, Wang & Pickart. 
2005; Besche, et al. 2014).  
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Figure 5.8. TRABID1-200 but not the TRABID1-200 TV/LV mutant is able to trap K29/ K33 
ubiquitin chains in HEK293T cell lysates. Pull down assay to determine the ability of 
TRABID1-200 to pull down endogenous ubiquitin from asynchronous HEK293T WT and KO1. 
For the IP GST fusions of bacterially expressed TRABID1-200 and TRABID1-200 TY/LV were 
used. Western blots of the immunoprecipitation (IP) and Input. Both HEK293T WT and KO1 
cells were lysed in TRABID1-200 IP lysis buffer and proteins levels were analysed on a 4-
12% SDS PAGE. Following western blotting on PVDF, the membrane was blocked in 3%-
BSA-PBST and incubated overnight with anti-Ub antibody (BML-PW0930) and anti-
HECTD1 (ab101992) followed by detection with an appropriate secondary HRP antibody. 
The anti-Ub antibody was selected as per the optimisation seen in Appendix Figure A.5. 
Both anti-GST (27-4577-01) and anti-beta-actin (A5441) were used as loading controls. * = 
GST and ** = GST-TRABID1-200 and GST-TRABID1-200 TY/LV. Of note is that there is a 
difference in loading between the TY/LV mutant and WT TRABID1-200. A Coomassie gel 
showing even loading of 5µg of GST, GST-TRABID1-200, and GST-TRABID1-200 TY/LV 
(Appenix Figure A.4). Here, proteins were normalised to 5µg based on the concentration of 
protein, which was also used for this experiment. Molecular weight markers are 
superimposed on the left-hand side of the immunoblot.  
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Figure 5.9.  TRABID1-200 can trap K29/ K33 ubiquitin chains in HEK293T cells treated 
with or without MG132. Pull down assay to determine the ability of TRABID1-200 to pull 
down endogenous ubiquitin from asynchronous HEK293T WT. Samples were treated with 
DMSO or 10µM MG132 for 6hrs before lysis. For the IP GST fusions of bacterially 
expressed TRABID1-200 and TRABID1-200 TY/LV were used. HEK293T WT cells were lysed in 
TRABID1-200 IP lysis buffer and proteins levels were analysed on a 4-12% SDS PAGE. 
Following western blotting on PVDF, the membrane was blocked in 3%-BSA-PBST and 
incubated overnight with anti-Ub antibody (BML-PW0930) and anti-HECTD1 (ab101992) 
followed by detection with an appropriate secondary HRP antibody. Both anti-GST (27-
4577-01) and anti-beta-actin (A5441) were used as loading controls. * = GST and ** = GST-









5.2.5. K29/K33 ubiquitin chains and HECTD1 are present throughout the cell cycle 
Having optimised a protocol to enrich for K29 and K33 chains in HEK293T cell lysates in 
the absence of proteasomal inhibition, the next step was to determine whether these 
ubiquitin chain types might be enriched in specific stages of the cell cycle. Indeed, based 
on the data presented so far it is expected that the chains that are synthesised by HECTD1, 
and hypothesised to be K29 and K48 based on in vitro studies, might be present and even 
enriched during M phase of the cell cycle.  
 
To establish the presence of K29 branched ubiquitin chains in the cell cycle, HEK293T WT 
cells were synchronised using three different cell synchronisers. As identified in the cell 
cycle synchroniser characterisation in Chapter 3, different synchronisers should be used to 
enrich for cells in particular phases of the cell cycle. Therefore, to enrich cells in G1, 
HEK293T WT cells were synchronised using Aphidicolin, and harvested at 0hr (no release). 
S phase cells were enriched by using a double thymidine block, and a 2hr release. Finally, 
G2 and M cells were enriched by using RO-3306 and harvested at 0hr and 20mins post-
release respectively (Figure 5.10). Using GST-TRABID1-200, ubiquitin chains containing 
most likely K29 and K33-linked ubiquitin were found to be present in all phases of the cell 
cycle. Interestingly, the levels of these chains appeared to be lower in M phase compared 
to G1, S, and G2 samples, and this is despite more ubiquitin being present in the input for 
the M phase. This suggests that there may be fewer K29-modified proteins during mitosis 
(Figure 5.10A). Despite no increase in the K29/K33 linked ubiquitin chains during mitosis, 
as hypothesised, this does not rule out the possibility that HECTD1 is active during mitosis. 
The reduction of K29/K33 linked polyubiquitin could be due to increased activity of the DUB 
TRABID during mitosis, to ensure the correct regulation of mitotic regulators. Additionally, 
given that the proteasome is not inhibited, the reduced chains in mitosis could be as a result 
of increased substrate turnover, therefore less modified species would be pulled down by 
GST-TRABID1-200. HECTD1 was also found to immunoprecipitate along with ubiquitin using 
GST-TRABID1-200 in all phases of the cell cycle, suggesting that it synthesises these chains 
throughout the whole of the cell cycle. However to confirm this, similar pulldown assays 
should be carried out in the knockout cells (HEK293T KO1) as a subtractive comparison.  
 
The background staining of HECTD1 in the GST-only S phase sample may be a result of 
protein loading as seen in the beta actin of the S phase input. This demonstrates that there 
may some background interaction of HECTD1 and GST when high levels of protein are 
loaded in the sample. For the other samples where less protein had been loaded the 
background signal was much weaker. Finally, to ensure that the cell synchronisation was 
successful, and that cells were indeed in their expected cell cycle phase, flow cytometry 
with PI staining was carried out (Figure 5.10B). Samples were harvested from the cells used 




for the IP, and taken to analyse their cell cycle profile. As expected, it can be seen that cells 
were successfully synchronised in G1, S, G2, and M phase.  
 
Having fully shown for the first time the presence of K29 and/or K33-linked ubiquitin chains 
during all stages of the cell cycle, similar experiments were carried out to explore specifically 
the different phase of mitosis. Cells were synchronised using RO-3306 and harvested at 
0h, 20mins, 2hrs, and 20hrs post-release (Figure 5.11). Here, K29 and/or K33 chains were 
present in G2 (0hr) and M phase (20mins and 2hr), and a time point when cells have exited 
mitosis (20hrs). This indicates that these chains are present from the G2/M transition, 
through mitosis, and after mitosis, and suggests that these K29/K33 chains may have a 
function in mitotic processes. However, the data does not suggest that during mitosis there 
are any drastic changes in the levels of K29/K33, indicating that their presence is relatively 
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Figure 5.10. TRABID1-200 captures K29/ K33 ubiquitin chains in all stages of the cell 
cycle. Pull down assay to determine the ability of TRABID1-200 to pull down endogenous 
ubiquitin from synchronised HEK293T WT. HEK293T WT cells were synchronised using 
4µg/ml Aphidicolin to enrich for G1 phase cells, 2mM Thymidine with a 2hr release (double 
thymidine block) to obtain S phase cells, and 9µM RO-3306 to obtain G2 and 20mins 
release from RO-3306 to obtain M phase cells. For the IP the GST fusion of bacterially 
expressed TRABID1-200 was used. A) Western blots of the immunoprecipitation (IP) and 
Input. HEK293T WT cells were lysed in TRABID1-200 IP lysis buffer and proteins levels were 
analysed on a 4-12% SDS PAGE. Following western blotting on PVDF, the membrane was 
blocked in 3%-BSA-PBST and incubated overnight with anti-Ub antibody (BML-PW0930), 
anti-HECTD1 (ab101992), and anti-pHistone H3 (ser28) (ab10543) followed by detection 
with an appropriate secondary HRP antibody. Both anti-GST (27-4577-01) and anti-beta-
actin (A5441) were used as loading controls. B) Cell cycle profile of HEK293T WT cells. 
Cells were fixed using 70% ethanol, cells were stained using 2µg/ml PI, with 100µg/ml 
RNase A, for 30mins at room temperature. Stained samples were then analysed 
immediately by flow cytometry. Histograms for each cell cycle phase. PI-A of 50 is 
equivalent to 2N (G1 population), and PI-A of 100 is equivalent to 4N (G2/M population). 
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Figure 5.11. TRABID1-200 captures K29/ K33 ubiquitin chains throughout mitosis.  Pull 
down assay to determine the ability of TRABID1-200 to pull down endogenous ubiquitin from 
synchronised HEK293T WT. HEK293T WT cells were synchronised using 9µM RO-3306 
for 20hrs. Cells were released and harvested at 0mins, 20mins, 2hrs, and 20hrs post-
release. For the IP the GST fusion of bacterially expressed TRABID1-200 was used. 
HEK293T WT and KO1 cells were lysed in TRABID1-200 IP lysis buffer and proteins levels 
were analysed on a 4-12% SDS PAGE. Following western blotting on PVDF, the membrane 
was blocked in 3%-BSA-PBST and incubated overnight with anti-Ub antibody (BML-
PW0930), anti-HECTD1 (ab101992), anti-pHistone H3 (ser28) (ab10543), and anti-cyclin 
B1 (sc-254) followed by detection with an appropriate secondary HRP antibody. Both anti-
GST (27-4577-01) and anti-beta-actin (A5441) were used as loading controls. * = GST and 
** = GST-TRABID1-200. pHistone H3 (ser28) was used as a mitotic marker to show 
synchronisation, whilst Cyclin B1 was used as a G2/M marker. As seen in the input, cells 
were successfully synchronised, with Cyclin B1 appearing in the 0hr, 20mins, and 2hrs 
samples, and pHistone H3 present in the 20mins only. Molecular weight markers are 
superimposed on the left-hand side of the immunoblot. 
  





The putative role of HECTD1 in mitotic regulation has been further demonstrated by the 
increase in the early mitotic marker pHistone H3 (ser28) in HECTD1 depleted or knockout 
cells using both cellular and molecular readouts. Due to time constraints it was not possible 
to establish whether HECTD1 depletion resulted in enrichment of the SAC marker BUBR1 
or mitotic spindle defects. As a parallel approach to identify a HECTD1 putative mitotic 
function, the UBD TRABID1-200 was used as a new tool to show that K29/K33 chains are 
readily detectable by IP and are a present during the cell cycle and mitosis. This was used 
because it is known that HECTD1 is able to synthesise K29/K48 chains (Figure 3.1). 
Therefore, K29 linkages synthesised by HECTD1 would be detected by TRABID1-200 and 
may serve as a way to enrich for potential mitotic substrates modified with K29.  
 
5.5.1. Increase in the early mitotic marker pHistone H3 (ser28) 
Given previous data suggesting a delay in mitosis, pHistone H3 (ser28) was used as a 
mitotic marker. It was observed that upon depletion of HECTD1, pHistone H3 (ser28) 
increased by western blot and to a lesser extent by immunofluorescence. There appears to 
be no change in Cyclin B1 expression over two independent experiments, however given 
the broad expression of Cyclin B1 (Pines & Hunt. 1987; Murray & Kirschner. 1989), it is 
likely the increase of early mitotic cells is masked, unlike with pHistone H3 (Gurley, et al. 
1978) (Figure 5.12).  Cyclin B1 levels increase during G2, before peaking in early mitosis, 
which is followed by the degradation of the protein (Pines & Hunt. 1987; Murray & Kirschner. 
1989). This degradation was found to be as a result of the ubiquitin proteasome pathway, 
where a D box was found at the N terminus of Cyclin B1 (Glotzer, et al. 1991). Cyclin B1 
turnover is triggered at anaphase onset by the recognition of its N-terminal D-box degron 
(Glotzer, et al. 1991) by APC/CCdc20 (Visintin, et al. 1997; Chang, et al. 2003). pHistone H3 
(ser28), was found to be phosphorylated during mitosis during chromosomal condensation 
and dephosphorylated during exit from anaphase (Gurley, et al. 1978) (Figure 5.15). Aurora 
B kinase is responsible for the phosphorylation of Histone H3 at ser10 and ser28 (Goto, et 
al. 1999; Wei, et al.1999; Giet & Glover. 2001; Hauf, et al. 2003). Similarly, 
dephosphorylation of Histone H3 at both ser10 and ser28, was found to be as a result of 
the phosphatase PP1 (Murnion, et al. 2001; Goto, et al. 2002). In contrast to 
phosphorylation of ser10, which has been observed during interphase as well as mitosis, 
phosphorylation of ser28 is specific to mitosis suggesting that it is a more accurate readout 
for mitosis (Goto, et al. 1999). 
 
Taken together the increase in metaphase cells and pHistone H3 indicates an enrichment 
of cells potentially caused by prolonged spindle assembly checkpoint activation. An 




accumulation of early mitotic cells, as implicated by the enrichment of pHistone H3 (ser28) 
and the enrichment of metaphase cells (Chapter 4), has been associated with spindle 
regulation phenotypes in other studies. For example, depletion of the histone H3 lysine 36 
dimethylation demethylase, JMJD5, is associated with an increase in metaphase cells, in 
addition to an increase in pHistone H3 (Ser10). JMJD5 was shown to colocalise with the 
mitotic spindle during mitosis, showing strongest staining at metaphase. When depleted, 
there was an associated decrease in a-tubulin acetylation, resulting in failure to generate 
enough inter-kinetochore tension to satisfy the SAC (He, et al. 2016). Furthermore, 
depletion of spindle regulatory proteins such as NuMA, and Tankyrase-1 result in increased 
mitotic index (Chang, et al. 2005; Haren, et al. 2009). In addition, NuMA depletion was 
associated with delayed microtubule regrowth, and reduced inter-kinetochore tension 
(Haren, et al. 2009). HECTD1 exhibited a similar phenotype to these spindle regulator 
proteins, which further suggest that HECTD1 might be involved in mitotic spindle regulation, 
which in turn could result in a lack of sufficient inter-kinetochore tension and a prolonged 




Figure 5.12. Diagram illustrating Cyclin B1 and pHistone H3 expression throughout 
the cell cycle. Expression of Cyclin B1 and pHistone H3 (ser10 and ser28) over the course 
of the cell cycle, red dashed line indicates anaphase onset.  
 
 
5.3.2. BUBR1 staining as a marker for prolonged SAC activation 
To address the hypothesis that in HECTD1-depleted or knockout cells the SAC is active for 
longer, synchronised cells were stained for the SAC marker BUBR1 and examined by 
immunofluorescence. BUBR1 is a SAC component, which together with CDC20, MAD2, 
and BUB3 forms the MCC (Sudakin, et al. 2001). Therefore, BUBR1 was used as a marker 




to assess whether the SAC is active for longer in HECTD1 knockout cells. BUBR1 
successfully stained unattached kinetochores, however due to time restraints it was not 
possible to quantify unattached kinetochores in HECTD1 knockout or depleted cells. To 
establish whether there is a prolonged SAC activation in HECTD1-depleted cells, the 
number of BUBR1 positive kinetochores in each cell, instead of BUBR1 positive cells can 
be scored as seen with JMJD5 depletion (He, et al. 2015). This would provide a less crude 
way of monitoring SAC activation. Furthermore, the use of another SAC marker, such as 
MAD2 would help to demonstrate persistent SAC activation, as seen in NuMA depleted 
cells (Haren, et al. 2009). Again, the number of MAD2 positive cells and kinetochores could 
be scored to demonstrate increased SAC activation in HECTD1 depleted cells.   
 
It is hypothesised that there will be an increase in the number of BUBR1 positive cells in 
HECTD1 knockout cells compared to WT cells post-release from RO-3306. This would 
therefore suggest a prolonged SAC activation. For example, the mitotic spindle protein, 
JMJD5 was shown to regulate the mitotic spindle, by microtubule acetylation. The 
phenotype of increased metaphase cells, early mitotic markers, and prolonged NEBD to 
anaphase onset upon JMJD5 depletion is similar to that of the phenotype associated with 
HECTD1 depletion and knockout (He, et al. 2016).  Interestingly, the authors reported an 
increase in the spindle assembly checkpoint marker BUBR1 when cells were depleted with 
JMJD5 indicating failure to satisfy the SAC (He, et al. 2016). However, further work with 
more SAC markers such as MAD2, and BUB3 would be required to establish whether the 
SAC is active for longer in HECTD1 depleted and knockout cells.  
 
 
5.3.3. Mitotic spindle formation in HECTD1-depleted cells  
To elucidate whether the phenotype observed in Chapter 4 is as a result of improper mitotic 
spindle regulation, microtubule dynamics in HECTD1 depleted cells were characterised by 
immunofluorescence.  However, due to time constraints it was not possible to establish 
whether HECTD1 depletion or knockout resulted mitotic spindle formation defects. It is 
hypothesised, based on the phenotype seen in Chapter 4, that HECTD1 depletion or 
knockout may result in defects in mitotic spindle formation.  
 
In cells depleted of the tumour suppressor DUB, CYLD (Cylindromatosis), involved in mitotic 
spindle regulation, nocodazole treatment to depolymerise the microtubules resulted in 
delayed microtubule regrowth (Gao, et al. 2008; Yang, et al. 2014). Depletion resulted in 
dramatically delayed microtubule regrowth, with only a few small microtubule asters 
detected after 5mins of regrowth, suggesting that CYLD regulates the dynamic property of 
microtubule assembly and enhances microtubule stability (Gao, et al. 2008). This regulation 




of microtubules has been proposed to be mediated by the interaction of CYLD with EB1 
(End-Binding 1) protein at the plus end of microtubules (Li, et al. 2014). Interestingly, CYLD 
has been reported to regulate spindle orientation by the stabilisation of astral microtubules. 
Where, it was shown mechanistically to deubiquitinate dishevelled and promote the 
formation of a dishevelled-NuMA-dynein/dynactin complex at the cell cortex, which is 
required for the generation of pulling forces on astral microtubules (Yang, et al. 2014).  
 
The majority of mitotic cell cycle defects are not catastrophic and result in a subtle 
phenotype. For example, in NuMA depleted cells that have been cold treated, spindles were 
reported to have a lower density, lacking K fibre bundles, and were less compact compared 
to control cells, with no reported change to overall microtubules in the cell (Haren, et al. 
2009), demonstrating the role that NuMA has in mitotic spindle formation. Similarly, the 
ubiquitin receptor protein, UBASH3B, was reported to facilitate mitotic recruitment of Aurora 
B to mitotic microtubules (Krupina, et al. 2016). Cold treatment of metaphase cells showed 
a decrease in the formation of stable kinetochore bundles upon UBASH3B depletion 
(Krupina, et al. 2016). This demonstrates the need for high-resolution microscopy, such as 
SIM, SMLM or STED microscopy (Alonso. 2013; Wegel, et al. 2016), to monitor spindle 
defects in HECTD1 depleted or knockout cells. As previously discussed, SIM or SMLM 
microscopy would be the most appropriate type of super resolution microscopy to study 
microtubule dynamics (Wegel, et al. 2016). Using super resolution microscopy would help 
to determine whether HECTD1-depleted cells exhibit spindles that, for example, lack K fibre 
bundles or other less obvious phenotypes that would not readily be identifiable from use of 
a regular confocal microscope.  
 
Finally, in C. elegans, the HECTD1 orthologue, HECD-1, was found to be an activator of 
meiotic double strand break formation protein (MEI1) during meiosis but an inhibitor of the 
same protein during mitosis (Beard, et al. 2016). MEI1 together with MEI2 forms a katanin-
like microtubule-severing complex essential for meiotic spindle formation, that has to be 
inactivated to allow for proper formation of the mitotic spindle (Srayko, et al. 2000). Failure 
to eliminate this severing complex during mitosis results in lethality due to excess 
microtubule cleavage (Mains, et al. 1990). It is hypothesised that HECTD1 does not regulate 
the protein levels of MEI1. Instead, ubiquitination of the substrate by HECTD1 leads to 
increased activation, however the exact mechanism remains unclear (Beard, et al. 2016). 
This suggests that in addition to the role that HECD-1 has in meiotic spindle formation in C. 








5.3.4. TRABID1-200 can be used to trap K29 and K33 linked chains 
In order to characterise the presence of K29 ubiquitin chains synthesised by HECTD1 in 
the cell cycle, GST-TRABID1-200 was used to demonstrate the ability to trap K29/K33 
ubiquitin chains in asynchronous and synchronised cell lysates. Importantly, GST-TRABID1-
200 was successfully used as a binding domain to trap ubiquitin in cell lysates. As 
demonstrated by Figure 3.1 (Chapter 3), HECTD1 is able to synthesise atypical ubiquitin 
chains, linked via K29/K48. Furthermore, recent work has used the NZF1 of TRABID to trap 
branched K29/K48 ubiquitin chains (Crowe, et al. 2017). Therefore, given that TRABID1-200 
can bind K29/K33 chains, it was hypothesised that this domain can be used as a ubiquitin 
binding domain (UBD) to pull down HECTD1 K29/K48 modified substrates by recognising 
the K29 linked ubiquitin modification. In resting mammalian cells, K33 (≤0.5%) is at a much 
lower abundance than K29 (8%) (Dammer, et al. 2011). Therefore, on this basis, in a pull 
down assay the majority of the ubiquitin captured is predicted to comprise more K29 linked 
ubiquitin than K33 linkages. Indeed, GST-TRABID1-200 was able to pull down polyubiquitin 
chains in cell lysates, predicted to be polyubiquitin that contained K29/K33 linkages, given 
the specificity of NZF1 (Kristariyanto, et al. 2015a; Michel, et al. 2015). This is interesting, 
because it demonstrates the ability of this isolated domain to be used as a UBD to capture 
polyubiquitin from cell lysates. From this assay alone it is not possible to confirm that the 
captured K29 species are as a result of HECTD1-modification. A further consideration is 
that the use of proteasomal inhibitor MG132, has been shown to result in increased activity 
of UBE3C, which would lead to enrichment of K29/K48 (Besche, et al. 2014, Wang & 
Pickart. 2005; Besche, et al. 2014). Therefore, it was decided that use of MG132 would only 
function to mask any K29 linked chains synthesised by HECTD1, by the increased activity 
of UBE3C. Therefore, using TRABID1-200 in combination with proteomics (as will be 
discussed in Section 5.4. Future Work), may identify whether some of the captured species 
are as a result of HECTD1 ubiquitination and not UBE3C (Wang & Pickart. 2005).  
 
 
5.3.5. K29/ K33 linked chains are present throughout the cell cycle and mitosis  
Using TRABID1-200, it was demonstrated that HECTD1 is present in each stage of the cell 
cycle, where some K29 and K33-linked chains have been captured. This implies that 
HECTD1 activity in conjugating K29/K48 chains is present throughout the cell cycle. This is 
a novel and exciting observation because to date these chains have not been implicated in 
cell cycle function. Currently the main type of ubiquitin linkage driving mitosis is K11, which 
are conjugated onto substrates by the APC/C (Jin, et al. 2008). More compellingly branched 
K11/K48 synthesised by the APC/C and UBE2S, have been implicated in enhanced 
proteasomal degradation of cell cycle substrate such as NEK2A and p21 (Meyer & Rape. 
2014). This demonstrates the potential scope of further mixed and branched linkages 




involved in cell cycle regulation. Of the known HECT ligases with a cell cycle related 
function, only K48 has been implicated in the role of HERC2 and centrosome duplication 
most conclusively (Al-Hakim, et al. 2012). This highlights the lack of understanding of the 
type of ubiquitin chains synthesised by these HECT ligases in the cell cycle and the potential 
to implicate the activity of HECTD1 in synthesising K29/K48 linked ubiquitin chains in cell 
cycle regulation. 
 
Interestingly, it has been reported that K29/K48 branched ubiquitin chains enriched by the 
NZF1 domain only, do not appear to target substrates to the proteasome (Crowe, et al. 
2017). Therefore, since UBE3C activity is linked to the proteasome and degradation, it could 
suggest that UBE3C does not conjugate branched K29/K48 ubiquitin chains. This may 
suggest that only HECTD1 is able to conjugate K29/K48 branched chains in the cell. 
However, it has been suggested in S. cerevisiae, that branched K29/K48 ubiquitin chains 
promoted degradation of modified substrates (Liu, et al. 2017). Thus, demonstrating the 
infancy of our understanding of the role that branched ubiquitin chains have in cellular 
functions. As for HECTD1, it is not yet possible to know whether its cell cycle regulation is 
mediated by synthesis of K29/K48 onto its substrates either resulting in reduced or 
enhanced turnover by the proteasome. 
 
The presence of K29/K33 ubiquitin chains and HECTD1 in the other phases of the cell cycle 
is expected and explained by the already known functions that HECTD1 in the cell, for 
example in Wnt signalling and cell migration (Tran, et al. 2013; Li, et al. 2013). Therefore, it 
is not surprising that there are K29 ubiquitinated species through the cell cycle because 
HECTD1 is active in different stages of the cell cycle. However, and against the previous 
hypothesis, there was no observed increase in K29/K33 ubiquitin chains pulled down by 
TRABID1-200 during mitosis. This may not rule out a potential role for HECTD1 in mitosis, 
and as previously mentioned, the decrease in K29/K33 polyubiquitin could be due to 
increased activity of TRABID during mitosis. Here, the DUB would function to cleave the 
K29 and/or K33 chains from modified substrates. This would result in a reduction of 
substrates modified with K29/K33. An increase in DUB activity could be monitored using 
the ABPs that were previously discussed in Chapter 3. Here, the first generation of ABPs 
would be most appropriate because they are much more effective in labelling DUBs 
(Borodovsky, et al. 2002; Hemelaar, et al. 2004). The first generation of these probes Ub-
ABP comprise a C-terminal modification of ubiquitin whereby the G76 is modified with a 
variety of thiol-reactive groups, known as warheads, which covalently modify the catalytic 
cysteine of the DUB (Love, et al. 2007). Thus, these ABPs would allow for the study of 
TRABID activity during mitosis to explore this hypothesis further. Additionally, as with Liu, 
et al. (2017), if branched K29/K48 result in increased turnover of potentially mitotic driven 




HECTD1-modification of substrates that would be pulled down using TRABID1-200, then this 
would result in a reduction of these chains during mitosis. Additionally, MG132 was not used 
for these experiments, because of the effect in increasing the activity of UBE3C (Besche, 
et al. 2014), meaning that these chains would be readily degraded and not detected in the 
pull down assay. A final consideration is that through this study the overall ubiquitination 
status within the cell is being detected rather than protein-specific ubiquitination, which is 
likely to be quite different. However, a substrate will first need to be identified to be able to 
fully assess the role of these ubiquitin chains in the role of HECTD1 in mitosis,.  
 
  




5.4. Future work: 
To rule out HECTD1 as a regulator of all microtubules in cells, western blot analysis could 
be carried out to quantify the ratio of tubulin polymer (MTs) to soluble dimer in HECTD1-
depleted or knockout cells. Here, HEK239T cells can be transfected with control or HECTD1 
siRNAs. After performing a microtubule regrowth assay, samples can be collected and 
analysed by western blot to examine tubulin partitioning between the polymer and soluble 
dimer. This ratio can be measured by densitometric analysis of the western blot bands. This 
could therefore demonstrate the need for HECTD1 in MTs assembly as demonstrated with 
CYLD (Gao, et al. 2008). As previously mentioned, deletion of mitotic regulators such as 
NuMA and UBASH3B, showed a subtle phenotype during mitotic spindle regrowth, 
compromising K-fibre formation (Haren, et al. 2009; Krupina, et al. 2016). Therefore, 
HECTD1 may have a similar subtle mitotic spindle phenotype. In the NuMA study of mitotic 
spindle regulation, mitotic cells were scored based on the percentage of cells with regular 
compact spindles over time during the regrowth (Haren, et al. 2009). Time points for 
HECTD1 knock out or depleted cells were taken at 0, 5, 15, 30, 60, 90, and 120mins after 
nocodazole and cold treatment to depolymerise the spindle.  However, as seen with NuMA, 
time points were taken at 2min intervals, between 0 and 15mins, with the full number of 
spindles restored after 15mins post-release (Haren, et al. 2009). Therefore, future work 
studying microtubule regrowth should be conducted over a smaller time frame from 
recovery from nocodazole and cold treatment.  
 
Spindle regulation phenotypes have also been characterised by measuring the orientation 
of the mitotic spindle (Gallini, et al. 2016). Representative confocal z-sections of metaphase 
cells treated with DMSO or the Aurora A inhibitor, MLN8237, are scored based on the angle 
measured between the spindle axis and the plane of the coverslip. Here, it was found that 
phosphorylation of NuMA by Aurora A was required to ensure correct spindle orientation 
(Gallini, et al. 2016). Therefore, to understand the role HECTD1 has in spindle formation, 
further microscopy analysis would need to be conducted. In addition, another approach to 
identify whether HECTD1 is required for mitotic spindle formation, is to measure the inter-
kinetochore distance. The DUB, BRISC, was shown to be required for the assembly of the 
mitotic spindle, where loss of BRISC resulted in unstable kinetochore-microtubule 
interactions, resulting in reduced inter-kinetochore tension contributing to increased time 
taken from NEBD to anaphase onset, increased cells with multipolar spindle, lagging 
chromosomes, and misaligned metaphase plate (Yan, et al. 2015). Furthermore, in NuMA 
depleted cells, there was an increase in inter-kinetochore distance due to the requirement 
of NuMA in spindle formation (Haren, et al. 2009). Therefore, further future work could 
include measuring the inter-kinetochore distance in HECTD1-depeleted cells to help identify 
if it is involved in mitotic spindle regulation.  




The use of GST-TRABID1-200 has been successful in trapping polyubiquitin in synchronised 
cell lysates. However, this would need to be confirmed to show that indeed K29/K33 are 
trapped by GST-TRABID1-200. A method known as UbiCRest can be used to help determine 
ubiquitin chain linkages (Hospenthal, et al. 2015). UbiCRest helps to determine linkages by 
the treatment of polyubiquitin chains with a panel of linkage-specific DUBs in parallel 
reactions, followed by gel based analysis (Hospenthal, et al. 2015). For example, if the 
polyubiquitin chain was composed of K29 and K48 linkages, it is expected that TRABID 
(K29 specific) and Otubain 1 (K48 specific) would be able to partially cleave the smear 
(Licchesi, et al. 2012; Edelmann, et al. 2009). The DUBs USP21 or vOTU would be used 
as a control because they are able to cleave all linkages (Ye, et al. 2011; Hospenthal, et al. 
2015). Therefore, this method would enable confirmation of the composition of the 
polyubiquitin captured by GST-TRABID1-200. To confirm the topology of the polyubiquitin 
chains, proteomics can be used. As described in Meyer, et al. (2014), insertion of a Tobacco 
Etch Virus (TEV) protease cleavage sequence into the Glu-53 residue within ubiquitin can 
be used to demonstrated the presence of branched ubiquitin chains, the method of which 
is discussed in the final discussion (Chapter 7).  
 
Ubiquitin linkage specific antibodies can be used to identify different chain linkages. For 
example, K48 and K63 specific antibodies have been used to study K48 and K63 linked 
ubiquitin in immune signalling (Newton, et al. 2008). Furthermore, K11/K48 bispecific 
antibodies have been generated to detect K11/K48 linked heterotypic chains (Yau, et al. 
2017). This bispecific, K11/K48 antibody, was used to show the presence of those 
heterotypic chains within a mitotic cell by immunofluorescence (Yau, et al. 2017). Therefore, 
the generation of a K29/K48 antibody would facilitate detection of these heterotypic chains 
in the ubiquitin captured by GST-TRABID1-200 and their localisation in the cell using 
immunofluorescence. However, a significant drawback is that linkage-specific antibodies 
are only available for 5 of the 8 different ubiquitin linkages, these include Met1, K11, K27, 
K48, and K63 (Michel, et al. 2017). Recently to overcome this limitation, K6 and K33 linkage 
specific “affimers” have been designed, which can be used in techniques such a western 
blot, immunofluorescence, and pull down assays to identify these linkages (Michel, et al. 
2017). Affimers are 12kDa non-antibody scaffold that are based on the cystatin fold and 
importantly, provide an alternative specific high-affinity reagent (Tiede, et al. 2014; Tiede, 
et al. 2017). Therefore, using western blot the K33 linkage specific affimer could be used to 
confirm the specificity of GST-TRABID1-200. Although, a current limitation is that no antibody 
or affimer is available that can detect K29 so more work is need in the field to expand this 
method of detection of ubiquitin linkages (Michel, et al. 2017). Furthermore, both antibodies 
and affimers present an alternative to the use of the TRABID1-200, so would only be used to 
help confirm previous observations using this domain.  




GST-TRABID1-200 comprises NZF1, NZF2, and NZF3 domains, however only NZF1 has 
reported ubiquitin binding selectivity towards K29/K33 (Kristariyanto, et al. 2015a; Michel, 
et al. 2015). Recent work has used the NZF1 to trap branched K29/K48 ubiquitin chains 
(Crowe, et al. 2017). Here, Ubiquitin Chain Enrichment Middle-down Mass Spectrometry 
(UbiChEM-MS) was used to identify branched chains. Specifically, NZF1 TUBEs were used 
to enrich for chains from human cells. It was found that ∼1% of chains isolated with TUBEs 
contain Ub branch points, with this value rising to ∼4% after proteasome inhibition (Crowe, 
et al. 2017).  This demonstrates a method for detecting and characterising the dynamics of 
branched conjugates under different cellular conditions, which could be used to study cell 
cycle K29 modified-substrates. Therefore, the NZF1 domain in isolation could be used to 
enrich for K29/K33 linked ubiquitin chains in future work as demonstrated in work carried 
out by Kristariyanto, et al. (2015a) and Michel, et al. (2015).  TUBEs have been designed 
based on UBA domains to enhance that capture of polyubiquitinated proteins (Hjerpe, et al. 
2009). They are designed with multiple UBAs to provide a higher affinity for polyubiquitin 
providing an increased capture of polyubiquitin within cell lysates (Hjerpe, et al. 2009). NZF1 
TUBEs are now commercially available (UBPBio) and their use could improve detection of 
the K29/K33 linked polyubiquitin for use in future assays. An NZF1 TUBE could result in 
increased binding in comparison to TRABID1-200 because the NZF1 domain is reported to 
be the K29/K33 ubiquitin binding domain (Michel, et al. 2015; Kristariyanto, et al. 2015a). 
Therefore, repeating units of NZF1 domains is likely to have a higher affinity towards 













Figure 5.13. Schematic of downstream applications for the enrichment of 
polyubiquitin using ubiquitin associated domains. Example of a NZF1 domain trapping 
K29/K33 linked polyubiquitinated substrate in an immunoprecipitation assay for 
identification using mass spectrometry, such as Ubiquitin chain enrichment middle-down 
mass spectrometry (UbiChEM-MS) (Crowe, et al. 2017).  




Identification of substrates can be carried out by a proteomics analysis of different cell cycle 
phases. Either an anti-HECTD1 antibody or GST-TRABID1-200 can be used for a proteomics 
based analysis of interactors. Using an anti-HECTD1 antibody will help to identify HECTD1 
interactors and potential substrates at different cell cycle phase, specifically the comparison 
of mitotic and non-mitotic cells. Whilst, an IP using GST-TRABID1-200 should identify proteins 
modified with K29 or K33 linked ubiquitin at different cell cycle stages. This will confirm the 
association of HECTD1 with these ubiquitin chains during the cell cycle, but may also show 
that potential HECTD1 interactors identified using an anti-HECTD1 antibody are also 
modified with these ubiquitin chains. Additionally, proteomics can be carried out in 
HEK293T cells in comparison to HEK293T KO1 cells to see if HECTD1 depletion affects 
overall protein stability in a group of proteins.  
 
There are two different techniques, which can be used to carry out quantitative mass 
spectrometry; stable isotopic labelling by amino acids in cell culture (SILAC) and tandem 
mass tag (TMT) labelling (Ong, et al. 2002; Thompson, et al. 2003). In SILAC two differently 
labelled samples can be studied by mass spectrometry to identify substrates. Where, 
mammalian cell lines are supplemented with a ‘light’ or ‘heavy’ form of an amino acid, which 
is incorporated into proteins, this allows for quantification of proteins and therefore 
comparison between the two samples (Ong, et al. 2002). In comparison, TMT labelling 
allows for the labelling of up to 10 different samples and are designed as such to allow 
identical proteins labelled with different TMTs to exactly comigrate in all separations. Each 
tag is chemically identical with the exception of different isotopes that have been substituted 
at various positions, allowing distinction between the samples (Thompson, et al. 2003). Both 
SILAC and TMT labelling have been used to identify cell cycle substrates (Singh, et al. 
2014; Lafranchie, et al. 2014). SILAC was used to identify potential APC/CCDH1 samples by 
comparing cells that have been synchronised with nocodazole and lysed immediately 
(mitotic) and cells that were released for 2.5hrs before lysis (non-mitotic) (Lafranchie, et al. 
2014). Using this approach alongside bioinformatics, CTLP was identified as an APC/CCDH1 
target during the cell cycle and DNA damage response (Lafranchie, et al. 2014). TMT 
labelling has also been employed to identify APC/C targets (Singh, et al. 2014). Here, 6 
samples were labelled with a TMT, cells were synchronised in S phase, G2/M phase, 
Metaphase/Anaphase, Anaphase/Cytokinesis, Telophase/ Cytokinesis, and late G1 phase, 
which led to the identification of kinesins as APC/C substrates (Singh, et al. 2014). However, 
a consideration is that with SILAC, samples are labelled before cell lysis, whereas with TMT 
labelling samples are labelled post lysis, therefore allowing for greater variability between 
samples when using TMT (Ong, et al. 2002; Thompson, et al. 2003; Singh, et al. 2014; 
Lafranchie, et al. 2014).  
 



































6.1.1. Cancer  
Cancer is a disease that develops when normal cells begin to grow out of control 
unmonitored. Specifically, cancer arises due to the culmination of disruptions to the controls 
of cellular proliferation, immortality, angiogenesis, cell death, invasion, and metastasis 
(Hanahan & Weinberg. 2011; Shen & Laird. 2013). Previously, it was considered that  
cancer is a disease based primarily on genetics because genetic mechanisms such as 
mutation, copy number alteration, insertion, deletion, and recombination are all vehicles of 
persistent phenotypic change (Shen & Laird. 2013). However, more recently epigenetic 
mechanisms have been considered to also contribute to the development of cancer, 
providing a new “generation” of oncogenes and tumour suppressor genes (Esteller. 2006). 
 
Two of the main types of genes that result in cancer formation are oncogenes and tumour 
suppressor genes (Lee & Muller. 2010). An oncogene is defined as a gene that has the 
potential to cause cancer and a proto-oncogene is defined as a normal gene that becomes 
an oncogene through mutation or overexpression (Lee & Muller. 2010). The first oncogene, 
src, was discovered in Rous Sarcoma Virus (RSV), a domestic foul virus, first discovered 
by Rous P. (1911) (Weiss & Vogt. 2011). Later, the first oncogenic human virus discovered 
was the Epstein-Barr virus (Epstein, et al. 1964). Finally, the first human oncogene, ras, 
was discovered in bladder carcinoma (Pulciani, et al. 1982; Parada, et al. 1982).  In contrast, 
a tumour suppressor gene is a gene that protects a cell from one step on a pathway that 
will lead to cancer. A mutation that results in a loss or reduced function of the gene can 
result in cancer development (Lee & Muller. 2010). Tumour suppressor genes were first 
characterised using somatic cell hybridisation experiments, which involved fusion of normal 
cells with tumour cells. These experiments suggested that genes from normal non-
cancerous cells functioned to inhibit tumour development (Harris, et al. 1969). The first 
tumour suppressor gene identified was Rb, discovered in retinoblastoma (Knudson. 1971; 
Fung, et al. 1987).  The next tumour suppressor identified was p53 (Lane & Crawford. 1979), 
which has been suggested to be mutated in almost every cancer with mutation rates of 
38%-50% in ovarian, oesophageal, colorectal, head and neck, larynx, and lung cancers 
(Olivier, et al. 2010). These key discoveries of both oncogenes and tumour suppressor 
genes helped to understand cancer development at the genetic level.  
 
 
6.1.2. Epigenetics and cancer 
Epigenetic mechanisms are essential for normal development and maintenance of tissue 
specific gene expression patterns in animals (Sharma, et al. 2010). However, disruption of 
epigenetic processes can lead to altered gene function and malignant cellular 
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transformation (Sharma, et al. 2010). It is typically considered that global changes in an 
epigenetic landscape is a hallmark of cancer (Jones & Baylin. 2002; Hanahan & Weinberg. 
2011). This results in the reprogramming of every component of the epigenetic machinery 
(Sharma, et al. 2010). Chromatin is composed of repeating units that consist of DNA that is 
wrapped around an octamer of four histone proteins: H3, H4, H2A, and H2B (Luger, et al. 
1997). Epigenetic mechanisms that modify chromatin structure are subdivided into four 
main categories: DNA methylation, covalent histone modifications, nucleosome remodelling 
and non-coding RNAs (long non-coding RNAs). Together these modifications regulate the 
structural dynamics of the genome influencing its accessibility (Sharma, et al. 2010). 
 
An example of epigenetic gene regulation is DNA methylation, which is a gene silencing 
mechanism required for maintaining genome stability (Kulis & Esteller. 2010). DNA 
methyltransferases (DNMTs), are responsible for the conversion of cytosine to 5-
methylcytosine, by the transfer of a methyl group from the universal methyl donor, S-
adenosyl-L-methionine (SAM) (Fienberg & Tycko. 2004; Kulis & Esteller. 2010). DNA 
methyltransferases, DNMT1, DNMT3A, and DNMT 3B, are responsible for DNA methylation 
whilst DNMT3L has no inherent enzymatic activity (Okano et al. 1998; Kareta, et al. 2006). 
DNMT3A and DNMT3B are de novo methyltransferases that act independent of replication 
showing a preference for both unmethylated and hemimethylated DNA, whereas DNMT1 
acts during replication and preferentially methylates hemimethylated DNA (Okano, et al. 
1999; Kim, et al. 2002). 5-methylcytosine is found at CpG islands, which comprise CpG 
dinucleotides, typically found overlapping or upstream of a gene promoter (Bird. 1980). 
Hypermethylation of a CpG island can result in gene silencing, and this was originally 
hypothesised to prevent transcription factor binding (Watt & Molloy. 1988).  
 
Aberrant silencing of cell cycle regulators and hypermethylation of tumour suppressor 
genes can result in cancer (Robertson. 2005). For example, two cyclin dependent kinase 
inhibitor genes p16INK4a and p15INK4a, that regulate G1 arrest, are silenced by DNA 
methylation in different types of cancer (Drexler. 1998; Kulis & Esteller. 2010). While, 
hypermethylation of the tumour suppressor gene, death associated protein kinase 1 
(DAPK1), results in cancer cell survival, by preventing interferon-g-induced apoptosis 
(Michie, et al. 2010). 5-aza-2’-deoxycytidine, is a drug that is incorporated into DNA instead 
of cytosine during DNA replication. When a DNMT binds to the DNA, it binds irreversibly to 
5-aza-2’-deoxycytidine and cannot disengage. As a result, DNMTs, are rendered inactive 
and therefore the DNA remains unmethylated. 5-aza-2’-deoxycytidine was first synthesised 
in 1964 and was first used as a chemotherapy for acute myeloid leukaemia, however its 
general toxicity meant that other nucleoside analogues were used as an alternative 
(Christman. 2002).  
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In addition to DNA methylation, covalent histone modifications are another level of 
epigenetic regulation. They occur in the unstructured N-terminal tail of histones, which can 
undergo methylation, acetylation, ubiquitination, sumoylation and phosphorylation (Luger, 
et al. 1997; Kouzarides. 2007). Histone modifications can lead to either transcriptional 
activation or repression depending upon the type of modification and the residue that has 
been modified (Shen & Laird. 2013). For example, lysine acetylation results in 
transcriptional activation (Hebbes, et al. 1988), whereas lysine methylation results in 
transcriptional activation or repression depending of the residue modified (Liang, et al. 2004; 
Kouzarides. 2007). Histone acetyltransferases (HATs) acetylate histones, and histone 
methyltransferases (HMTs) methylate histones, whereas histone deacetylases (HDACs) 
and histone demethylases (HDMs) remove the acetyl and methyl groups respectively (Shi. 
2007; Haberland, et al. 2009).  
 
Furthermore, non-covalent mechanisms also play a role in chromatin restructuring, such as 
nucleosome remodelling and replacement of canonical histone proteins with histone 
variants (Sharma, et al. 2010). Nucleosome remodelling occurs by the action of 
“nucleosome remodelling ATPases” altering histone-DNA interactions in target 
nucleosomes (Becker & Workman. 2013). While histone variants are deposited by distinct 
nucleosome assembly complexes after DNA replication (Henikoff & Smith. 2015).  Finally, 
long non-coding RNAs are able to regulate chromatin remodelling to achieve transcriptional 
remodelling. For example, by regulating the transcriptional silencing of potassium voltage-
gated channel subfamily KT member 1 opposite strand/ antisense transcript 1 (KCNQ1OT1) 
(Fang & Fullwood. 2016).  
 
 
6.1.3. Ubiquitin ligases and cancer  
Ubiquitin E3 ligases are fundamental for the maintenance of protein homeostasis and 
dysregulation of their activity can result in cancer mediated by either oncogenic and tumour 
suppressive properties (Pickart. 2001; Satija, et al. 2013). For example, two F-box proteins 
that form the SCF E3 ligase, SKP2 and FBW7, have been shown to be involved in cancer 
formation (Nakayama & Nakayama. 2006). The F-box protein SKP2 acts as an oncogene 
where it is implicated in the degradation of the CDK inhibitor p27Kip1 (Pagano, et al. 1995; 
Shirane, et al. 1999; Bloom & Pagano. 2003). p27Kip1 is responsible for the cell cycle arrest 
at G1, preventing Cyclin E-CDK2 and Cyclin D-CDK4 activation (Shirane, et al. 1999; 
Besson, et al. 2008) (Figure 1.11). Decreased expression of p27Kip2, was found in various 
human cancers, and has been associated with poor prognosis (Bloom & Pagano. 2003). In 
contrast, the F-box protein and tumour suppressor, FBW7, is responsible for the 
degradation of known oncoproteins including Cyclin E, MYC, NOTCH1, and NOTCH4 
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(Koepp, et al. 2001; Tsunematsu, et al. 2003; Yada, et al. 2004; Nakayama & Nakayama. 
2006).  
 
Currently, the only current ubiquitin-proteasome pathway targeting drugs are proteasome 
inhibitors such as Bortezomib (Cohen & Tcherpakov. 2010) and Cafilzomib (Stewart, et al. 
2015). Inhibition of the proteasome has a large scope for side effects because it diminishes 
protein turnover in the whole cell, whereas targeting specific E3 ligases means that the 
scope of the side effects is reduced due to the specific nature of the enzyme (Bernassola, 
et al. 2008). Targeting of the ubiquitination pathway has the potential to yield many future 
therapeutics (Cohen & Tcherpakov. 2010). For example, drugs that target phosphorylation, 
a post translational modification that can be thought of as similar to ubiquitination, has 
resulted in many drugs for the treatments of different diseases (Cohen & Tcherpakov. 
2010). An example is Gefitinib, which targets EGFR kinase and is used a cancer therapeutic 
for non-small cell lung cancers (Paez, et al. 2004). Similarly, cancer drugs have been 
designed that inhibit phosphatases, demonstrating that dephosphorylation can also be 
targeted for therapeutics (Scott, et al. 2010). The ubiquitin pathway comprises many 
components that are available to be targeted due to their enzymatic nature (Burger & Seth. 
2004). For example, the enzymatic cascade components, E1 activating enzymes, E2 
conjugating enzymes, and E3 ligases, in addition to DUBs and the proteasome. Therefore, 
demonstrating the impact that the targeting of ubiquitination could have on yielding more 
therapeutics (Burger & Seth. 2004; Cohen & Tcherpakov. 2010). An example of this is the 
inhibitor VLX1570, which targets USP14 to induce apoptosis in multiple myeloma cells 
(Wang, et al. 2016) and overcomes resistance to bortezomib (Tian, et al. 2014). 
 
Interestingly, HECT ligases have been suggested as cancer targets with many different 
functions within the cell (Bernassola, et al. 2008) (Table 6.1). For example, HECT ligases 
such as E6-AP, HACE1, and HUWE1 have been implicated in p53 regulation that results in 
cancer formation (Scheffer, et al. 1990; Talis, et al. 1998; Yoon, et al. 2004; Zhang, et al. 
2007; Sakata, et al. 2009; Sakata, et al. 2013). Whilst the HECT ligases NED4L and 
UBE3C, regulate the Wnt signalling pathway, a key signal transduction pathway regulating 
stem cell fate and tumorigenesis in epithelial tissues (Tanksley, et al. 2013; Wen, et al. 
2015) (Table 6.1). Interestingly EDD, and HUWE1 have also been shown to regulate the 
Wnt signalling pathway, and may suggest that their role in cancer development also occurs 
via this pathway (Hay-Koren, et al. 2011; de Groot, et al. 2014; Gao, et al. 2014). Some 
HECT E3 ligases have been identified as tumour suppressors, whilst others have been 
shown to be oncogenic (Table 6.1). Interestingly, ligases such as HUWE1 and SMURF2 
have been identified as both tumour suppressive and oncogenic, highlighting the complexity 
of HECT ligases in cancer formation (David, et al. 2014; Liu, et al. 2014; Vaughan, et al. 
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2015; Myant, et al. 2016). Finally, HECT E3 ligases offer ideal therapeutic targets because 
they harbour a catalytic cysteine (Huibregtse, et al. 1995), which can be targeted. For 
example, small molecule inhibitors have been designed that target ligases such as HUWE1 
and ITCH, which appear to prevent ubiquitination of their target substrates (Peter, et al. 
2014; Rossi, et al. 2014). This demonstrates the importance of characterising the function 




Table 6.1. HECT Ligase expression in cancer. HECT ligases and their implicated 







Mechanism Alterations in Cancer References 
AREL1 Unknown. Unknown. High expression in lung 
cancer. 
Liu, et al. (2014).  











Overexpressed in breast, 
liver, and ovarian cancer. 
 
 
C terminal cluster of 
deleterious mutations, in 
mantle cell lymphoma. 
Clancy, et al. 
(2003); O’Brien, et 
al. (2008).  
 
Meissner, et al. 
(2013). 
E6-AP Apoptosis. Degradation of p53. Overexpressed in 
cervical cancers. 
Scheffer, et al. 
(1990); Talis, et 
al. (1998). 
HACE1 HACE1 regulates cell 





Depletion results in 
increased mobility 
and invasiveness.  
Cooperates with p53 
in cancer formation. 
Turnover of Cyclin 





Hypermethylation of CpG 
island upstream of the 
promoter. Found in 
Wilm’s tumour, prostate, 
and gastric carcinoma. 
 
Hypermethylation in 
breast, and HER 
activation. 
Zhang, et al. 
(2007); Sakata, et 
al. (2009); Sakata, 
et al. (2013).  
 
 
Goka & Lippman. 
(2015).  
HECTD2 Unknown. Overexpression of 
microRNA 221 
inhibits HECTD2.  
Downregulation of 
HECTD1 in prostate 
cancer. 
Sun, et al. (2014). 





Overexpressed in breast 
cancer. 
Li, et al. (2013c).  
HERC2 Overexpression 
results in reduced 
survival. 
Unknown. Increased expression in 
non-small lung cell 
cancer.  
Bonanno, et al. 
(2016).  
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HERC4 Tumorigenesis. Unknown. Overexpressed in lung 
and breast cancer. 
Zeng, et al. 
(2015); Zhou, et 
al. (2014).  
HERC5 Unknown. Unknown. Promoter 
hypermethylation in non-
small cell lung cancer. 
Wrage, et al. 
(2015).  
HUWE1 Cell adhesion, 






















Degradation of p53. 
 
 
Loss of HUWE1 
leads to increased 
Myc levels. 
 
Overexpression in lung 
cancer. 
 
Over expression in 
breast, colon, prostate, 




colorectal cancer.  
 
Down regulated in colon 
cancer. 
Vaughan, et al. 
(2015).  
 





Yoon, et al. 
(2004). 
 
Myant, et al. 
(2016).  
NEDD4 Tumorigenesis. p38 binds NEDD4 
and controls PTEN 
ubiquitination. 
Overexpressed in non-
small cell lung 
carcinomas, colon, and 
gastric cancers.  
Amodio, et al. 
(2010); Wang, et 
al. (2010); Hong, 
et al. (2014).  
NEDD4L Tumorigenesis. Inhibits Canonical 
Wnt signalling. 
Downregulated in colon 
cancer.  

















EGF induction of 

















Overexpressed in clear 
cell renal cell carcinoma.  
 
Overexpressed in lung 
cancer. 
Kwei, et al. 
(2011).  
 





Ke, et al. (2017).  
 
 












and AKT signalling. 
Downregulated in triple-
negative breast cancer.  
 
 
Overexpressed in breast 
cancer.  




David, et al. 
(2014).  
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TRIP12 DNA damage 
response. 
p16 overexpression 
leads to TRIP12 
downregulation, 




TRIP12 leads to poor 
survival in Head and 
Neck cancers. 
Wang, et al. 
(2017). 























inhibits WWP1.  
Overexpressed in breast 










and down regulated 
microRNA 452 in 
prostate cancer.  
Chen, et al. 
(2007); Nguyen 
Huu, et al. (2008); 
Lin, et al. (2013).  
 
 




Goto, et al. 
(2016).  












and activation of the 







HIF-1a regulation of 
WWP2.  
Overexpressed in 
endometrial cancer and 




Overexpressed in lung 
adenocarcinoma.  
 
Overexpressed in thyroid 
cancer.  
Maddika, et al. 
(2011); Fukumoto, 
et al. (2014); 
Clements, et al. 
(2015).  
 
Yang, et al. 
(2016).  
 
Ding, et al. (2016).  
UBE3C Increased epithelial 
to mesenchymal 
transition (EMT).  
 
 

















Activation of the Wnt/ 
b-catenin pathway.  
Overexpression in 









Overexpression in renal 
carcinoma. 
Jiang, et al. 


















Given the role that HECTD1 has in cell proliferation, it was hypothesised that this ligase 
may be dysregulated in cancer. Multiple HECT ligases function in cancer formation and 
have been identified as both tumour suppressive and oncogenic (Table 6.1). Therefore, to 
characterise the role of HECTD1 in cancer, both tumour suppressive and oncogenic 
functions were explored. The DNA methylation status of HECTD1 was screened to 
determine if HECTD1 is silenced in cancer, and acts as a tumour suppressor. Alternatively, 
overexpression studies were carried out to see whether HECTD1 is oncogenic and 
promotes cancer formation. To understand the regulation of HECTD1 in cancer, the 
following objectives were addressed: 
 
1. Determine whether HECTD1 is expressed or silenced by epigenetic mechanisms  in 
lung cancer cell lines (NSCLC). 
 
2. Examine whether HECTD1 is mutated in different cancers, such as glioblastoma 
using the cancer genomics database, cBioPortal, and the cancer microarray 
database, OncomineTM.  
 
3. Determine whether overexpression of HECTD1 increases cell proliferation in 
HEK293T and the glioblastoma cell line U87, using trypan blue cell counting.  
 
4. Establish whether depletion of HECTD1 results in a reduction in cell proliferation in 
glioblastoma cell lines U87 and U251, using trypan blue cell counting.  
 
5. Assess HECTD1 mRNA expression in a small cohort of glioblastoma samples 
provided by Dr Kathreena Kurian (Bristol Southmead Hospital), using qRT-PCR. 
 
  




6.2.1. HECTD1 expression does not appear to be affected by promoter methylation 
in lung cancer cell lines.  
Given its suggested role in migration (Li, et al. 2013b), Wnt signalling (Tran, et al. 2013), 
and cell cycle regulation and cell proliferation (this thesis), it was hypothesised that HECTD1 
expression could be altered in cancer cell lines and patient samples. Ubiquitin ligases have 
been shown to be both tumour suppressive and oncogenic in cancers, for example, FBW7 
(tumour suppressor) and SKP2 (oncogenic) (Nakayama & Nakayama. 2006). Therefore, it 
was hypothesised that HECTD1 may be tumour suppressive and silenced in cancer. 
Interestingly, the expression of HECT ligases HACE1 and HERC5 was found to be 
downregulated due to DNA promoter hypermethylation in breast, gastric, and non-small cell 
lung cancer (Zhang, et al. 2007; Sakata, et al. 2009; Sakata, et al. 2013; Goka & Lippman. 
2015; Wrage, et al. 2015). Therefore, the expression HECTD1, a close relative of HACE1, 
could also be under the regulation of epigenetic mechanisms such as DNA promoter 
methylation in cancer cell lines.  
 
To test the hypothesis that HECTD1 is silenced in cancer,  mediated by DNA methylation, 
a potential methylation site was first characterised in the sequence of HECTD1 using UCSC 
(University of California Santa Cruz) genome browser (https://genome-euro.ucsc.edu/cgi-
bin/hgGateway?redirect=manual&source=genome.ucsc.edu (accessed 29.08.2017)) 
(Kent, et al. 2002). Interestingly, a CpG island was found within the promoter region of 
HECTD1 (Figure 6.1). The CpG island was found to encompass the transcription start site 
of HECTD1 and suggests that HECTD1 could be regulated by DNA methylation. To further 
characterise the HECTD1 promoter and transcription factors that may bind within the 
promoter, Sabiosciences DECODE (Decipherment of DNA Elements) 
(http://www.sabiosciences.com/chipqpcrsearch.php?app=TFBS (accessed 30.08.2017)) 
was used to identify known transcription factor binding sites.  Five transcription factors were 
found to be located within the CpG island (Figure 6.1), including AHR, ARNT, C-MYC, 
MAX1 and PAX5. The transcription factors AHR, ARNT, C-MYC, and MAX1 all share the 
same DNA binding sequence, whilst PAX5 DNA binding sequence is downstream. Aryl 
hydrocarbon receptor (AHR) and aryl hydrocarbon receptor nuclear translocator (ARNT) 
form a heterodimeric transcription factor and can lead to the inhibition of cell proliferation 
(Puga, et al. 2002). Furthermore, both c-MYC and MAX1 form a heterodimeric transcription 
factor that promotes cell proliferation and growth (Blackwood & Eisenman. 1991). PAX5 is 
a transcription factor essential for commitment of lymphoid progenitors to the B cell 
lymphocyte lineage in addition to regulating cell adhesion and migration (Cobaleda, et al. 
2007; Schebesta, et al. 2007).  
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Having used bioinformatic tools to identify a CpG island in the sequence of HECTD1, the 
next aim was to determine whether HECTD1 expression might be regulated by DNA 
promoter hypermethylation at CpG islands. To examine this, HECTD1 mRNA expression 
was screened by RT-PCR using RNA from 8 non-small cell lung cancer (NSCLC) cell lines, 
which had been previously extracted from cell lines treated with DMSO or the demethylating 
agent 5-aza-2’-deoxycytidine (5-Aza) for 3-4 days (Figure 6.2) (Licchesi, et al. 2010). The 
DKO cell line was used as a negative control. The DKO cell line has two major DNMTs 
knocked out (DNMT1 and DNMT3b), therefore preventing gene silencing by methylation 
(Jacinto, et al. 2007). If HECTD1 was regulated by methylation there would be a low signal 
for the amplification in the DMSO-treated samples compared to the 5-Aza treated samples. 
However, all samples screened showed a band in the DMSO control suggesting that, in 
these non-small cell lung cancer cell lines, HECTD1 is expressed and therefore is not 
repressed by DNA promoter methylation. A limitation is that screening eight different lung 
cancer cell lines is not definitive and HECTD1 methylation may still occur in lung cancer 
and in other cancer and cell types. Furthermore, there is no 5-Aza positive control to 
demonstrate that the drug is working, which limits the interpretation of the data. A 5-Aza 
positive control would be to screen a known silenced gene, to see if 5-Aza treatment relieves 
















Figure 6.1. HECTD1 has a CpG island extending upstream and downstream of its 
transcription start site (TSS). Schematic representation of CpG island, showing the 
density of CpG dinucleotides within the island annotated with transcription factor binding 
sites. The sequence was extracted from UCSC genome browser (https://genome-
euro.ucsc.edu/cgi-bin/hgGateway?redirect=manual&source=genome.ucsc.edu (accessed 
29.08.2017)) and annotated using two-tone “lollipops” to represent potential methylation 
sites and CpG dinucleotides highlighted in red. The CpG island contains 167 CG 
dinucleotides, which could all be potential methylation sites. The CpG island comprises a 
71% CG content and 23.3% CpG content. Transcription factors that bind within the CpG 
island of HECTD1 are highlighted in pink, blue and green. (+) = sense, and (-) = antisense. 
Transcription factor binding sites were identified using Sabiosciences DECODE 
(Decipherment of DNA Elements) 
(http://www.sabiosciences.com/chipqpcrsearch.php?app=TFBS (accessed 30.08.2017)).  
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6.2.2. HECTD1 is mutated in cancer 
Given that HECTD1 does not appear to be regulated by methylation at least in the 8 NSCLC 
cell lines tested, it was next hypothesised that HECTD1 may be mutated or amplified in 
cancer cells, indicating an oncogenic role. Specifically, this latter hypothesis makes more 
sense in view of the data presented in this thesis, which suggest that HECTD1 has a role 
in cell proliferation, by regulation of the cell cycle. Using the cancer genomics database 
cBioPortal (Cerami, et al. 2012), HECTD1 was found to be mutated in multiple cancers, 
including prostate, bladder, lung, colorectal, and many others (Figure 6.3). The cBioPortal 
search result also suggests that HECTD1 is also amplified and deleted in some cancers, 
suggesting that HECTD1 could be a novel cancer target. In the cBioPortal database 
mutations encompass missense, truncating and inframe mutations. Interestingly mutations 
found within HECTD1 (Figure 6.4) occur at multiple sites across the protein sequence and 
no mutation hotspot could be identified. The majority of the mutations that occur within 
HECTD1 are missense mutations, which result in a nonsynonymous amino acid 
substitution, and could result in a gain of function or a loss of function resulting in cancer 
(Dittmer, et al. 1993; Sarraf, et al. 1999). Although, these databases provide general 
analysis of HECTD1 in large and diverse cancer cDNA datasets, it does suggest that 
HECTD1 may be altered in a variety of cancers. Further analysis would be needed to 
determine the exact role that HECTD1 has in individual cancers. Enhanced activity of 
oncogenes is often linked to specific mutations at functional sites. For example, there are 
multiple mutations present within the HECT domain of HECTD1, however none that occur 
at the position of the catalytic cysteine (2579). Some of these mutations that occur within 
the HECT domain could be characterised within cells to see whether they are associated 
with a change or increase in activity. Here, a crystal structure of the HECT domain would 
help to determine which particular mutations are likely to alter the architecture of the domain 
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6.2.3. HECTD1 is overexpressed in glioblastoma 
In order to understand a potential oncogenic function of HECTD1 in cancer development, 
the effect of its overexpression was studied in glioblastoma. Unpublished data from Dr K 
Kurian at Bristol Southmead Hospital suggested that HECTD1 may be overexpressed in 
glioblastoma patients. In agreement with this finding, using OncomineTM (Rhodes, et al. 
2004), HECTD1 mRNA appeared to be overexpressed in a glioblastoma cohort. 
Glioblastoma is the most common type of brain tumour in adults, representing 16% of all 
primary brain tumours (Davis, 2016). Glioblastoma is derived from neurological stem or 
progenitor cells, and accounts for 80% of malignant brain tumours (Weller, et al. 2015). It is 
therefore a very aggressive type of primary brain tumour in adults and is associated with a 
reported survival rate of 5% after 5 years (Haynes, et al. 2014; Delgado-López & Corrales-
Gárcia. 2016).  
 
To determine whether HECTD1 is overexpressed in glioblastoma, an analysis of cDNA 
microarray datasets was carried out using OncomineTM (Rhodes, et al. 2004). The 
OncomineTM cancer microarray database uses microarray data from different specific 
cancer study datasets, facilitating differential expression analysis. In the Bredel Brain 2 
dataset composed of 24 glioblastoma (GBM) samples and 4 normal brain samples, 
HECTD1 appeared to be overexpressed compared to Normal Brain samples (Figure 6.5). 
This finding can also be seen in the Sun Brain data set (reporter: 1557100_s_at), which 
compares 81 glioblastoma samples to 23 normal brain samples (Sun et al. 2006). This is 
potentially a very exciting finding, which if confirmed, would suggest that HECTD1 
overexpression could be used as a diagnostic marker. In addition this would also suggest 
that HECTD1 could be an attractive novel therapeutic target in glioblastoma.  
 
  

























Figure 6.5. HECTD1 mRNA expression in glioblastoma compared with Normal Brain, 
OncomineTM. Image obtained from Oncomine, a cancer microarray database. OncomineTM 
compiles data from cancer transcriptome profiles allowing analysis of cancer gene 
expression in different cancer types. The median ratio for Normal Brain samples is negative, 
which suggests that they express HECTD1 at a lower level compared to GBMs. The median 
ratio at zero lies close to the median of the GBMs however the distribution of the data is 
larger than that of the normal brain data. Overall indicating increased HECTD1 mRNA in 
GBMs compared to normal brains. 24 Glioblastoma samples and 4 normal brain samples 
were analysed on cDNA microarrays, from Bredel Brain 2 dataset, reporter: 1256904 
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6.2.4. HECTD1 overexpression in HEK293T and glioblastoma cell lines results in 
increased proliferation 
Given that HECTD1 appears to be overexpressed in glioblastoma patient microarray data 
(Figure 6.5), the effect of overexpression of HECTD1 on cell proliferation was monitored 
(Figure 6.6). To determine an oncogenic role for HECTD1, initially, overexpression of 
HECTD1 was carried out in HEK293T cells due to their high transfection efficiency 
(Durocher, et al. 2002). Interestingly, using an ATP proliferation assay (Maehara, et al. 
1987; Petty, et al. 1995), overexpression of HA-FL-mHectd1WT in HEK293T WT cells 
resulted in a statistically significant increase in relative luminescence, indicating that 
overexpression of HECTD1 resulted in increased proliferation. 
 
The above experiment was then repeated in the glioblastoma cell line U87, using a trypan 
blue cell counting assay. The glioblastoma cell line U87, has been frequently used as a 
model for glioblastoma because of its high transfectability, for example the cell line was 
used to demonstrate that RhoE inhibits glioblastoma cell line proliferation by inducing 
apoptosis (Poch, et al. 2007). U87 (also known as U87MG) was originally thought to have 
been derived from a stage 4 cancer patient, however a recent DNA profile revealed that 
whilst the cell line was indeed glioblastoma, it was from an unknown origin (Allen, et al. 
2016). This means that U87 may not be the best glioblastoma model, however at this early 
stage using a glioblastoma cell line that was easy to use was deemed to be appropriate. To 
observe a change in proliferation when HECTD1 is overexpressed, U87 cells were 
transfected with empty vector (eV), wild type HA-FL-mHectd1WT or the catalytically dead 
enzyme HA-FL-mHectd1C2579G (Figure 6.7A). 48hrs post-transfection, U87 cells 
overexpressing wild-type mouse Hectd1 (HA-FL-mHectd1WT) showed a significant 50% 
increase compared to the catalytic mutant and the empty vector control. This was also 
observed at 4 days post-transfection, which showed a 2-fold increase. However, at day 4, 
there was a significant increase in proliferation with the catalytic mutant compared to the eV 
control, however this is not to the same extent as the wild type protein. The viability of U87 
transfected with either eV, wild type, or catalytic mutant constructs remained similar 
between the conditions throughout the 4 days, implying that there was no cell death (Figure 
6.6B). Finally, a western blot confirmed the overexpression of HA-FL-Hectd1WT and HA-FL-
Hectd1C2579G expressed at similar levels in U87 cells. This data suggests that 
overexpression of mHectd1 increases cell proliferation in both HEK293T and glioblastoma 
cell lines, and that this effect is dependent on the E3 ubiquitin ligase activity (Figure 6.8A).  
 
Recently, it has been suggested that overexpression of HECTD1 in LN-299, a glioblastoma 
cell line, reduces colony formation in HECTD1 clones and negatively regulates Wnt 
signalling activity (Oikonomaki, et al. 2017). This suggests that in the LN-299 cell line, 
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HECTD1 overexpression may result in negative regulation of Wnt signaling. However, the 
evidence for this is limited because it is based on using HECTD1 overexpressing LN-299 
clones, which may be affected by clonal selection. Furthermore, the western blot evidence 
provided to demonstrate that overexpression of HECTD1 does not convincingly show 
increased levels of HECTD1 protein. Therefore, this does not contribute to explain why in 
our hands overexpression of HECTD1 results in an increase in proliferation.  
 
Finally, the localisation of HECTD1 in glioblastoma cell lines was identified, to elucidate 
whether HECTD1 would be likely to have a similar function in the cell cycle in glioblastoma 
cell lines as previously characterised in HEK293T, HEK293ET and HeLa cells. U87 cells 
were transfected with HA-FL-mHectd1WT, and visualised using immunofluorescence to 
establish the localisation of HECTD1 in glioblastoma cells. As seen in Figure 4.5 in 
HEK293ET cells, HA-FL-mHectd1WT localises to the mitotic spindle in U87 cells (Figure 6.8). 




































Figure 6.6. HA-FL-mHectd1WT overexpression in HEK293T WT cell line. HEK293T WT 
cells were transfected with HA-FL-mHectd1WT. Cells were transfected at 48hrs post-
transfection with  HA-FL-mHectd1WT and an HA-tagged empty vector using PEI, in a 24 well 
format. Samples were harvested at 48h post-transfection. Cell proliferation count (relative 
luminescence) measured by CellTiter-Glo assay. Data plotted as mean with error bars that 
represent ±S.E.M, over three independent experiments (n=3), **p<0.01 by a paired 







































































Figure 6.7. Increased cell proliferation upon overexpression of HA-FL-mHectd1WT in 
U87 glioblastoma cell line. A) Viable cell count (x104), and B) showing cell viability for U87 
cells transfected with 250ng either eV (empty vector), HA-FL-mHectd1WT (mHectd1WT), or 
HA-FL-mHectd1C2579G (mHectd1CM) and PEI. Samples were taken at intervals post-
transfection. Harvested cells were counted using trypan blue to assess the viability of the 
cells. Data plotted as mean with error bars that represent ±S.E.M., over three independent 
experiments (n=3). ***p<0.001, **p<0.01, *p<0.05 by one-way ANOVA with a Dunnett’s 
post-test. C) Western blot showing overexpression of HECTD1 in U87 cells. Molecular 

























































Figure 6.8. Localisation of HA-FL-mHectd1WT in U87 glioblastoma cell line during 
mitosis. Representative images of HA-FL-mHectd1WT in mitotic U87 cells. U87 cells were 
transfected with 500ng HA-mHectd1WT and an HA-tagged empty vector using PEI, in a 12 
well format. 24hrs post-transfection cells were fixed using 4% PFA, then stained with anti-
HA, anti-α-tubulin and Hoechst. Images were taken using the LSM Meta 510 Confocal 
Microscope Scale bar represents 10µm.  
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6.2.5. HECTD1 depletion results in reduced glioblastoma cell line proliferation 
This thesis has identified a cell cycle function for HECTD1, which appears to correlate with 
the increased proliferation seen in HEK293T and U87. It was therefore hypothesised that 
depletion of HECTD1 may result in decreased proliferation as seen in HEK283ET, 
HEK293T, and HeLa cells.  
 
In order to further implicate HECTD1 as a therapeutic target in glioblastoma, loss-of-function 
experiments were carried out in both U87 and U251 (Figure 6.9). The U251 cell line is 
derived from human glioblastoma astrocytoma, and like U87, has been used for cancer 
studies such as the molecular profiling of MPS1 gene silencing in glioblastoma 
(Shankavaram, et al. 2015). Here, both cell lines were used to ensure that any observed 
change in proliferation as a result of HECTD1 knockdown was not cell line specific. 
Interestingly in both U87 and U251, the number of viable cells decreased in the cells treated 
with HECTD1 SMARTpool (SP) siRNA when compared to the non-targeting (NT) siRNA 
control (Figure 6.9A, C). Here, the reduced proliferation phenotype is similar to the reduction 
of proliferation seen in Figure 3.1 with HEK293ET and HeLa cells. In U87 cells, by day 3, 
there is a significant decrease in the number of viable cells in HECTD1 SMARTpool (SP) 
siRNA treated cells compared to the NT control (35% decrease in HECTD1 SMARTpool 
(SP) treated U87). (Figure 6.9A). However, by day 4 the decrease is no longer significant 
suggesting that the knockdown may not be as efficient at 96h post-transfection. Again, there 
was no change in viability across the 4 days between the cell lines (Figure 6.9B) suggesting 
that the cells are not undergoing cell death mechanisms. In U251 cells, there was a 
sustained significant decrease in the number of viable cells observed when comparing 
those treated with HECTD1 SMARTpool (SP) siRNA and NT siRNA from day 2 to day 4 
(Figure 6.9C) (30% decrease in HECTD1 SMARTpool (SP) treated U251). Similarly, there 
was no change in viability between the NT and HECTD1 SMARTpool (SP) siRNA treated 
cells over the 4 days (Figure 6.9D), therefore indicating that the reduction in viable cell 
number is as a result of decreased proliferation, rather than increased cell death. Finally, 
western blots showed that in both U87 and U251, HECTD1 was efficiently knocked down 
at 48h post-transfection (Figure 6.9E,F). Taken together, this suggests that HECTD1 
depletion could be a strategy to reduce cell proliferation in glioblastoma cells and potentially 
other cancer cell lines where it is found to be overexpressed. Hence, given that the increase 
in proliferation has been shown to be driven by the ubiquitin ligase activity of HECTD1 in 
HEK293T cells, it is therefore speculated that targeting this activity could phenocopy the 
observed decrease in cell proliferation obtained upon HECTD1 depletion.  



























Figure 6.9. Reduced cell proliferation upon HECTD1 transient depletion but no effect 
in cell viability in glioblastoma cell lines. Viable cell count (x104) for U87 A) and U251 
C) and cell viability (%) for U87 B) and U251 D) which had been treated with non-targeting 
siRNA and HECTD1 smart pool siRNA. Samples were taken at intervals post-transfection 
with 20pmol siRNA and Lipofectamine 2000®. Harvested cells were counted using trypan 
blue to assess the viability of the cells. Data plotted as mean with error bars that represent 
±S.E.M., over three independent experiments (n=3). **p<0.01, *p<0.05 by paired student’s 
t-test. Western blots indicating knockdown for U87 E) and U251 F) 48h post knockdown. 
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6.2.6. qRT-PCR in glioblastoma samples 
To establish whether HECTD1 may be a novel biomarker or therapeutic target for 
glioblastoma, Dr K Kurian at Bristol Southmead Hospital provided the lab with cDNA from 
glioblastoma patients. Initially, 22 patients out of 50 cDNA samples provided by Dr K Kurian 
were analysed using qRT-PCR. The mRNA levels of HECTD1 were compared to two 
housekeeping genes RPS18 and RNA Pol II. These two housekeeping genes were selected 
because they are expressed at a relatively constant rate and at a high abundance (Kozera 
& Rapacz. 2013). RPS18 has been shown to be a reliable housekeeping gene for head and 
neck squamous cell carcinoma gene expression studies and for tumour neovascularisation 
studies (Lallemant, et al. 2009; Rienzo, et al. 2013). Furthermore, RNA pol II has been 
demonstrated to have the most constant expression in different tissues and in human acute 
lymphoblastic leukaemia cells compared to other housekeeping genes, making it a suitable 
housekeeping gene for cancer (Radoníc, et al. 2004).  
 
However, as seen in Figure 6.10, there were large variations between the normalisation to 
RPS18 and RNA Pol II. The HECTD1 mRNA relative expression was around 5-fold less 
when normalised with RNA Pol II, compared to RPS18. Furthermore, the trends of HECTD1 
expression vary between the samples normalised to the two reference genes. For example, 
in sample 5 the relative HECTD1 mRNA expression was the highest relative to the 6 
samples screened when normalised to RPS18 (Figure 6.10A), however this pattern was not 
seen when normalised to RNA Pol II (Figure 6.10B). This was seen in another sample set 
where, sample 8 showed the highest relative HECTD1 mRNA, in samples 7-14, when 
normalised to RPS18 (Figure 6.10C), which again was not reproduced when normalised to 
RNA Pol II (Figure 6.10D). Finally, sample 22 when normalised to RNA Poll II, showed the 
highest relative HECTD1 mRNA expression, in samples 15 - 22 (Figure 6.10F), which was 
not seen when normalised to RPS18 (Figure 6.10E).  
 
Taken together this suggests that either or both RNA Pol II and RPS18 are not the most 
appropriate reference genes to use for glioblastoma samples. Furthermore, the use of these 
two primer sets in combination result in data with a large degree of variance, potentially 
masking any observed changed in HECTD1 mRNA expression between different patients. 
Therefore, other primer sets should be used to assess HECTD1 relative expression in 
glioblastoma patient cDNA. A further consideration is that in some samples CT value of 
HECTD1 was very low, compared to the no sample control. The low levels of HECTD1 
mRNA may be due to no or very low levels of HECTD1 or to poor quality of the samples 
and therefore the data for HECTD1 may be less reliable. The cDNA was extracted from 
paraffin embedded archived tissues, which is known to lead to fragmented RNA (Zeka, et 
al. 2016), therefore this could affect the readout for HECTD1 expression.  
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Given the issues with the differences in normalisation with both RNA Pol II and RPS18 as 
housekeeping genes, a literature search was carried out to determine the most appropriate 
housekeeping genes for glioblastoma. Valente, et al. (2009) screened a panel of different 
primer sets for housekeeping genes for their suitability in human glioblastoma cDNA. This 
found that instead of the commonly used beta actin, GAPDH, and RPS18, the two most 
suitable reference genes were TATA-Box binding protein (TBP) and Hypoxanthine guanine 
phosphoribosyl transferase 1 (HPRT1) used in combination (Valente, et al. 2009). 
Therefore, using RNA extracted from U87 and U251, the TBP and HPRT1 primers were 
used alongside the original RNA Pol II and RPS18 primers to test for their suitability as 
primers for qRT-PCR (Figure 6.11). It can be seen by gel based RT-PCR that all of the 
primers were suitable for U251, giving a strong clear signal for each primer set (Figure 
6.11B). None of the primer sets showed contamination, with the exception of RPS18 
primers, which in both cell lines showed some level of background in the negative controls 
as a result of either contamination (Figure 6.11A) or primer dimers (Figure 6.11B). 
Furthermore, RPS18 primers in U87 yielded a weaker cDNA band in comparison to the 
other housekeeping primer sets (Figure 6.11A). Therefore, this suggests that RPS18 may 
not be a suitable housekeeping gene for qRT-PCR using glioblastoma patient cDNA and 
given the screen carried out by Valente, et al. (2009), TBP and HPRT1 should be used as 
reference genes in the future.  
 
Given that this study is still in progress, correlations between HECTD1 expression and the 
type of samples and the corresponding meta data were not carried out at this stage.   






Figure 6.10. HECTD1 mRNA expression in glioblastoma patient cDNA samples 
relative to RPS18 and RNA Pol II. Glioblastoma patient cDNA was provided by Dr K Kurian 
(Bristol Southmead Hospital). Relative HECTD1 mRNA levels were determined by qRT-
PCR and normalised to two reference genes, RPS18 and RNA Pol II. Samples 1-6 
normalised to A) RPS18 and B) RNA Poll II. Samples 7-14 normalised to C) RPS18 and D) 
RNA Poll II. Samples 15-22 normalised to E) RPS18 and F) RNA Pol II. Data are present 
























































































































































































































































































Figure 6.11. A panel screen of glioblastoma cancer cell lines to assess primers for 
qRT-PCR. 3% agarose gel stained with GelStarTM showing the resolution of RT-PCR 
products, including HECTD1 and housekeeping gene expression in A) U87 and B) U251 
glioblastoma cancer cell lines. Primers for HECTD1, RNA Pol II, RPS18, TBP, HPRT, and 
GAPDH were used on both cell lines. -RT and no cDNA were used as negative controls.   
A B 




In order to implicate HECTD1 in cancer development, both tumour suppressive and 
oncogenic functions were explored. Initially to explore the role of HECTD1 as a tumour 
suppressor, the epigenetic regulation of HECTD1 was characterised in lung cancer cell lines 
(NSCLC). A CpG island was identified in the promoter of HECTD1 using the UCSC genome 
browser, which suggested a possible site of DNA methylation within the sequence of 
HECTD1. Therefore, the DNA methylation status of HECTD1 in NSCLC cell lines was 
screened to see if HECTD1 functioned as a tumour suppressor in this type of cancer. 
However, it was revealed that HECTD1 expression does not appear to be regulated by DNA 
methylation in NSCLC, and therefore is likely to not have a tumour suppressor role in this 
cancer. To explore the role of HECTD1 as an oncogene, using cBioPortal, it was identified 
that HECTD1 is mutated and amplified in numerous cancers. To test, this predicted 
oncogenic role in a specific cancer model, a collaboration was established with Dr K Kurian. 
Unpublished data has previously reported that HECTD1 is overexpressed in glioblastoma 
patient samples. In agreement with this finding, the cancer database OncomineTM showed 
that HECTD1 mRNA was increased in glioblastoma patient samples in comparison to 
normal brain samples. HECTD1 overexpression in a glioblastoma cell line, U87, showed an 
increase in cell proliferation. Furthermore, HECTD1 depletion was associated with reduced 
proliferation in glioblastoma cell lines. This therefore suggests an oncogenic role of 
HECTD1 in glioblastoma. The final work carried out involved screening of 50 cDNA patient 
samples to confirm the overexpression of HECTD1 in patient samples, however this 
experiment required further optimisation.  
 
 
6.3.1. HECTD1 does not appear to be regulated by methylation in NSCLC cell lines 
To establish whether HECTD1 functioned as a tumour suppressor, the epigenetic regulation 
of HECTD1 was characterised. It was found that within the HECTD1 sequence, there is a 
CpG island that spans the first exon, suggesting that HECTD1 may be regulated by DNA 
methylation. However, a screen of lung cancer cell line cDNA revealed that HECTD1 is 
expressed in both the untreated DMSO samples and the Aza treated samples. Indicating 
that in NSCLC cell lines, HECTD1 expression does not appear to be regulated by DNA 
methylation. It is not possible to completely rule out the role of DNA methylation in the 
regulation of HECTD1 in NSCLC due to the lack of a positive control, however there are 
only two known examples of HECT ligases that are regulated by hypermethylation in cancer 
out of the 18 ligases that have been published in cancer formation (Zhang, et al. 2007; 
Sakata, et al. 2009; Sakata, et al. 2013; Goka & Lippman. 2015; Wrage, et al. 2015). 
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Screening of other cell lines may reveal that DNA methylation occurs in other cancers that 
result in downregulation of HECTD1. The database Oncomine, could be used to help 
identify cancers which show HECTD1 silencing, for example, in mixed gastric 
adenocarcinoma HECTD1 mRNA expression shows a negative 2.5-fold change compared 
to noncancerous cells (Oncomine, accessed 30/09/17). If DNA methylation is shown to be 
important for HECTD1 regulation in cancers such as gastric adenocarcinomas, the 
methylation status of the CpG island could be studied using bisulphite genome sequencing 
(Li & Tollefsbol. 2011). Bisulphite genome sequencing involves bisulphite treatment of DNA, 
converting exposed cytosine bases into uracil bases, whilst methylated cytosine bases are 
protected from conversion. Following this treatment, samples are sequenced to reveal the 
extent of the cytosine methylation (Li & Tollefsbol. 2011). However, DNA methylation is only 
one form of epigenetic regulation, and it is possible that other forms of epigenetic regulation 
are involved in HECTD1 regulation in other cancers. In addition to DNA methylation, 
histones can be modified by acetylation, methylation, ubiquitination, and phosphorylation 
affecting gene expression and result in cancer (Baxter, et al. 2014). For example, H3K27 
acetylation is associated with active enhancers which lead to promoting of gene expression 
(Creyghton, et al. 2010). The UCSC genome browser highlighted high H3K27 acetylation 
in the promoter region of HECTD1, indicating that this enhancer may be active potentially 
leading to increased gene expression. Furthermore, in colorectal cancer patient samples it 
was found that H3K27 acetylation of histones was increased, suggesting its role in 
regulating genes involved in the development of colorectal cancer (Karczmarski, et al. 
2014). As future work a Chromatin Immunoprecipitation Pulldown (ChIP) assay could be 
used to assess the histone modification status to understand HECTD1 regulation within 
different cancer samples (O’Geen, et al. 2011).  
 
 
6.3.2. HECTD1 is mutated and amplified in multiple cancers 
Since HECTD1 was expressed in the lung cancer cells screened, it appeared that it might 
not behave as a tumour suppressor in cancer.  In this thesis, HECTD1 has been shown to 
control cell cycle progression, regulating the timely progression through mitosis. 
Furthermore, HECTD1 has been previously reported to have a role in Wnt signalling, 
transcriptional regulation, cell adhesion and migration (Sarkar, et al. 2012; Li, et al. 2013b; 
Tran, et al. 2013; Li, et al. 2015; Shen, et al. 2017). In cancer, mechanisms that regulate 
cell cycle progression and cell migration are often exploited. For example, UBE3C is 
overexpressed in renal carcinoma and results in over-activation of the Wnt signalling 
pathway (Wen, et al. 2015). Whilst HUWE1 overexpression promotes cell migration by 
increased TIAM1 degradation in lung cancer (Vaughan, et al. 2015). Therefore, a 
hypothesis may be that HECTD1 is amplified in cancer. 
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Using cBioPortal it was found that in many different cancer types HECTD1 was amplified, 
furthermore it showed that HECTD1 was also mutated. Interestingly, both amplification and 
mutations of genes are oncogene activation mechanisms (Niedercher, et al. 1999), 
supporting the hypothesis that HECTD1 behaves as an oncogene. In the two lung cancer 
studies (Figure 6.3), it was found that the majority of HECTD1 alterations were 
amplifications, however in most other cancers the HECTD1 alterations were as a result of 
mutations. In addition, the mutations that occur within HECTD1 were found to occur 
throughout its sequence and not located at one loci, indicating that there was no mutation 
hotspot in the sequence of HECTD1. Mutations are regarded as a hallmark of cancer and 
facilitate the evolution of the cancer (Loeb & Loeb. 2000). A number of cancer candidate 
(CAN) genes have seen identified by somatic screens of mutations to search for cancer 
therapeutics. In glioblastoma, melanoma, and pancreatic cancers, 19 CAN genes were 
identified because they displayed a mutation frequency above 10% in these cancers. In 
addition, some of these genes were found to encode protein kinases, opening the possibility 
for drug discovery (Balakrishnan, et al. 2007). Therefore, a high mutation frequency in 
HECTD1 could suggest that its function needs to be modified in order to provide cancer 
cells with a growth advantage. Mutations can result in a gain of function, for example 
expression of mutant p53 resulted in enhanced tumorigenic potential (Dittmer, et al. 1993), 
which may result in a cancer promoting mutant of HECTD1. Mutations in HECTD1 could 
occur within a localisation domain, changing the functional localisation or within the HECT 
domain of HECTD1 resulting in an increase in ligase activity. This may lead to oncogenic 
mutations that result in a new activity for HECTD1 or increased activity that leads to cancer 
development. However, without functional characterisation of the effect on these mutations, 
the mechanism by which these mutations can cause cancer is only speculative. 
 
 
6.3.3. HECTD1 as a novel biomarker or therapeutic target for glioblastoma 
Finally, to test an oncogenic role for HECTD1 in a cancer model, a collaboration was 
established with Dr K Kurian at Bristol Southmead Hospital, to elucidate the role of HECTD1 
in glioblastoma. Taking into account the data in Chapters 3, 4, and 5 showing that HECTD1 
regulates cell cycle progression, it was next hypothesised that this mechanism could be at 
play and contribute to an increase in cell proliferation upon overexpression of wild-type, but 
not the catalytic dead HECTD1.  
 
Currently, there are 4 commonly used biomarkers used to detect and grade glioblastoma 
allowing for personalised treatment. These are isocitrate dehydrogenase 1 (IDH1)  
mutations, 1p/19q codeletion, TERT promoter methylation, and O-6-methylguanine-DNA 
methyltransferase promoter methylation (Haynes, et al. 2014; Weller, et al. 2015). For 
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example, IDH1 mutations are more common in lower grade gliomas in younger patients. 
These patients with IDH1 mutations are further subdivided into those with either 1p/19q 
codeletion or TERT promoter methylation. Finally, O-6-methylguanine-DNA 
methyltransferase (MGMT), is a DNA repair protein, and interestingly, patients with MGMT 
promoter methylation had a higher survival rate when treated with temozolomide (TMZ) 
than those without MGMT promoter methylation (Weller, et al. 2015). TMZ, one of the only 
chemotherapies for glioblastoma, works by alkylating or methylating DNA, often occurring 
at the N-7 or O-6 positions on guanine residues and results in DNA damage and cell death 
of tumour cells (Newlands, et al. 1997; Jacinto & Esteller. 2007). However, in patients 
without O-6-methylguanine-DNA methyltransferase promoter methylation, MGMT is able to 
repair this DNA damage and prevent cell death, reducing the efficacy of TMZ (Jacinto & 
Esteller. 2007). Highlighting that despite the research into glioblastoma, the cancer is still 
related with a poor prognosis, and presents limited treatment options for the patients. 
Furthermore, there is only one main chemotherapy available to patients limiting the 
treatment options.  
 
Interestingly, the HECT ligase UBE3C has been shown to be overexpressed in glioblastoma 
and correlated with high grade tumours, poor survival and early tumour recurrence (Pan, et 
al. 2015). Here, UBE3C ubiquitinates and degrades the calcium-dependent phospholipid 
binding protein, Annexin A7, facilitating migration and invasion of glioblastoma (Pan, et al. 
2015). This provided the first example that the ubiquitin system might be an attractive target 
for cancer therapies, specifically in GBM. Therefore, targeting of the ubiquitin system, 
specifically HECT ligases, may provide further treatment options for patients with 
glioblastoma. Given that TMZ is one of the only chemotherapies for glioblastoma, and this 
is ineffective in patients without O-6-methylguanine-DNA methyltransferase promoter 
methylation, there is great demand for a new therapeutic. The potential of HECTD1 as a 
novel therapeutic holds large promise, given that it can be enzymatically targeted, and the 
ubiquitin proteasome system has the potential to furnish many cancer therapeutics 
(Weathington & Mallampalli. 2014). Compellingly, knockdown of HECTD1 resulted in 
decreased proliferation in glioblastoma cell lines, and this suggests that the inhibition of the 
catalytic activity of HECTD1 could result in reduced proliferation, potentially providing a 
novel glioblastoma therapeutic target. There is already evidence to suggest that targeting 
the ubiquitin proteasome system is an attractive therapeutic. For example, VLX1570 has 
been shown to inhibit proteasome associated DUB, USP14, and induce apoptosis in 
multiple myeloma cells (Wang, et al. 2016). When USP14 was transiently knocked down 
this mimicked the effect caused by VLX1570, reducing proliferation and viability of multiple 
myeloma cells (Wang, et al. 2016).  
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6.4. Future work: 
To further establish a clinical relevance for HECTD1 in glioblastoma, in addition to the qRT-
PCR screen of glioblastoma patient samples, immunohistochemistry (IHC) on glioblastoma 
tissue sections could be performed to look for HECTD1 protein expression in these tissues. 
Here, HECTD1 could be validated as a diagnostic marker, by screening different cohorts of 
glioblastoma patients. HECTD1 expression could be correlated with patients of different 
age or with different grades of glioblastoma. For example, IDH1 mutations are more 
common in lower grade gliomas in younger patients. HECTD1 and IDH1 expression by IHC 
can be used to see whether HECTD1 expression correlated with IDH1 in young patients 
with a lower grade of glioblastoma.  
 
To validate the hypothesis that HECTD1 depletion results in a decrease in cell proliferation, 
HECTD1 depletion mouse models can be carried out. Here, shRNA can be transfected into 
a glioblastoma cell line, such as U87, that is luciferase-expressing (Seibler, et al. 2007). 
These cells can then be injected into the tail vein of a mouse, for example a T-cell deficient 
nude mouse (Ikehara, et al. 1984). The bioluminescence of HECTD1 depleted cells 
compared to control cells will reveal the extent of tumour formation. The aim here would be 
to demonstrate that HECTD1 depletion decreases glioblastoma cell proliferation in vivo, 
and would implicate it as a potential new drug target.  
 
Finally, using a retroviral virus containing a selectable marker (such as neomycin) for 
longer-term overexpression (Deregowski & Canalis. 2008) of full length human HECTD1 in 
U87 and U251, a colony formation assay could be performed to demonstrate how the 
increase in the proliferation could result in tumour formation.  To establish whether HECTD1 
plays an oncogenic role in the pathogenesis of glioblastoma, HECTD1 should be 
overexpressed in vivo, such as in transgenic mice, in a xenograft cancer model. For 
example, as demonstrated with the transcription factor, PDX1, transgenic mice models can 
be generated that express the gene of interest using the Tetracycline inducible system. The 
Tetracycline transactivator (tTA) can be targeted to specific cell populations using Bacterial 
Artificial Chromosomes (BAC) transgenic mice to produce, in this case, pancreatic 
progenitor cells that overexpress the gene of interest (Blondeau, et al. 2012). For use in this 
project, this system could be used to induce overexpression of HECTD1 in astrocytes, for 
example, to monitor for tumour formation and to demonstrate that HECTD1 overexpression 
results in glioblastoma in vivo. However, an important consideration is that for this 
experiment to be successful, HECTD1 would have to first be identified as a key driver of 
glioblastoma.  
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7.1. The role of HECTD1 in cell cycle regulation 
In this thesis HECTD1 has been identified as a novel cell cycle regulator. Transient 
depletion and knockout of HECTD1 resulted in a delayed mitotic phenotype. Interestingly, 
whilst the mechanism behind the regulation of HECTD1 in the cell cycle was not fully 
characterised, the cell cycle phenotype identified was similar to those cell cycle phenotypes 
associated with delayed SAC satisfaction. For example, as seen with the mitotic spindle 
regulator, JMJD5 (He, et al. 2015). The delay in NEBD to Anaphase onset associated with 
HECTD1-depletion suggests that cells are unable to progress through mitosis as quickly as 
cells that express HECTD1 (Figure 7.1). This was further evidenced by the enrichment of 
cells in metaphase observed in HECTD1-depleted and knockout cells. This enrichment of 
cells in metaphase suggests that cells are prolonged at this phase, where the SAC is active. 
Eventual satisfaction of the SAC results in cells that can progress from metaphase to 
anaphase and go on to complete mitosis (Murray. 1994; Stern & Murray. 2001). Satisfaction 
of the SAC depends on microtubule attachment resulting in sufficient inter-kinetochore 
tension (Stern & Murray. 2001; Uchida, et al. 2009; Mansfeld, et al. 2011). This then results 
in the activation of the APC/C, resulting in proteasomal degradation of Cyclin B1 and 
securin, triggering sister chromatid separation and exit from mitosis (Glotzer, et al. 1991; 
Holloway, et al. 1993; Cohen-Fix & Koshlan. 1999). Furthermore, it was shown that the E3 
ligase activity of HECTD1 is required to rescue the mitotic phenotype, so therefore, the 
K29/K48 ubiquitin chains synthesized by HECTD1 may be involved in its function in the cell 
cycle. 
 
A possible explanation for the hypothesised delay in SAC satisfaction, is that HECTD1 has 
a role in regulating mitotic spindle formation. Mitotic spindle regulators such as NuMA and 
JMJD5 show similar phenotypes to HECTD1 depletion (Haren, et al. 2009; He, et al. 2015). 
Despite the lack of a clear mechanism for the regulation of the mitotic spindle by HECTD1 
(Chapter 5), there is evidence to suggest that this may be an area worth further investigation 
in the future. For example, Tran, et al. (2013) found that HECTD1 depletion resulted in cells 
that had reduced microtubule stability. Here, it is hypothesised that the negative regulation 
of the APC conferred by HECTD1 results in destabilisation of microtubules (Tran, et al. 
2013). The APC is a tumour suppressor protein that is also a conventional microtubule 
associated protein, which functions to bind to microtubules to stabilise them (Mimori-
Kiyosue & Tsukita. 2003). The APC has been implicated in the regulation of the mitotic 
spindle, together with its binding partner, EB1, a tubulin binding protein (Berrueta, et al. 
1998; Mimori-Kiyosue & Tsukita. 2003; Green, et al. 2005). Furthermore, EB1 has been 
shown to be associated with familial and sporadic forms of colorectal cancer (Berrueta, et 
al. 1998). Interestingly, Cyclin A/CDK2-dependent phosphorylation of APC in late G2, is 
required for mitotic spindle localisation to the central position in cells (Beamish, et al. 2009). 
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The APC has been identified as a substrate for HECTD1 (Tran, et al. 2013). Therefore, 
HECTD1 may be recruited to the mitotic spindle during mitosis to function in its regulation 
of the cell cycle. This is possibly mediated through APC or its binding partner, EB1, which 
has been shown to colocalise with the mitotic spindle (Berrueta, et al. 1998; Green, et al. 
2005), showing similar staining to HECTD1 in mitosis. Here, HECTD1 may facilitate the 
regulation of the mitotic spindle.   
 
Additionally, another previously identified HECTD1 substrate, HSP90, was shown to be 
required for the localisation of Cyclin B1 and Msps/ch-TOG to the mitotic spindle in both 
Drosophila. M and Humans (Basto, et al. 2007). Msps/ch-TOG is required for  microtubule 
dynamics and mitotic spindle formation (Byrnes & Slep. 2017). Therefore, a hypothesis is 
that HECTD1 regulates HSP90 localisation as seen in Sarkar, et al. (2012), which in turn 
regulates localisation of the mitotic spindle regulator Msps (Byrnes, & Slep. 2017). 
Therefore, in HECTD1-depleted cells, a potential hypothesis is that the localisation of 
HSP90 is perturbed resulting in aberrant MSPS localisation, preventing correct formation of 
the mitotic spindle, and so resulting in prolonged SAC activation. Alternatively, another 
explanation for the phenotype observed in HECTD1-depleted and knockout cells is that 
HECTD1 regulates the inter-kinetochore distance directly. It has been shown that HECTD1 
is associated with condensins I and II, which function to recruit HECTD1 to active gene 
enhancers (Li, et al. 2015). Codensins have been previously implicated in facilitating 
kinetochore tension at the centromeres, to ensure correct segregation of sister chromatids 
(Yong-Gonzalez, et al. 2009). In cells depleted of condensin I, the inter-kinetochore 
stretching is not sufficient to inactivate the spindle assembly checkpoint. The associated 
phenotype results in cells with an increased NEBD to Anaphase onset, similar to the 
observed phenotype upon HECTD1 depletion or knockout (Uchida, et al. 2009). Therefore, 
HECTD1 could be recruited by condensin I to the kinetochores to mediate sufficient inter-
kinetochore tension. Whilst, conversely, a loss of HECTD1 may result in loss of inter-
kinetochore tension. A final consideration is that future experiments may identify a novel 
HECTD1 substrate, which is cell cycle specific. From the experiments outlined in Chapter 
5, it would be possible to probe for novel HECTD1 substrates, which may begin to elucidate 
the mechanism by which HECTD1 regulates the cell cycle.  
 
 




Figure 7.1. Schematic of the hypothesised role of HECTD1 in mitotic progression. 
HECTD1-depleted cells and control cells are able to enter mitosis at the same time, where 
they progress until metaphase. Here, at metaphase the SAC acts as a checkpoint to prevent 
mitotic progression until each kinetochore is attached to the mitotic spindle. It is 
hypothesised that in HECTD1-depleted cells, the observed delay in NEBD to anaphase 
onset is as a result of prolonged SAC activation. This delay in the satisfaction of the 
checkpoint results in a delay until anaphase onset, where cells are then able to progress to 
complete mitosis.  
 
 
7.2. K29/K48 ubiquitin chains in cell cycle regulation? 
The E3 ligase activity of HECTD1 was shown to be required to rescue the mitotic phenotype 
associated with HECTD1-depletion. In addition, K29-linked ubiquitin chains were found to 
be present during the cell cycle and mitosis. Therefore, a hypothesis is that the K29/K48 
atypical activity of HECTD1 is involved in its cell cycle function. Atypical ubiquitin chains 
have been demonstrated to function in the cell cycle. For example, it has been shown that 
K11/K48 chains synthesised by the APC/C together with UBE2S and UBE2C result in the 
degradation of cell cycle substrates such as Cyclin A, CDC20, p21, and NEK2A (Meyer & 
Rape. 2014; Yau, et al. 2017).  
 
The role that mixed and branched ubiquitin chains have in different cellular functions is still 
largely unknown. This is in part due to the difficulty in discerning the chain topology in 
heterotypic chains. Each unique ubiquitin chain topology confers different functions within 
the cell (Komander. 2009). Therefore, a consideration is that whilst HECTD1 has been 
shown to synthesise K29/K48-linked ubiquitin chains, the topology of these chains and the 
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signal they confer is unknown. A combination of linkage selective UBDs and DUBs has 
been used to investigate the different composition of heterotypic chains (Emmerich & 
Cohen. 2015; Heap, et al. 2017). Heterotypic ubiquitin chains come in two forms: mixed and 
branched. Mixed ubiquitin chains are defined by comprising different linkages but each 
ubiquitin is modified with only one other ubiquitin molecule. Whilst branched ubiquitin chains 
are composed of single ubiquitin subunits that have been modified with two or more ubiquitin 
molecules (Yau & Rape. 2016) (Figure 1.8). Interestingly, biophysical studies have implied 
that mixed and branched ubiquitin chains confer distinct signals (Nakasone, et al. 2013). 
Linkage-selective receptors from hHR23A and RAP80 were found to bind preferentially to 
K48 or K63 linkages that were in a branched trimer, furthermore the 26S proteasome 
recognised and processed these branched chains (Nakasone, et al. 2013).  
 
Interestingly, Meyer, et al. (2014) demonstrated that heterotypic ubiquitin chains of K11/K48 
synthesised by the APC/C were branched and not mixed linkages. This was achieved by 
the insertion of a Tobacco Etch Virus (TEV) protease cleavage sequence into the Glu-53 
residue within ubiquitin. This enabled protease cleavage at this site, which generated a TEV 
sequence-containing signature peptide upon cleavage of the polyubiquitin chains using 
TEV. The proteins were then analysed by western blot to show a change in molecular weight 
in accordance with the number of TEV cleavage peptides as evidence for branched ubiquitin 
chains (Meyer, et al. 2014) (Figure 7.2). Furthermore, the generation of a bi-specific 
antibody against K11/K48 permitted the recognition and characterisation of branched 
K11/K48 chains synthesised by the APC/C in cells (Yau, et al. 2017). Here, branched 
ubiquitin chains are suggested to serve a role in substrate degradation (Meyer, et al. 2014; 
Yau, et al. 2017).  
 
Interestingly, it has been recently found that branched chains containing K29-linked 
ubiquitin are more likely to be involved in non-degradative signalling (Crowe, et al. 2017).  
UbiChEM-MS has been demonstrated to characterise branching in polyubiquitin chains (Xu, 
& Peng. 2008; Valkevich, et al. 2014; Lee, et al. 2014). Recently, it was shown that minimal 
trypsinolysis and limited acid cleavage retains information of the connectivity of Ub chains, 
especially branched chains (Crowe, et al. 2017). If a branch point was found to be present 
within the ubiquitin chain, the ubiquitin moiety that harbours the branch point is modified 
with two Gly-Gly modifications; left behind from the two branching ubiquitin moieties. 
Interestingly, the NZF1 domain was used to enrich the pool of branched ubiquitin chains for 
the UbiChEM-MS. Here, they confirmed that the NZF1 domain of TRABID enriches for 
K29/K48 branched ubiquitin chains. Strikingly, using this technique, Crowe, et al. 2017 
concluded that while chain branching does target substrates for the proteasome, branched 
chains containing K29 linkages are likely to serve non-degradative roles. A hypothesis for 
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this, is that the K29-linkage “caps” the K48 linkage, resulting in a non-degradative signal. 
However, work conducted in S. cerevisiae, suggests that K29-linked ubiquitin chains, that 
have been modified with K48-linked ubiquitin resulting in branched chains, promoted the 
degradation of modified substrates (Liu, et al. 2017). More compellingly, this modification is 
mediated by Ufd2 and Ufd4, the latter of which is a HECTD1 orthologue. Here, the K48 
branching modifies the K29-linkage transforming the ubiquitin chain into a degradative 
signal (Liu, et al. 2017). Therefore, the exact composition of the K29/K48-linked ubiquitin 
chains synthesised by HECTD1 needs to be elucidated to understand whether they serve 
as a degradative or a non-degradative signal. Therefore, the above techniques used in 
combination could be used in the future to confirm the topology of the ubiquitin chains 
synthesised by HECTD1. 
 
In the context of the proposed mechanism that HECTD1 has in regulating the cell cycle, it 
is important to understand whether the K29/K48 linkage targets cell cycle substrates to the 
proteasome. For example, if these atypical ubiquitin chains are indeed shown to serve as a 
degradative signal, then this would rule out the hypotheses regarding the previously known 
substrates and interactors of HECTD1. This would include the substrates where HECTD1 
has been demonstrated to ubiquitinate substrates leading to a change in localisation (APC 
and HSP90) (Sarkar, et al. 2012; Tran, et al. 2013). The exception is condensin I where, 
HECTD1 is required for the degradation of RIP40, however this does not tie in with a role 
in mitosis (Li, et al. 2015). Therefore, this opens up the avenue that there is another 
unidentified substrate of HECTD1, required for the cell cycle function. This substrate is 
hypothesised to be modified with K29/K48 leading to its degradation by the proteasome. 
However, if these chains are non-degradative then they may facilitate the localisation of cell 
cycle substrates, which in turn facilitates mitotic progression. However, this is only 
speculative, and more work would be required in the future to confirm the function of 
K29/K48 linked ubiquitin chains in the context of cell cycle regulation. Finally, a further 
consideration is the role that these K29/K48 linked chains have in the UFD pathway. 
Interestingly, Ufd4, is a HECTD1 ortholog in S. cerevisiae, that has been demonstrated to 
be a UFD pathway ligase and conjugates K29/K48 branched ubiquitin chains together with 
Ufd2 (Liu, et al. 2017).  This may suggest that the role that HECTD1 has in mitosis may be 
mediate through the UFD pathway, however further work would be required to demonstrate 
a direct link. 
 
 



















Figure 7.2. Schematic of how to determine ubiquitin chain topology using the 
Tobacco Etch Virus (TEV). The TEV protease cleavage sequence is inserted into the Glu-
53 residue of ubiquitin. Upon cleavage of this protease cleavage site, TEV sequence-
containing peptides are left on each ubiquitin. Here, where linkages are mixed, ubiquitin will 
only be modified with one signature peptide, whilst branched ubiquitin will be modified with 




7.3. HECTD1 as a novel therapeutic target 
Interestingly, overexpression of wild-type mHectd1 in glioblastoma cell lines was shown to 
lead to an increase in cell proliferation, demonstrating a possible oncogenic function.  
Speculatively, this increase in proliferation could be due to the reported role that HECTD1 
has in Wnt signalling (Tran, et al. 2013) and in regulation of mitochondrial metabolism 
(Segref, et al. 2014) as discussed in Chapter 6. However, given the reported role that 
HECTD1 has as a negative regulator in Wnt signaling (Tran, et al. 2013), it is unlikely that 
its overexpression would result in increased proliferation. Furthermore, HECTD1 is reported 
to regulate mitochondrial protein turnover, and its depletion resulted in increased ROS 
production in C. elegans (Segref, et al. 2014). This again does not easily align with the 
increased in proliferation observed. Therefore, this led to the hypothesis that the increased 
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has in cell cycle regulation. Strikingly, immunofluorescent staining of HA-FL-mHectd1WT 
was observed at the mitotic spindle during metaphase, aligning with previous observations 
in HEK293ET cells in Chapter 4. Therefore, based on the assumption that HECTD1 
regulates the mitotic spindle as hypothesised from Chapters 3-5, it is conceivable that when 
overexpressed, HECTD1 may lead to aberrant regulation of the mitotic spindle. Here, an 
increase in proliferation could be seen as a result of a decrease in the time taken from 
NEBD to anaphase onset. Interestingly, depletion of the E3 ligases TRAIP and SMURF22 
have been shown to lead to a decrease in the time taken from NEBD to anaphase onset 
(Osmundson, et al. 2008; Chapard, et al. 2014). Both ligases are reported to regulate the 
stability and localisation of MAD2 at unattached kinetochores (Osmundson, et al. 2008; 
Chapard, et al. 2014). Therefore, a speculative model for how HECTD1 overexpression 
leads to increased cell proliferation in glioblastoma cell lines, it that it causes the SAC to be 
compromised. A compromised SAC leads to a decrease in the time taken from NEBD to 
anaphase onset (Pines. 2006). This may result by aberrant regulation of a SAC component, 
for example MAD2. Based on the assumption that K29/K48-linked ubiquitin chains have a 
degradative role (Liu, et al. 2017), overexpression of HECTD1 could result in the 
degradation of MAD2, and therefore a compromised SAC (Figure 7.3). Therefore, 
implicating HECTD1 in the fine tuning of MAD2 levels. This would result in a decrease in 
the length of time taken to progress through mitosis leading to an increase in cell 
proliferation. Additionally, a compromised SAC will result in an unchecked mitosis, 
potentially causing chromosomal aberrations and aneuploidy (Osmundson, et al. 2008). 









Figure. 7.3. Hypothesis for HECTD1 overexpression in cancer. As shown in 
Osmundson, et al. (2008), SMURF2 regulates the SAC by stabilising MAD2, ensuring the 
integrity of the checkpoint. In this proposed model, overexpression of HECTD1 could lead 
to the polyubiquitination and degradation of MAD2, resulting in a compromised checkpoint, 
and therefore a reduction in the time taken to progress from NEBD to anaphase onset.  
 
 
Strikingly, overexpression of the catalytically active version and not the mutant of mHectd1 
in a glioblastoma cell line, resulted in increased proliferation. Furthermore, depletion of 
HECTD1 resulted in a decrease in cell proliferation in glioblastoma cells. This therefore 
strongly suggests that depletion of HECTD1 in glioblastoma could be a strategy to reduce 
cell proliferation. Given that the increase in proliferation has been shown to be driven by the 
E3 ligase activity of HECTD1, targeting of this activity could lead to a reduction in cell 
proliferation. Targeting of the catalytic activity of HECTD1 could provide a novel cancer 
therapeutic for glioblastoma and other cancers where HECTD1 is found to be 
overexpressed. This inhibition would phenocopy the depletion of HECTD1 in glioblastoma 
cell lines leading to a reduction in proliferation, potentially by restoration of the SAC. 
Therefore, targeting HECTD1 may provide another potential UPS based cancer therapy, in 
addition to the currently used proteasome inhibitors; Bortezomib (Cohen & Tcherpakov. 
2010) and Cafilzomib (Stewart, et al. 2015). Inhibiting proteasomes have a large scope for 
side effects, whereas targeting specific E3 ligases reduces these side effects because of 
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the high substrate specific nature of the enzymes (Bernassola, et al. 2008). Furthermore, 
given that TMZ is one of the only chemotherapies for glioblastoma, and this is ineffective in 
patients without O-6-methylguanine-DNA methyltransferase promoter methylation, there is 
great demand for a new therapeutic (Weller, et al. 2015).  
 
Small molecule and peptide inhibitors have been made to target RING E3s with the example 
of MDM2, which targets p53 (Chang, et al. 2013; Yang, et al. 2005). More recently small 
molecule and peptide inhibitors of HECT E3 ligases have been produced. Using phage 
display bicyclic peptide inhibitors of HECT domains of SMURF2, NEDD4, WWP1, and 
HUWE1 were isolated, which targeted the E2 binding site and prevented binding. The small 
molecule Heclin was found to inhibit several HECT ligases in tissue culture cells and led to 
cell death in HEK293. In this case it does not prevent binding of the E2, instead it induces 
a conformational change leading to the oxidation of the active site cysteine. Heclin was 
found not to lead to oxidation of other cysteine containing enzymes such as E1 or E2 
enzymes, suggesting that it has a specific binding site in HECT ligases (Mund, et al. 2014). 
However, Heclin targets all HECT E3 ligases, and for a viable cancer therapeutic it would 
be desirable for the targeting to be to a specific ligase. For example, specific small molecule 
inhibitors of HUWE1 (B18622 and B18626) were identified via high throughput screening. 
HUWE1 associates with MYC and MIZ1, and upon inhibition of HUWE1, transcriptional 
activation by MYC is reduced in colon cancer cells, because MIZ1 is not degraded by 
HUWE1 and therefore is able to bind and repress MYC-activated genes (Peter, et al. 2014). 
In addition, a small molecule inhibitor, clomipramine an antidepressant, was found to 
prevent ITCH autoubiquitylation, as well as p73 ubiquitylation. A panel of breast, prostate, 
and bladder cancer cell lines were treated with clomipramine, or its homologs, which led to 
reduced cancer cell growth (Rossi, et al. 2014). Taken together, this therefore shows 
promise for the future of designing small molecule or peptide cancer therapeutics, which 
target HECT E3 ligases. Furthermore, with more research a small molecule inhibitor could 
be designed to target HECTD1 in the context of glioblastoma. For example, small molecule 
inhibitors of HECTD1 can be designed based on the structure of the active site of the ligase. 
This can be achieved by using X-ray crystallography to determine the structure of the HECT 
domain of HECTD1 to model compounds in the catalytic site, as achieved with the active 
site of the metalloprotease Neproilysin (Voisin, et al. 2004). From this, small molecules can 
be screened from a compound library such as the NCI/DTP Open Chemical Repository. 
Using molecular docking, these compounds can be modelled into the active site to limit the 
number of candidate compounds. Finally, once a limited number of compounds have been 
screened, a high throughput cell proliferation assay could be conducted to assess for 
reduction in proliferation in glioblastoma cell lines. This reduction would phenocopy the 
observed reduction in proliferation as observed in Chapter 6. This rationale for designing 
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small molecule inhibitors of enzymes is well characterised and has been used for the design 
of an inhibitor of the Ras GEF, SOS1 (Evelyn, et al. 2014). Thus, demonstrating how an 




7.4. New tools in studying HECT ligase activity 
Recently with the expansion of the Ub toolbox, there are increasingly more ways to study 
HECT ligase activity. Activity based probes have been designed, which are able to assess 
the activity of HECT ligases. Activity based protein profiling (ABPP) utilises chemical probes 
that target the active site of enzymes, to profile their activity within complex mixtures of 
proteins (Love, et al. 2007). Development of these probes has led to increased 
understanding of deubiquitinases, whereby new members of DUB families have been 
identified (Borodovsky, et al. 2002; Hemelaar, et al. 2004). The first generation of these 
probes Ub-ABP comprise a C-terminal modification of ubiquitin whereby the G76 is modified 
with a variety of thiol-reactive groups, known as warheads, which covalently modify the 
catalytic cysteine of the enzyme (Love KR, et al. 2007). These C-terminal warheads include 
aldehyde, vinyl sulfone, vinylmethylester (VME), and propargylamide (PA) (Hershko, & 
Rose. 1987; Palmer, et al. 1995; Borodovsky, et al. 2001; Borodovsky, et al. 2002; Ekkebus, 
et al. 2013). Both Ub-VME-ABP and Ub-PA-ABP have been used to covalently modify 
HUWE1 (Love, et al. 2009; Ekkebus, et al. 2013). Ub-VME-ABP was used to covalently 
modify the recombinant HECT domain of HUWE1, and interestingly, when characterising 
the interaction between Ub-VME-ABP and the HECT domain of HUWE1, it was revealed 
that the probe labelled multiple cysteines within the domain (Love, et al. 2009). Mutation of 
the catalytic cysteine of HUWE1 resulted in reduced but not a total loss of ligase activity, 
suggesting that the other cysteine residues may contribute to the activity of HUWE1. Finally, 
Ub-VME-ABP was shown to label HUWE1, E6AP, and TRIP12 ligases in mouse and human 
cell lysates (Love, et al. 2009). Therefore, demonstrating the ability of these first-generation 
probes to label HECT ligases and facilitate the understanding of the catalytic residues 
involved in their activity.  
 
However, the next generation of ABPs are much more suited to probing the activity of HECT 
ligases and specifically HECTD1. The first generation Ub-ABPs are much more effective in 
labelling DUBs and less physiologically relevant when labelling E3 ligases. Therefore, the 
next generation of activity based probes were based on the substrate of E3 ligases, Ub-E2. 
These probes known as E2-based ABPs, mimic a ubiquitin-charged E2 that contains a C-
terminal electrophilic warhead, that is able to label RBR and HECT E3 ubiquitin ligases. 
This allows for specific labelling of RBR and HECT ligases, as only active sites with an E2 
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binding site will result in covalent modification of the cysteine, thus excluding labelling of 
deubiquitinases (Pao, et al. 2016). Use of this novel probe enabled direct and quantitative 
labelling of endogenous activity of the RBR ligase, Parkin (Pao, et al. 2016). Since, Byrne, 
et al. (2017) have used this E2-Ub-ABP to label recombinant HECT domains of NEDD4, 
UBE3C, and HECTD1. Only UBE3C was successfully labelled by the E2-Ub-ABP in human 
cell-line lysates under basal conditions (Byrne, et al. 2017). These novel reagents, with 
further optimisation provide the future for assessing the activity of HECT ligases in cellulo. 
For example, these E2-Ub-ABP could be used to probe the activity of HECTD1 throughout 
the cell cycle, and understand the physiological conditions that result in its activation.  
 
Interestingly, in addition to modifying E3 ligases only, a cascading activity-based probe can 
be used to sequentially target the E1-, E2-, and E3- ubiquitin enzymes (Mulder, et al. 2016). 
The cascading activity based-probe, was developed to comprise a C-terminal 
dehydroalanine (Dha) residue, which upon E1 activation by ATP can travel downstream 
labelling E2 enzymes and E3 enzymes. At each step, the probe can irreversibly label the 
active site cysteine of the enzyme, thus enabling its detection, without transfer to 
subsequent substrates. The probe was able to successfully label NEDD4 family members, 
NEDD4, SMURF2, WWP1 and WWP2, in addition to HECTD1, UBE3A, UBE3C, and 
TRIP12 (Mulder, et al. 2016). Therefore, presenting another reagent to probe HECT ligase 
activity. Finally, ubiquitin variants (UbVs) have been employed to inhibit or activate HECT 
ligases (Zhang, et al. 2016). These UbVs were previously used as inhibitors to block active 
sites in DUBs, however it was also found that a UbV bound weakly to the HECT domain of 
NEDD4 leading to the activation of the enzyme instead of inhibition (Ernst, et al. 2013). In 
a later screen of these UbVs to study HECT ligase activation, structural analysis of six 
HECT-UbV complexes showed that they can behave as inhibitors, hijacking the E2-binding 
exosite, and activators, occupying a ubiquitin-binding exosite. Thus, providing a tool for 
understanding functions of HECT ligases and providing modulators of enzymatic activity 
(Zhang, et al. 2016). Interestingly, this reagent may be used in future studies to inhibit or 
modulate HECTD1 activity in the cell cycle to probe predicted function in the cell cycle.  
 
Therefore, the expansion of the ubiquitin tool kit is providing new methods to probe HECT 
ligases and enable deeper understanding of mechanisms underlying ubiquitination in 
cellular functions. The use of this toolkit could help with the understanding and manipulation 
of HECTD1 to elucidate the mechanism by which HECTD1 regulates the cell cycle.  
 
 




In conclusion, targeting the ubiquitin proteasome system is a promising avenue for the 
future of cancer therapeutics. HECTD1 has been identified to function in the cell cycle and 
cell proliferation, and therefore could provide a novel target for the treatment of cancer. The 
short term aim would be to characterise the molecular mechanisms by which HECTD1 
regulates the cell cycle through proteomics and ABPs. The mid-term aim, would be to study 
specifically the role that HECTD1 has in cancer, such as glioblastoma, by using mouse 
genetics and orthotopic models of brain cancer. Additionally, to evaluate the potential that 
HECTD1 has as a diagnostic and prognostic marker of glioblastoma. Finally, the long term 
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Figure A.1. Sequencing of HEK293T HECTD1 KO2. Sequencing carried out to confirm 
that the mutation induced by CRISPR/Cas9 causes a frame shift and premature stop codon 




Table A.1. siRNA specificity to each HECTD1 isoform. Each siRNA was compared to 
each variant of HECTD1 nucleotide sequence, below is a table to show, which siRNA can 



















































































mHECTD1      MADVDPDTLLEWLQMGQGDERDMQLIALEQLCMLLLMSDNVDRCFETCPPRTFLPALCKI 60 
hHECTD1      MADVDPDTLLEWLQMGQGDERDMQLIALEQLCMLLLMSDNVDRCFETCPPRTFLPALCKI 60 
             ************************************************************ 
 
mHECTD1      FLDESAPDNVLEVTARAITYYLDVSAECTRRIVGVDGAIKALCNRLVVVELNNRTSRDLA 120 
hHECTD1      FLDESAPDNVLEVTARAITYYLDVSAECTRRIVGVDGAIKALCNRLVVVELNNRTSRDLA 120 
             ************************************************************ 
 
mHECTD1      EQCVKVLELICTRESGAVFEAGGLNCVLTFIRDSGHLVHKDTLHSAMAVVSRLCGKMEPQ 180 
hHECTD1      EQCVKVLELICTRESGAVFEAGGLNCVLTFIRDSGHLVHKDTLHSAMAVVSRLCGKMEPQ 180 
             ************************************************************ 
 
mHECTD1      DSSLEICVESLSSLLKHEDHQVSDGALRCFASLADRFTRRGVDPAPLAKHGLTEELLSRM 240 
hHECTD1      DSSLEICVESLSSLLKHEDHQVSDGALRCFASLADRFTRRGVDPAPLAKHGLTEELLSRM 240 
             ************************************************************ 
 
mHECTD1      AAAGGTVSGPSSACKPGRSTTGAPSAAADSKLSNQVSTIVSLLSTLCRGSPLVTHDLLRS 300 
hHECTD1      AAAGGTVSGPSSACKPGRSTTGAPSTTADSKLSNQVSTIVSLLSTLCRGSPVVTHDLLRS 300 
             *************************::************************:******** 
 
mHECTD1      ELPDSIESALQGDERCVLDTMRLVDLLLVLLFEGRKALPKSSAGSTGRIPGLRRLDSSGE 360 
hHECTD1      ELPDSIESALQGDERCVLDTMRLVDLLLVLLFEGRKALPKSSAGSTGRIPGLRRLDSSGE 360 
             ************************************************************ 
 
mHECTD1      RSHRQLIDCIRSKDTDALIDAIDTGAFEVNFMDDVGQTLLNWASAFGTQEMVEFLCERGA 420 
hHECTD1      RSHRQLIDCIRSKDTDALIDAIDTGAFEVNFMDDVGQTLLNWASAFGTQEMVEFLCERGA 420 
             ************************************************************ 
 
mHECTD1      DVNRGQRSSSLHYAACFGRPQVAKTLLRHGANPDLRDEDGKTPLDKARERGHSEVVAILQ 480 
hHECTD1      DVNRGQRSSSLHYAACFGRPQVAKTLLRHGANPDLRDEDGKTPLDKARERGHSEVVAILQ 480 
             ************************************************************ 
 
mHECTD1      SPGDWMCPVNKGDDKKKKDTNKDEEECNEPRGDPEMAPLYLKRLLPVFAQTFQHTMLPSI 540 
hHECTD1      SPGDWMCPVNKGDDKKKKDTNKDEEECNEPKGDPEMAPIYLKRLLPVFAQTFQQTMLPSI 540 
             ******************************:*******:**************:****** 
 
mHECTD1      RKASLALIRKMIHFCSEALLKEVCDSDVGHNLPTTLVEITATVLDQEDDDDGHLLALQII 600 
hHECTD1      RKASLALIRKMIHFCSEALLKEVCDSDVGHNLPTILVEITATVLDQEDDDDGHLLALQII 600 
             ********************************** ************************* 
 
mHECTD1      RDLVDKGGDIFLDQLARLGVISKVSALAGPSSDDENEEESKPEKEDEPQEDAKELQQGKP 660 
hHECTD1      RDLVDKGGDIFLDQLARLGVISKVSTLAGPSSDDENEEESKPEKEDEPQEDAKELQQGKP 660 
             *************************:********************************** 
 
mHECTD1      YHWRDWSIIRGRDCLYIWSDAAALELSNGSNGWFRFILDGKLATMYSSGSPEGGSDSSES 720 
hHECTD1      YHWRDWSIIRGRDCLYIWSDAAALELSNGSNGWFRFILDGKLATMYSSGSPEGGSDSSES 720 
             ************************************************************ 
 
mHECTD1      RSEFLEKLQRARGQVKPSTSSQPILSAPGPTKLTVGNWSLTCLKEGEIAIHNSDGQQATI 780 
hHECTD1      RSEFLEKLQRARGQVKPSTSSQPILSAPGPTKLTVGNWSLTCLKEGEIAIHNSDGQQATI 780 
             ************************************************************ 
 
mHECTD1      LKEDLPGFVFESNRGTKHSFTAETSLGSEFVTGWTGKRGRKLKSKLEKTKQKVRTMARDL 840 
hHECTD1      LKEDLPGFVFESNRGTKHSFTAETSLGSEFVTGWTGKRGRKLKSKLEKTKQKVRTMARDL 840 
             ************************************************************ 
 
mHECTD1      YDDHFKAVESMPRGVVVTLRNIATQLESSWELHTNRQCIEGENTWRDLMKTALENLIVLL 900 
hHECTD1      YDDHFKAVESMPRGVVVTLRNIATQLESSWELHTNRQCIESENTWRDLMKTALENLIVLL 900 
             ****************************************.******************* 
 
mHECTD1      KDENTISPYEMCSSGLVQALLTVLNNSIDLDMKQDCSQLVERINVFKTAFSESEDDESRP 960 
hHECTD1      KDENTISPYEMCSSGLVQALLTVLNNSMDLDMKQDCSQLVERINVFKTAFSENEDDESRP 960 
             ***************************:************************.******* 
 
mHECTD1      AVALIRKLIAVLESIERLPLHLYDTPGSTYNLQILTRRLRFRLERAPGETSLIDRTGRML 1020 
hHECTD1      AVALIRKLIAVLESIERLPLHLYDTPGSTYNLQILTRRLRFRLERAPGETALIDRTGRML 1020 
             **************************************************:********* 
 
mHECTD1      KMEPLATVESLEQYLLKMVAKQWYDFDRSSFVFVRKLREGQNFIFRHQHDFDENGIIYWI 1080 
hHECTD1      KMEPLATVESLEQYLLKMVAKQWYDFDRSSFVFVRKLREGQNFIFRHQHDFDENGIIYWI 1080 




mHECTD1      GTNAKTAYEWVNPAAYGLVVVTSSEGRNLPYGRLEDILSRDNSALNCHSNDDKNAWFAID 1140 
hHECTD1      GTNAKTAYEWVNPAAYGLVVVTSSEGRNLPYGRLEDILSRDNSALNCHSNDDKNAWFAID 1140 
             ************************************************************ 
 
mHECTD1      LGVWVIPSAYTLRHARGYGRSALRNWVFQVSKDGQNWTSLYTHVDDCSLNEPGSTATWPL 1200 
hHECTD1      LGLWVIPSAYTLRHARGYGRSALRNWVFQVSKDGQNWTSLYTHVDDCSLNEPGSTATWPL 1200 
             **:********************************************************* 
 
mHECTD1      DPAKDEKQGWRHVRLKQMGKNASGQTHYLSLSGFELYGTVNGVCEDQLGKAAKEAEANLR 1260 
hHECTD1      DPPKDEKQGWRHVRIKQMGKNASGQTHYLSLSGFELYGTVNGVCEDQLGKAAKEAEANLR 1260 
             ** ***********:********************************************* 
 
mHECTD1      RQRRLVRSQVLKYMVPGARVIRGLDWKWRDQDGSPQGEGTVTGELHNGWIDVTWDAGGSN 1320 
hHECTD1      RQRRLVRSQVLKYMVPGARVIRGLDWKWRDQDGSPQGEGTVTGELHNGWIDVTWDAGGSN 1320 
             ************************************************************ 
 
mHECTD1      SYRMGAEGKFDLKLAPGYDPDTVASPKPVSSTVSGTTQSWSSLVKNNCPDKTSAAAGSSS 1380 
hHECTD1      SYRMGAEGKFDLKLAPGYDPDTVASPKPVSSTVSGTTQSWSSLVKNNCPDKTSAAAGSSS 1380 
             ************************************************************ 
 
mHECTD1      RKGSSSSVCSVASSSDISLASTKTERRSEIVMEHSIVSGADVHEPIVVLSSAENVPQTEV 1440 
hHECTD1      RKGSSSSVCSVASSSDISLGSTKTERRSEIVMEHSIVSGADVHEPIVVLSSAENVPQTEV 1440 
             *******************.**************************************** 
 
mHECTD1      GSSSSASTSTLTAETGSENAERKLGPDSSVRAPGESSAISMGIVSVSSPDVSSVSELTNK 1500 
hHECTD1      GSSSSASTSTLTAETGSENAERKLGPDSSVRTPGESSAISMGIVSVSSPDVSSVSELTNK 1500 
             *******************************:**************************** 
 
mHECTD1      EAASQRPLSSSASNRLSVSSLLAAGAPMSSSASVPNLSSRETSSLESFVRRVANIARTNA 1560 
hHECTD1      EAASQRPLSSSASNRLSVSSLLAAGAPMSSSASVPNLSSRETSSLESFVRRVANIARTNA 1560 
             ************************************************************ 
 
mHECTD1      TNNMNLSRSSSDNNTNTLGRNVMSTATSPLMGAQSFPNLTTPGTTSTVTMSTSSVTSSSN 1620 
hHECTD1      TNNMNLSRSSSDNNTNTLGRNVMSTATSPLMGAQSFPNLTTPGTTSTVTMSTSSVTSSSN 1620 
             ************************************************************ 
 
mHECTD1      VATATTVLSVGQSLSNTLTTSLTSTSSESDTGQEAEYSLYDFLDSCRASTLLAELDDDED 1680 
hHECTD1      VATATTVLSVGQSLSNTLTTSLTSTSSESDTGQEAEYSLYDFLDSCRASTLLAELDDDED 1680 
             ************************************************************ 
 
mHECTD1      LPEPDEEDDENEDDNQEDQEYEEVMILRRPSLQRRAGSRSDVTHHVVTSQLPQVPSGAGS 1740 
hHECTD1      LPEPDEEDDENEDDNQEDQEYEEVMILRRPSLQRRAGSRSDVTHHAVTSQLPQVPAGAGS 1740 
             *********************************************.*********:**** 
 
mHECTD1      RPVGEQEEEEYETKGGRRRAWDDDYVLKRQFSALVPAFDPRPGRTNVQQTTDLEIPPPGT 1800 
hHECTD1      RPIGEQEEEEYETKGGRRRTWDDDYVLKRQFSALVPAFDPRPGRTNVQQTTDLEIPPPGT 1800 
             **:****************:**************************************** 
 
mHECTD1      PHSELLEEVECTPSPRLALTLKVTGLGTTREVELPLTNFRSTIFYYVQKLLQLSCNGNVK 1860 
hHECTD1      PHSELLEEVECTPSPRLALTLKVTGLGTTREVELPLTNFRSTIFYYVQKLLQLSCNGNVK 1860 
             ************************************************************ 
 
mHECTD1      SDKLRRIWEPTYTIMYREMKDSDKEKENGKMGCWSIEHVEQYLGTDELPKNDLITYLQKN 1920 
hHECTD1      SDKLRRIWEPTYTIMYREMKDSDKEKENGKMGCWSIEHVEQYLGTDELPKNDLITYLQKN 1920 
             ************************************************************ 
 
mHECTD1      ADAAFLRHWKLTGTNKSIRKNRNCSQLIAAYKDFCEHGTKSGLNQGAISSLQSSDILNLT 1980 
hHECTD1      ADAAFLRHWKLTGTNKSIRKNRNCSQLIAAYKDFCEHGTKSGLNQGAISTLQSSDILNLT 1980 
             *************************************************:********** 
 
mHECTD1      KEQPQAKAGNGQSPCGVEDVLQLLRILYIVASDPYSRISQEDGDEQPQFTFPPDEFTSKK 2040 
hHECTD1      KEQPQAKAGNGQNSCGVEDVLQLLRILYIVASDPYSRISQEDGDEQPQFTFPPDEFTSKK 2040 
             ************. ********************************************** 
 
mHECTD1      ITTKILQQIEEPLALASGALPDWCEQLTSKCPFLIPFETRQLYFTCTAFGASRAIVWLQN 2100 
hHECTD1      ITTKILQQIEEPLALASGALPDWCEQLTSKCPFLIPFETRQLYFTCTAFGASRAIVWLQN 2100 
             ************************************************************ 
 
mHECTD1      RREATVERTRTTSSVRRDDPGEFRVGRLKHERVKVPRGESLMEWAENVMQIHADRKSVLE 2160 
hHECTD1      RREATVERTRTTSSVRRDDPGEFRVGRLKHERVKVPRGESLMEWAENVMQIHADRKSVLE 2160 




mHECTD1      VEFLGEEGTGLGPTLEFYALVAAEFQRTDLGTWLCDDNFPDDESRHVDLGGGLKPPGYYV 2220 
hHECTD1      VEFLGEEGTGLGPTLEFYALVAAEFQRTDLGAWLCDDNFPDDESRHVDLGGGLKPPGYYV 2220 
             *******************************:**************************** 
 
mHECTD1      QRSCGLFTAPFPQDSDELERITKLFHFLGIFLAKCIQDNRLVDLPISKPFFKLMCMGDIK 2280 
hHECTD1      QRSCGLFTAPFPQDSDELERITKLFHFLGIFLAKCIQDNRLVDLPISKPFFKLMCMGDIK 2280 
             ************************************************************ 
 
mHECTD1      SNMSKLIYESRGDRDLHCTESQSEASTEEGHDSLSVGSFEEDSKSEFILDPPKPKPPAWF 2340 
hHECTD1      SNMSKLIYESRGDRDLHCTESQSEASTEEGHDSLSVGSFEEDSKSEFILDPPKPKPPAWF 2340 
             ************************************************************ 
 
mHECTD1      NGILTWEDFELVNPHRARFLKEIKDLAIKRRQILGNKSLSEDEKNTKLQELVLRNPSGSG 2400 
hHECTD1      NGILTWEDFELVNPHRARFLKEIKDLAIKRRQILSNKGLSEDEKNTKLQELVLKNPSGSG 2400 
             **********************************.**.***************:****** 
 
mHECTD1      PPLSIEDLGLNFQFCPSSRIYGFTAVDLKPSGEDEMITMDNAEEYVDLMFDFCMHTGIQK 2460 
hHECTD1      PPLSIEDLGLNFQFCPSSRIYGFTAVDLKPSGEDEMITMDNAEEYVDLMFDFCMHTGIQK 2460 
             ************************************************************ 
 
mHECTD1      QMEAFRDGFNKVFPMEKLSSFSHEEVQMILCGNQSPSWAAEDIINYTEPKLGYTRDSPGF 2520 
hHECTD1      QMEAFRDGFNKVFPMEKLSSFSHEEVQMILCGNQSPSWAAEDIINYTEPKLGYTRDSPGF 2520 
             ************************************************************ 
 
mHECTD1      LRFVRVLCGMSSDERKAFLQFTTGCSTLPPGGLANLHPRLTVVRKVDATDASYPSVNTCV 2580 
hHECTD1      LRFVRVLCGMSSDERKAFLQFTTGCSTLPPGGLANLHPRLTVVRKVDATDASYPSVNTCV 2580 
             ************************************************************ 
 
mHECTD1      HYLKLPEYSSEEIMRERLLAATMEKGFHLN 2610 
hHECTD1      HYLKLPEYSSEEIMRERLLAATMEKGFHLN 2610 




Figure A.2. mHectd1 and hHECTD1 amino acid sequence alignment. Sequence 
alignment to identify the catalytic cysteine in mHectd1. Using the Pairwise Sequence 
































































KEN = KEN box 
RxxN = potential D box 
RxxN = more likely D box  
 
Figure A.3. Identification of KEN and D box sequences in hHECTD1. KEN and D box 
sequences within HECTD1 predicted based on the APC/C degron repository 
(http://slim.ucd.ie/apc/index.php?page=instances&instance_set=dboxes (accessed 



































Figure A.4. Coomassie SDS-PAGE for GST, GST-TRABID1-200, GST-TRABID1-200 3XNZF 
(TY/LV). GST fusions of bacterially expressed TRABID1-200 and TRABID1-200 TY/LV were 
loaded on a on a 4-12% SDS PAGE. GST and GST-fusion proteins were loaded at 5µg 
each. The gel was then stained in Coomassie Blue reagent, destained and imaged using 
the GelDoc-ItTM Imaging System (UVP). Here, proteins were normalised to 5µg based on 


























































Figure A.5. Anti-Ub antibody optimisation. Optimisation of three different anti-Ub 
antibodies on non-boiled and boiled PVDF membranes. Antibodies were tested on  
TRABID1-200 pull down assay samples. For the IP GST fusions of bacterially expressed 
TRABID1-200 and TRABID1-200 TY/LV were used. Western blots of the immunoprecipitation (IP) 
and Input. Samples were treated with DMSO or 10µM MG132 for 6hrs before lysis. 
Following western blotting on PVDF, the membrane was blocked in 3%-BSA-PBST and 
incubated overnight with A) Abcam Ubi-1 anti-Ub antibody (ab7254), B)  Enzo P4D1 anti-
Ub antibody (BML-PW0930),  or C) Millipore anti-Ub antibody (07-375) followed by 
detection with an appropriate secondary HRP antibody. From this optimisation, Enzo P4D1 
anti-Ub was chosen, with membranes that were boiled. All western blots were cropped and 
































Figure A.6. A panel screen of lung cancer cell lines to assess the presence of HECTD1 
promoter methylation (Full Gels). 3% agarose gel of RT-PCR products, showing 
HECTD1 (JL7 + 8) expression in multiple cancer cell lines. A) H1435 and H1703, B) H1666 
and H385, C) H23 and H1395, and D) H920 and H1993. Each cell line was treated with 
DMSO (M = Mock treated) or 5-aza-2’-deoxycytidine (2µM) (A = “Aza” treated). HECTD1 
was compared to RNA Pol IIA housekeeping gene. DKO cell line was used as a positive 
control, -RT and no cDNA were used as a negative control in the reaction. Multiplex sample 
= HECTD1 and RNA Pol II primers in the same reaction.  
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